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Abstract
Avian pneumovirus (APV) has remained an important pathogen of domestic fowl since its
isolation in the 1970s. A reverse genetics system for APV was developed that affords direct
manipulation and analysis of the molecular biology, pathogenicity, and tropism of APV.
Using a synthetic minigenome system, the M2-1 protein was found to enhance transcription
but not be essential for replication and the APV M2-2 protein was shown to inhibit
transcription of a reporter gene. The viral cis-acting sequences were mutated to determine
their role in transcription. Initially, a series of mutations originating from vaccine candidates
were introduced into the gene end sequence of the LUC gene. The levels of LUC reporter
protein expression in the mutants was 40-70% of normal, thus demonstrating a mechanism
for reduction of virus immunogenicity as the result of a single point mutation. Heterologous
rescue of the APV minigenome was carried out using plasmids expressing the RSV, PVM
and hMPV proteins and showed that homologous protein: protein interactions were necessary
for minigenome transcription. An APV cloned virus rescue system (Naylor et al., 2004) was
used to create APV viruses which contained the gene encoding enhanced green florescent
protein (eGFP) either within intact APV, or in mutants lacking the SH and G genes or lacking
the SH gene alone. It was demonstrated that the SH and G genes are not essential for APV
replication in vitro and in vivo and that the APV genome is capable of accepting insertions of
foreign material. Expression of eGFP from the recombinant viruses was investigated in vivo
in turkeys at 3 and 5 days post infection. eGFP was found in the sinus tissue of the birds
infected with the virus containing the full complement of virus genes in addition to that
encoding eGFP.
  
 
Chapter 1: 
Introduction to Avian Pneumovirus and 
Reverse Genetics Systems 
 2
1.1 Introduction  
1.1.1 Pneumovirus taxonomy and virion structure 
Avian pneumovirus (APV), also known as avian metapneumovirus (Lamb et al., 2000) 
and previously known as turkey rhinotracheitis virus, is a member of the virus family 
Paramyxoviridae, the subfamily Pneumovirinae and the genus Metapneumovirus 
(Bermingham et al., 2007; Cavanagh and Barrett, 1988; Collins and Gough, 1988; 
Njenga et al., 2003; Pringle, 1995; Pringle, 1996; Pringle, 1998; Yu et al., 1991).  Within 
the Pneumovirinae subfamily, the viruses of the Pneumovirus genus are the best studied, 
especially the human pathogen respiratory syncytial virus (RSV).  The viruses of the 
Pneumovirinae have an enveloped, non-segmented, negative-sense RNA genomes that 
are 13 to 15kb in length.  The APV genome encodes eight mRNAs and directs the 
expression of nine proteins (figure 1.1 and section 1.3) (Collins and Gough, 1988; Ling 
and Pringle, 1988).  APV is classified into the subfamily Pneumovirinae and genus 
Metapneumovirus based on electron microscopy studies, mRNA profiles, genome 
sequences, and the molecular weights of its proteins (Bachi and Howe, 1973; Bhella et 
al., 2002; Cavanagh and Barrett, 1988; Compans et al., 1967; Joncas et al., 1969).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5' 
SH
 3’ N M LF M2 P G
5' 3’  N  M  F L 
NS1 
NS2 
 P 
 SH 
 G  M2 
Figure 1.1 Genome organization of the Pneumovirinae. 
Sub-Family: Pneumovirinae 
Genus Pneumovirus:  
Human, bovine and ovine respiratory syncytial viruses (RSV, BRSV and ORSV), 
Pneumonia virus of mice (PVM).  PVM  lacks the overlap between the M2-1 and L 
genes. 
Genus Metapneumovirus:  
Avian pneumovirus (APV), Human metapneumovirus (hMPV) 
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The virions of the pneumoviruses and metapneumoviruses are spherical but pleomorphic 
(the appearance of two or more distinctly different forms is common) and approximately 
200nm diameter (Collins and Gough, 1988; Gough et al., 1988b; Wyeth et al., 1986).  
The virion consists of the ribonucleoprotein (RNP) complex surrounded by the matrix 
(M) protein and a cell-derived lipid envelope with the attachment glyco- (G) and fusion 
(F) proteins protruding 13-14nm from the surface (Collins and Gough, 1988) (figure 1.2).  
A small hydrophobic (SH) glycoprotein has also been isolated, although the exact 
location of the SH protein in the virion is not known.  The RNP complex consists of the 
negative sense RNA genome tightly bound with nucleocapsid (N) protein and associated 
with phospho- (P) and large polymerase (L) proteins (Huang et al., 1985; Peeples and 
Levine, 1979).  This complex has been visualized using negative staining and electron 
microscopy for the Paramyxoviridae and shows a distinctive herring-bone structure 
(figure 1.3).  The APV nucleocapsid (the N protein associated with the RNA genome) is 
smaller (12-15nm in diameter) than the 18nm helical nucleocapsid of the 
Paramyxovirinae (Alexander, 1991; Collins and Gough, 1988).  
 
Matrix 
(M) 
Attachment (G) 
Fusion 
(F) 
RNP 
Complex 
Lipid 
Membrane 
Figure 1.2 Model of the Pneumovirinae virion.  The pneumovirus virus virion is 
made up of the RNP complex surrounded by the matrix (M) protein and a host-
derived lipid membrane with the viral glycoproteins (the fusion and attachment 
proteins) embedded (reproduced from (Dimmock et al., 2006)). 
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1.1.2 APV incidence and distribution 
APV was first observed as an agent causing respiratory disease in turkeys and chickens in 
South Africa in the 1970s (Buys and Du Preez, 1980; Buys et al., 1989a).  The virus was 
isolated as the causative agent of respiratory disease in turkeys and as an agent 
contributing to swollen head syndrome in chickens (section 1.2) during outbreaks that 
occurred in France and England (Giraud et al., 1986; McDougall and Cook, 1986; 
Wilding et al., 1986).  Viral proteins have been detected in turkeys using 
immunofluorescence (IF) (Jones et al., 1986; Jones et al., 1988) and immunoperoxidase 
(IP) assays (O'Loan and Allan, 1990).  APV isolated from turkeys has also been shown to 
be able to infect chickens, verified by IP, virus isolation, and histology (Jones et al., 
1987; Majo et al., 1995). 
 
APV appears to be present in flocks of domestic birds in most areas of the world, with 
serological evidence of APV infection reported in most of Europe, South Africa, Asia 
(Lu et al., 1994), Israel (Weisman et al., 1988), Japan (Otsuki et al., 1996), south and 
central America (Dani et al., 1999), China, Nigeria (Owoade et al., 2006), and the USA 
Figure 1.3 Paramyxovirus ribonucleoprotein capsid structure.  The electron 
microcopy image is courtesy of Linda M Stannard (University of Cape Town, 
http://web.uct.ac.za/depts/mmi/stannard/paramyx.html).  
Nucleoprotein (N) 
Phosphoprotein (P) 
Polymerase (L) 
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(Bennett et al., 2004; Cook et al., 1999; Goyal et al., 2000).  Virus has been isolated from 
birds in France, Great Britain, Italy (Alexander, 1991), South Africa (Buys and Du Preez, 
1980) and Israel (Weisman et al., 1988) (reviewed by Jones (1996)).  
 
APV primarily infects domestic flocks of turkeys and chicken, but may also persist in 
populations of wild birds.  APV causes major economic losses in infected flocks and 
turkeys as young as one day old are susceptible to infection (Gough et al., 1988a).  Once 
introduced into an area, the spread of APV is rapid with morbidity reaching 100% 
(Alexander, 1991; Anon., 1985; Cook et al., 1991; Gough et al., 1988a), though how the 
virus spreads from farm to farm is unknown.  Stuart (1986) suggested APV could be 
spread via migratory birds as it has been shown to infect wild fowl, although the role of 
wild birds in the spread of APV to and between domestic populations remains unclear 
(Bennett et al., 2002; Bennett et al., 2004; Gough et al., 1988a; Gough et al., 2001; 
Gough et al., 1994; Lwamba et al., 2002; Turpin et al., 2008).  Evidence for APV in wild 
birds comes from its ability to cause disease following experimental infection in 
pheasants, and guinea fowl (Gough et al., 1988a), the detection of antibodies to APV in 
guinea fowl (Picault et al., 1987) and the isolation of virus from wild flocks of pheasants 
(Gough et al., 2001) and wild Canada geese (Bennett et al., 2002).  APV RNA has also 
been found in blue-winged teals (Bennett et al., 2002).  There have been no reports of 
natural or experimental infection outside of avian species (Naylor and Jones, 1993).   
 
Four subgroups of APV have been established based initially on the relatedness of the 
sequence of the G protein and serological cross reactivity.  APV subgroups A and B have 
been found in Europe, Africa, Asia, and the Middle East (Banet-Noach et al., 2005), 
(Collins et al., 1993; Cook et al., 1993a; Hafez et al., 2000; Juhasz and Easton, 1994; Li 
et al., 1996; Mase et al., 2003).  Subgroup C was initially isolated in Colorado, but has 
now been found in the states of Minnesota, North Dakota, South Dakota, Iowa and 
Wisconsin in the USA as well as in France and Korea (Bennett et al., 2004; Cook et al., 
1999; Dar et al., 2002; Goyal et al., 2000; Seal, 1998).  Subgroup D was found in France 
in farmed ducks (Bayon-Auboyer et al., 2000), although this subgroup has not been seen 
outside of these samples isolated in 1985. 
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1.2 Virus pathogenesis 
1.2.1 Disease: turkey rhinotracheitis, swollen head syndrome, and co-infection.  
APV causes respiratory illness in domestic fowl and was initially characterised as the 
pathogen causing outbreaks of turkey rhinotracheitis (TRT).  APV primarily infects 
turkeys and chickens, although seroconversion of wild birds with asymptomatic infection 
has been reported, as described above.  In experimentally infected turkeys, APV causes 
coughing, and ocular and sinus discharge.  Associated clinical signs are sneezing, head 
shaking, egg loss and production of eggs with thinned shells (Anon., 1985; Cook et al., 
1996; Cook et al., 2000; Jones et al., 1988; Lister and Alexander, 1986; O'Brien, 1985; 
Sugiyama et al., 2006; Wyeth et al., 1987).  In broiler breeders, extreme cases of 98% 
drop in egg production have been observed (Naylor and Jones, 1993).  
 
In chickens, APV infection has been linked to swollen head syndrome (SHS)(Aung et al., 
2008; Gough et al., 1994; Jones et al., 1987; Jones et al., 1991; Lister and Alexander, 
1986; Lu et al., 1994; Morley and Thomson, 1984; Nakamura et al., 1997; O'Brien, 1985; 
Pattison et al., 1989; Picault et al., 1987; Tanaka et al., 1995; Wyeth et al., 1987), 
although secondary infection clearly plays a role in the disease.  An agent that is now 
known to be APV was first implicated when the virus was isolated from chickens with 
SHS (Buys et al., 1989b; Jones et al., 1991; Nakamura et al., 1997; Picault et al., 1987).  
While APV antibodies have been found in commercial chicken flocks, antibodies were 
found in birds with and without SHS or respiratory disease (Cook et al., 1988) and SHS 
has also been shown to occur in the absence of APV infection (Droual and Woolcock, 
1994; Shirai et al., 1993).  It seems clear that APV infection alone is not sufficient to 
induce, or may not be the sole cause of, SHS.  However, as attempts to reproduce SHS 
experimentally in boiler chicks by 32 days with co-infection of APV and the most 
commonly found co-isolate in SHS (E. coli) failed, the role of APV in this syndrome 
remains unclear (Al-Ankari et al., 2001).   
 
In the field, APV infection is seldom the only pathogen infecting commercial flocks and 
co- infection can result in up to 90% mortality (Alexander, 1991; Gough et al., 1988b), 
although mortality without co-infection is more normally 2-5% (Jing et al., 1993).  APV 
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infection appears to have an immunosuppressive effect in turkeys (Chary et al., 2002a; 
Jones et al., 1992; Timms, 1986) such that prior APV infection rendered hemorrhagic 
enteritis virus vaccine approximately 50% less effective than vaccination alone (Chary et 
al., 2002b). This immunosuppression may leave birds open to bacterial infection (Jirjis et 
al., 2004; Van de Zande et al., 2001), possibly increasing the susceptibility of turkeys to 
secondary infection by damaging the ciliated and non-ciliated epithelia cells of the 
turbinates (Majo et al., 1996).  A mechanism of ‘viral priming’ has been proposed, based 
on the finding that APV infection prior to infection with Ornithobacterium 
rhinotracheale was show to cause respiratory disease where bacterial infection alone did 
not (Marien et al., 2005).  Experimental co-infection of APV and E. coli O78:K80 
resulted in increased respiratory symptoms and lesions in chickens (Majo et al., 1997). 
Co-infection of APV with Bordetella avium and Pasteurella-like organisms showed an 
increased range of virus infection to the heart, liver, spleen, kidneys and caecal tonsils for 
a short time post infection, and increased the number of sites of infection of Pasteurella-
like organisms (Cook et al., 1991).  Mycoplasma gallisepicum infection following APV 
infection was more invasive and increased levels of mortality were reported, although the 
severity of illness in dually infected birds was not affected (Naylor et al., 1992).  Al-
Ankari et al. (2001) found in broiler chicks that co-infection of APV and a mix of 
pathogenic E. coli strains exacerbated the disease presentation in the birds.  
 
1.2.2 Tissue tropism 
As with all pneumoviruses, APV is thought to be primarily a respiratory pathogen though 
the exact tropism of the virus has been shown to be strain and host (chickens or turkeys) 
dependent (Cook et al., 1993b).  APV subgroup A virus was found in the turbinates, 
sinuses, upper and lower trachea, lungs and air sacs of experimentally infected turkeys 
periodically up to 10 d.p.i. whereas APV subgroup B was found mainly in the upper 
respiratory tract (Buys et al., 1989a; Cook et al., 1991; Jones et al., 1988; McDougall and 
Cook, 1986; Van de Zande et al., 1999).  Indirect immunofluorescence experiments 
confirmed the presence of APV antigen in the turbinates and trachea but not lungs or air 
sacs (Jones et al., 1988).  Turkey poults and chickens experimentally infected with APV 
showed that the virus associated with the epithelial ciliated cells of the turbinates and 
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trachea (Majo et al., 1995).   
   
In chickens, in vitro experiments have shown ciliostasis in tracheal organ cultures and 
syncytia formation in chicken embryo cell cultures following of APV infection (Gough et 
al., 1988a).  In experimentally infected chickens, virus was isolated from the respiratory 
tract (nasal tissue, sinuses, trachea, and lung), although it was found most abundantly in 
the upper respiratory tract tissues.  In these experiments, no virus was isolated from the 
kidney, liver, duodenum, bursa of Fabricius or caecal tonsils.  Using IP, virus was found 
most consistently in nasal turbinates up to 5 days post infection (d.p.i.) and was found 
occasionally in sinuses and trachea on days 4 and 5 d.p.i.  Histology of the upper 
respiratory tract tissues showed changes most strikingly in the nasal turbinates and less 
severely in the sinuses and trachea (Catelli et al., 1998).  
 
The association of APV infection with egg drop syndrome suggested that the virus was 
capable of infecting the reproductive tract.  However, direct experimental evidence is 
mixed, with Giraud et al. (1986) finding no evidence of transmission of the virus to eggs 
in turkeys, but several other groups finding APV in the reproductive tract of broiler 
breeders and laying turkeys (Anon., 1985; Lister and Alexander, 1986; O'Brien, 1985; 
Wyeth et al., 1987).  In chickens, Jones et al. (1988) found APV in the reproductive tract 
of laying hens, as well as in the upper respiratory tract, but not in blood or ovaries and 
APV antigen has been detected by IP in oviduct in laying hens (Cook et al., 2000).  
Shedding of small amounts of APV from turkeys up to 14 d.p.i. has been reported (Cook 
et al., 1991), again suggesting that APV is able to infect tissues outside of the respiratory 
tract.  
 
1.2.3 Vaccines 
The production of live-attenuated APV vaccines that cannot revert to virulence in the 
field, or killed vaccines that effectively protect the birds from further infection is an on 
going challenge for APV research.  A method of priming with live-attenuated virus 
followed by administration of inactivated virus was shown to be required to protect 
turkeys and chickens against both respiratory symptoms and loss of egg production 
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resulting from APV challenge (Cook et al., 1996; Cook et al., 2000).  Sugiyama et al. 
(2006) showed that the choice of challenge virus was important in establishing efficacy 
of a vaccine against egg drop and respiratory symptoms.  Problems of reversion to 
virulence were found with a live attenuated APV subgroup A vaccine which was shown 
to persists in turkeys (Catelli et al., 2006).  Additionally, Kapczynski et al. (2008) showed 
that a simple intranasal vaccination with an inactivated APV did not protect turkeys from 
APV challenge, indicating that the method of vaccine delivery also needs to be taken into 
consideration.  Encouragingly, initial trials of a cold-adapted strain of APV showed that it 
protects turkeys for 14 weeks without causing disease (Patnayak and Goyal, 2006; 
Patnayak et al., 2002).  Additionally, Ganapathy and Jones (2007) showed that chicks 
could be protected with an APV subgroup B live attenuated vaccine for up to 49 day after 
vaccination.  Due to the possibility of APV vaccination affecting the outcome of infection 
with other avian pathogens (section 1.2.1), concerns about the use of APV vaccines 
remain.   
 
The mechanisms of protection of APV vaccines have been investigated and it is clear that 
more research is required in this area.  Interestingly, it has been shown that poults can be 
vaccinated even when they have circulating maternal antibodies to APV without decrease 
in protection (Catelli et al., 1998; Cook et al., 1989).  Jones et al. (1992) showed that 
even with immunosuppression of antibody production using cyclophosphamide, turkey 
poults vaccinated with a live attenuated APV strain were protected from challenge 21 
days later.  For an APV subgroup C vaccine, the absence of antibodies in turkey poults 
following vaccination still resulted in protection from challenge with APV (Patnayak and 
Goyal, 2004; Patnayak et al., 2002).    
 
The immunopathogenesis of the virus is not well studied, but it has been shown that APV 
may mediate the inhibition of T cells (Chary et al., 2002a), trigger the accumulation of 
CD4+ T cells, and the release of cytokines (Liman and Rautenschlein, 2007).  
Specifically, APV induces increased CD4+ T cell proliferation in the spleen and 
Harderian gland of turkeys.  APV infection also induced humoral and cell-mediated 
responses as well as protective antibodies in turkeys (Liman and Rautenschlein, 2007). 
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1.3. Pneumovirinae genome organization and protein products 
1.3.1 Pneumovirinae genomes 
The APV subgroup A isolate CVL14/1 genome is 13370 base in length, which 
comparable to the hMPV isolate 001 genome (13387 bases) but shorter than either the 
RSV strain S2 (15190 bases) or PVM strain 15 (14887 bases) genomes (for Genbank 
accession numbers, see section 2.15).  As can be seen in figure 1.1, all pneumoviruses 
encode three proteins that form the RNP complex (the N, P, and L proteins), three 
glycoproteins (the G, F and SH proteins), a structural matrix protein (M) and an M2 gene 
that has two overlapping ORFs.  The M2 mRNA produces an anti-termination factor 
(M2-1) and a protein of unknown function (M2-2).   
 
The APV genome differs from the RSV and PVM genomes in several respects.  APV 
lacks the NS1 and NS2 genes (Randhawa et al., 1997) and the genes of APV differ in 
order from RSV and PVM: the F and M2 genes of APV are found between M and SH 
instead of between G and L as is seen for RSV and PVM.  Additionally, PVM has been 
shown to encode a second P protein (P-2) from the P gene (Barr et al., 1994).  For APV, 
only the M2 gene and possibly the N gene express more than one protein (Alvarez and 
Seal, 2005).     
 
A comparison of representative genomes of APV subgroups A, C (full genome sequences 
for subgroups B and D are not currently available), hMPV, RSV and PVM was carried 
out (table 1.1, section 2.15).  Overall, the representative viruses of the subfamily 
Pneumovirinae have between 40 and 66% homology, with the APV subgroup A genome 
having the highest levels of homology with the APV subgroup C genome (59%), 
followed closely by the hMPV genome (57%) and more distantly by the RSV and PVM 
genomes (39 and 43%, respectively).  Interestingly, the APV subgroup C genome has the 
highest level of homology with hMPV (66%).  Lwamba et al. (2005) speculated that the 
high levels of homology seen between the APV subgroup C and hMPV SH, G, and L 
sequences indicated an evolutionary relationship. 
Table 1.1 Nucleotide homologies of the pneumovirus genomes.  The 
percentage homologies (in green boxes) of the genomes of RSV strain RSS-2, 
APV subgroup A isolate CVL141, APV subgroup C, hMPV isolate 001 and 
PVM strain 15 were compared as described in section 2.15.  Genomes were not 
rearranged to account for the differences in gene order of the viruses, possibly 
leading to artificially low levels of homology between the pneumovirus and 
the metapneumovirus genomes.  The levels of nucleotide homology and amino 
acid identity for the individual virus genes and proteins are detailed in tables 
1.3 through 1.13.
52404139RSV
434543PVM
6657hMPV
59APV 
subgroup 
C
PVMhMPVAPV 
subgroup 
C
APV 
subgroup 
A
Percentage 
homology 
(%)
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1.3.2 Pneumovirinae genes and proteins  
1.3.2.1 N protein  
The subfamily pneumovirus N proteins are well conserved in length, with APV subgroup 
A, B and RSV having 391 amino acids, APV subgroup C and hMPV having 394 amino 
acids, and PVM having 393 amino acids (table 1.2).  The levels of homology between the 
pneumovirus N genes and of amino acid identity between the N proteins were also 
determined (table 1.3).  The levels of nucleotide homology between the APV subgroups 
A, B and C ranged from 65% to 76%, with the highest levels seen between subgroups A 
and B (76%).  Within the genus Metapneumovirus, the highest levels of homology were 
seen between the APV subgroup C and the hMPV N genes (65%).  The nucleotide 
homology levels within the pneumovirus genus and between the pneumovirus and 
metapneumovirus genera were lower, with the highest level being between the PVM and 
RSV N proteins (62%).  The protein identity levels showed a similar pattern, although 
here the highest level was seen between APV subgroups A and B (91%).  The amino acid 
identity levels within the Metapneumovirus genus were higher than their nucleotide 
homology levels and ranged from 69 to 91%.  As before, the level of homology between 
APV subgroup C and hMPV (88%) was higher than that seen between APV subgroup C 
or hMPV and any other virus.      
 
The model for the functional processes undertaken by the pneumovirus RNP complex 
suggests the N protein is an essential structural pneumovirus protein that encapsidates the 
viral RNA and binds to the P and M2-1 proteins.  Experimental evidence for this model is 
extensive.  The bRSV N protein can spontaneously form nucleocapsid structures with 
RNA even when expressed in the absence of any other viral proteins (Maclellan et al., 
2007).  Khatter et al. (2000) showed that the bRSV N protein has the ability to 
encapsidate RNA, is integral to RNA synthesis, and binds to the P protein.  Evidence for 
N:P protein binding was found when the RSV N and P protein complex was shown to be 
required for the formation of inclusion bodies in cells.  The RSV M2-1 protein was also 
bound to the N protein in these bodies (Garcia et al., 1993).  The RSV N, P and M2 
proteins have been shown to co-localize using immunofluorescence staining (Ghildyal et 
al., 2002).  The bRSV N protein has been shown to have specific, separate regions to  
Table 1.2 Amino acid and nucleotide lengths of the pneumovirus ORF and proteins.  
The lengths of the ORFs (nucleotides, in bold) and proteins (amino acids, in italics) of RSV 
strain RSS-2, APV subgroup A isolate CVL141, APV subgroup B, APV subgroup C, APV 
subgroup D, hMPV isolate 001 and PVM strain 15 (section 2.15). Shown are the lengths of 
the N (nucleocapsid), P (phospho-), L (large polymerase), M2 (second matrix), M2-1 (second 
matrix ORF 1), M2-2 (second matrix ORF 2), G (glyco-), F (fusion), M (matrix), SH (small 
hydrophobic), NS-1 (first non-structural), NS-2 (second non-structural) open reading frames 
(ORFs) and proteins.  *For M2, the length indicated is the number of nucleotides in the M2 
mRNA.
Not 
applicable
Not 
available
Not 
available
Not 
available
1170
389
Not 
available
Not 
available
Not 
available
Not 
available
APV 
subgroup D
771
256
774
257
765
254
765
254
805
266
765
254
M
1725
574
1614
537
1620
539
1614
537
Not 
available
1617
538
F
897
298
1092
363
711
236
1758
585
Not 
available
1176
391
G
RSVPVMhMPV
APV 
subgroup C
APV 
subgroup B
APV 
subgroup ALength
420
139
375
124
342
113
471
156
Not 
applicable
Not 
applicable
Not 
applicable
NS-1
NS-2
195
64
279
92
552
183
528
175
Not 
available
525
174
SH
961
585
194
273
90
875
531
176
297
98
746
564
187
216
71
748
555
184
216
71
Not 
available
762
561
186
222
73
M2*
M2-1
M2-2
6498
2165
6123
2040
6018
2005
6018
2005
Not 
available
6015
2004
L
726
241
888
295
885
294
885
294
840
279
837
278
P
1176
391
1183
393
1185
394
1185 
394
1176
391
1176
391
N
Not 
applicable
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Table 1.3 Percentage nucleotide homology and amino acid identity of the 
pneumovirus N ORF and proteins.  The percentage homologies of the nucleotides of 
the N ORFs (green boxes) and percentage identity of the proteins (grey boxes) of RSV 
strain RSS-2, APV subgroup A isolate CVL141, APV subgroup B isolate 98103, APV 
subgroup C, hMPV isolate 001 and PVM strain 15 were compared as described in 
section 2.15.  
6250495048RSV
6051505050PVM
4144756665hMPV
4043886665APV 
subgroup 
C
3943697176APV 
subgroup 
B
3942687091APV 
subgroup 
A
RSVPVMhMPVAPV 
subgroup 
C
APV 
subgroup 
B
APV 
subgroup 
A
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bind to itself, as well as the P and M2 proteins (Samal et al., 1993).  Little of the N 
protein sequence appears to be superfluous, as two-hybrid system experiments showed 
that deletion of any region of the RSV N protein obliterated N protein binding (Garcia-
Barreno et al., 1996; Slack and Easton, 1998).    
 
1.3.2.2 P protein  
The subfamily pneumovirus P proteins vary in length from the RSV protein of 241 
residues to the 295 residue PVM P protein (table 1.2).  The APV subgroup C and hMPV 
P proteins are identical in length (294 residues) whereas the APV subgroup A and B P 
proteins are shorter, at 278 and 279 residues, respectively.  The levels of homology or 
identity of the P genes and proteins were determined (table 1.4).  The highest levels of 
nucleotide homology were seen between APV subgroups A and B (69%) and between 
APV subgroup C and hMPV (67 1%).  The P protein identity levels were also highest 
between APV subgroups A and B at 72% and between APV subgroup C and hMPV P 
proteins (68%).  RSV and PVM had no more than 42% nucleotide homology or 27% 
amino acid identity with any of the metapneumoviruses and only 49% nucleotide 
homology or 33% amino acid identity between themselves.      
 
The pneumovirus P protein is essential, making up part of the viral polymerase complex.  
The bRSV P protein has been shown to bind the N and L proteins in co-
immunoprecipitation studies (Khattar et al., 2001).  The regions of the RSV P protein that 
are involved in binding have been found to be two regions in carboxyl-terminus of the P 
protein for N protein binding by two hybrid studies, co-immunoprecipitation and the 
formation of inclusion bodies (Garcia-Barreno et al., 1996; Slack and Easton, 1998).  
Further RSV two-hybrid system studies showed that the RSV P protein can bind to itself, 
N protein, and NS1 protein (Hengst and Kiefer, 2000).  The P protein also appears to be 
responsible for host specificity for human and bovine RSV (Buchholz et al., 2000; 
Schmidt et al., 2004). 
 
 
Table 1.4 Percentage nucleotide homology and amino acid identity of the 
pneumovirus P ORF and proteins. The percentage homologies of the nucleotides of 
the P ORFs (green boxes) and percentage identity of the proteins (grey boxes) of RSV 
strain RSS-2, APV subgroup A isolate CVL141, APV subgroup B isolate 98103, APV 
subgroup C, hMPV isolate 001 and PVM strain 15 were compared as described in 
section 2.15.  
RSVPVMhMPVAPV 
subgroup 
C
APV 
subgroup 
B
APV 
subgroup 
A
4934353336RSV
3342423841PVM
2125675757hMPV
2125685758APV 
subgroup 
C
2027505069APV 
subgroup 
B
2227555172APV 
subgroup 
A
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1.3.2.3 L protein  
The L proteins of the pneumovirus subfamily vary in length from 2004 amino acids for 
APV subgroups A and C to 2164 amino acids for RSV (table 1.2).  The L gene sequences 
for APV subgroups B and D are not currently available.  The levels of nucleotide 
homology for the L gene are over 50% for all members of the pneumovirus subfamily 
(table 1.5), with the highest levels found between hMPV and APV subgroup C at 71%.  
The APV subgroup A L gene has a 63% nucleotide homology with those of the APV 
subgroup C and hMPV, but only 55 and 50% homology with those of PVM and RSV, 
respectively.  The levels of identity between the L proteins are similar, with APV 
subgroup C and hMPV having 80% amino acid identity and APV subgroup A having 
identical amino acid identity percentages as nucleotide homology percentages to APV 
subgroup C and hMPV.  
 
The L protein is the large polymerase subunit and has been shown to be the main 
catalytic unit of the polymerase complex for negative-strand RNA viruses (Grdzelishvili 
et al., 2005; Hercyk et al., 1988; Ogino et al., 2005).  As discussed above, the L protein 
for RSV binds the P protein to make up the viral RNA dependent RNA polymerase.  
Analysis of the polymerase proteins of five negative sense RNA viruses (Sendai virus, 
Newcastle disease virus, measles virus, vesicular stomatitis virus and rabies virus) 
defined six conserved domains (Poch et al., 1990).  No direct study of the APV L protein 
functionality has been carried out.   
       
1.3.2.4 M2-1 and M2-2 proteins  
The M2 mRNA of the pneumovirus subfamily is unique, with no homologue in any other 
system.  The organization of the M2 mRNA is unusual in that it contain two overlapping 
ORF, both of which produce viral proteins.  Translation of the M2-2 protein from the M2 
mRNA is coupled to translation of the M2-1 protein as the overlapping region of the M2-
1 and M2-2 ORFs has been shown to direct the ribosome back to the start codon of the 
M2-2 ORF from the M2-1 stop codon (Ahmadian et al., 2000; Gould and Easton, 2005; 
Gould and Easton, 2007).  The M2 mRNAs of the pneumoviruses vary in length from 
727 nucleotides for hMPV to 952 nucleotides for RSV (table 1.2).  The levels of 
Table 1.5 Percentage nucleotide homology and amino acid identity of the 
pneumovirus L genes and proteins. The percentage homologies of the nucleotides of 
the L ORFs (green boxes) and percentage identity of the proteins (grey boxes) of RSV 
strain RSS-2, APV subgroup A isolate CVL141, APV subgroup B isolate 98103, APV 
subgroup C, hMPV isolate 001 and PVM strain 15 were compared as described in 
section 2.15.
RSVPVMhMPVAPV 
subgroup C
APV 
subgroup A
54525050RSV
49555455PVM
43497163hMPV
43488063APV subgroup C
43506363APV subgroup A
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50413939RSV
383735PVM
7363hMPV
63APV 
subgroup 
C
PVMhMPVAPV 
subgroup 
C
APV 
subgroup 
A
Percentage 
homology 
(%)
Table 1.6 Nucleotide homologies of the pneumovirus M2 mRNA.  The 
percentage homology of the mRNAs of RSV strain RSS-2, APV subgroup A 
isolate CVL141, APV subgroup C, hMPV isolate 001 and PVM strain 15 were 
compared as described in section 2.15.  
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homology for the M2 mRNAs of the pneumovirus subfamily also vary widely, with APV 
subgroup C and hMPV having the highest levels of homology at 71% and PVM having 
no more than 38% homology with any of the pneumoviruses (table 1.6).The RSV M2-1 is 
the largest of the pneumovirus M2-1 proteins at 194 amino acids (table 1.2). The M2-1 
proteins of APV subgroups A and C, hMPV and PVM are smaller, but similar in length at 
186, 184, 187, and 176 amino acids, respectively.  The level of amino acid identity (table 
1.7) between the pneumoviruses is low (below 40%) apart from between APV subgroup 
C and hMPV (84%) and between APV subgroup A and APV subgroup C (70%) or 
hMPV (72%).         
 
The M2-1 protein is produced from the first ORF of the M2 gene.  The RSV M2-1 
protein has been shown to be hydrophilic and basic (Collins and Wertz, 1985) and was 
characterized as the second RSV envelope-associated matrix protein (Huang et al., 1985).  
The RSV M2-1, L, N, P proteins and genome RNA have been shown to co-localize in 
cells (Garcia-Barreno et al., 1996; Li et al., 2008), suggesting a potential role for M2-1 
protein.  The expression of RSV M2-1 protein along with the N, P, L proteins and the 
genome RNA significantly enhanced viral full-length transcript production, suggesting 
that the M2-1 protein acts as a transcriptional elongation factor (Collins et al., 1995; 
Collins et al., 1996; Fearns and Collins, 1999; Grosfeld et al., 1995; Yu et al., 1995). 
 
The RSV M2-2 protein is 90 amino acid in length, similar to the 93 residue PVM M2-2 
protein.  In contrast, the M2-2 proteins of APV and hMPV are considerably shorter (71 or 
73 amino acids, table 1.2).  However, the M2-2 ORFs and proteins of the pneumovirus 
subfamily lack any significant sequence homology or amino acid identity, apart from 
hMPV and APV subgroup C that have a 64% nucleotide homology (table 1.8). 
 
A protein expressed from the second ORF of the M2 mRNA was detected for RSV and 
PVM, but not for APV, by western blot.  These M2-2 proteins for RSV and PVM were 
visualized in cells by immunofluorescence and shown to localize in the cytoplasm to 
inclusion bodies (Ahmadian et al., 1999).  The M2-2 protein is not required for virus  
52504847RSV
39454542PVM
36347666hMPV
36348465APV 
subgroup 
C
39357270APV 
subgroup 
A
RSVPVMhMPVAPV 
subgroup 
C
APV 
subgroup 
A
Table 1.7 Percentage nucleotide homology and amino acid identity of the 
pneumovirus M2-1 genes and proteins. The percentage homology of the M2-
1 ORFs (green boxes) and percentage identity of the proteins (grey boxes) of 
RSV strain RSS-2, APV subgroup A isolate CVL141, APV subgroup C, hMPV 
isolate 001 and PVM strain 15 were compared as described in section 2.15.
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39302931RSV
14353236PVM
1386452hMPV
1685649APV 
subgroup 
C
1692620APV 
subgroup 
A
RSVPVMhMPVAPV 
subgroup 
C
APV 
subgroup 
A
Table 1.8 Percentage nucleotide homology and amino acid identity of the 
pneumovirus M2-2 genes and proteins. The percentage homology of the M2-2 ORFs 
(green boxes) and percentage identity of the proteins (grey boxes) of RSV strain RSS-
2, APV subgroup A isolate CVL141, APV subgroup C, hMPV isolate 001 and PVM 
strain 15 were compared as described in section 2.15.
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growth and can be deleted from RSV to give a virus which is an attenuated in vitro and in 
vivo (Bermingham and Collins, 1999; Jin et al., 2000b).  For hMPV, a deletion of the 
M2-2 ORF in a recombinant virus resulted in an increased number of mutations to the 
genome, up-regulation of transcription, and attenuated growth in hamsters.  As in RSV, 
the hMPV M2-2 protein appears to play a role in regulation of transcription (Schickli et 
al., 2008).   
 
1.3.2.5 F protein  
The F genes of the pneumoviruses are 1614 to 1725 nucleotides in length and have levels 
of nucleotide homology ranging from 45 to 70% (tables 1.2 and 1.9).  As with the other 
APV genes, the highest levels of homology are seen between the APV subgroup C and 
the hMPV F genes.  The Pneumovirinae F protein is a glycoprotein which is expressed as 
a precursor F0 protein that is subsequently cleaved into two protein (F1 and F2).  Disulfide 
bonds covalently link the F1 and F2 proteins.  The RSV F1 component is involved in 
fusion of the virus envelope with the host cell membrane (González-Reyes et al., 2001; 
Zimmer et al., 2002; Zimmer et al., 2001).  Expression of the RSV F protein in 
recombinant vesicular stomatitis virus has been shown to be sufficient for cell infection 
and fusion (Kahn et al., 1999).   
 
The F protein is essential for virus growth and has several functions beyond cell fusion.  
The F protein may also be responsible for the host specificity human and bovine RSV.  
Recombinant bRSV viruses lacking the SH and/or G genes were shown to specifically 
infect bovine cells and similar recombinant RSV mutants to specifically infect human 
cells (Karron et al., 1997).  Also the RSV F protein has been shown to have 15 heparin 
binding domains (six in the F2 subunit and nine in the F1 subunit) that may be involved in 
binding or infectivity of the virus (Feldman et al., 2000; Schmidt et al., 2004).  The RSV 
F protein is responsible for inhibition of T cell proliferation (Schlender et al., 2002; 
Schlender et al., 2003).  In human and bovine RSV, a 27 amino acid peptide that is 
released upon cleavage of the F0 protein may play a role in immune evasion (Begona 
Ruiz-Arguello et al., 2002) though no analogous protein is seen in APV, PVM or hMPV.   
 
52474546RSV
40474545PVM
33377065hMPV
34388168APV 
subgroup 
C
34376772APV 
subgroup 
A
RSVPVMhMPVAPV 
subgroup 
C
APV 
subgroup 
A
Table 1.9 Percentage nucleotide homology and amino acid identity of the 
pneumovirus F genes and proteins. The percentage homology of the F ORFs (green 
boxes) and percentage identity of the proteins (grey boxes) of RSV strain RSS-2, APV 
subgroup A isolate CVL141, APV subgroup C, hMPV isolate 001 and PVM strain 15 
were compared as described in section 2.15.
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The active domains of the RSV F protein have been probed using deletion mutagenesis.   
In this way, it has been shown that the F protein can bind to the G protein independently 
of any SH protein being present and the domain responsible for binding has been 
determined to be between amino acids 335 and 574 in the F1 subunit region of the F 
protein (Schmidt et al., 2004).  No information on the capacity of the APV F protein to 
interact with the G protein has been reported.   
 
1.3.2.6 G protein  
The G protein of the pneumoviruses varies greatly in length, from 236 and 298 residues 
for hMPV and RSV, respectively, to 585 residues for APV subgroup C.  The APV 
subgroup C G protein is 194 residues and 196 residues longer than the APV subgroup A 
and subgroup B G proteins and has no more than 12% amino acid identity with any of the 
pneumoviruses (Govindarajan and Samal, 2004).  Generally, for the virus sequences 
examined, there is a lack of significant nucleotide or amino acid homology between any 
of the G genes or proteins of the viruses of the pneumovirus subfamily (tables 1.2 and 
1.10).   
 
For RSV, the G protein is the viral attachment protein and has been shown to be a type 2 
glycoprotein (Levine et al., 1987; Wertz et al., 1985).  The search for a cellular receptor 
has shown that the RSV G protein can bind to heparin and glycosaminoglycans (GAGs) 
at a heparin-binding domain (Feldman et al., 2000; Schmidt et al., 2004) and that the 
hMPV G protein also binds cellular GAGs (Thammawat et al., 2008).  The G gene has 
been deleted from recombinant RSV, resulting in a significantly attenuation virus 
(Bermingham and Collins, 1999; Teng et al., 2001).  In a primary human epithelial 
airway cell culture system, while the RSV F protein is the only required glycoprotein for 
infection, the G protein was found to be necessary for efficient spread of the virus 
(Mellow et al., 2004; Zhang et al., 2002). 
 
The G protein may also have a role in immune evasion, as a second form of G protein 
that is shorter that the full-length G protein and soluble has been shown to be produced 
by RSV (Roberts et al., 1994).  It may be that this form of G protein is used as an 
Table 1.10 Percentage nucleotide homology and amino acid identity of the 
pneumovirus G genes and proteins. The percentage homology of the G ORFs (green 
boxes) and percentage identity of the proteins (grey boxes) of RSV strain RSS-2, APV 
subgroup A isolate CVL141, APV subgroup C, APV subgroup D isolate Fr/85/2, 
hMPV isolate 001 and PVM strain 15 were compared as described in section 2.15.
RSVPVMhMPVAPV 
subgroup 
D
APV 
subgroup 
C
APV 
subgroup 
A
1921213020RSV
516233022PVM
75182816hMPV
5453253APV 
subgroup D
98121230APV 
subgroup C
565289APV 
subgroup A
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 immunomodulator or as a decoy for the immune system (Johnson and Graham, 1999; 
Johnson et al., 1998).  Johnson et al. (2004) showed that the removal G protein did not 
reduce vaccine-associated disease, but the removal did decrease vaccine protectivity.       
 
For APV, recombinant viruses have been created which lacks the G genes.  It was found 
that APV lacking the G gene grew well in cell culture but was attenuated in turkeys (Ling 
et al., 2008; Naylor et al., 2004).  Similar results were seen with the hMPV recombinant 
virus lacking the G gene (Biacchesi et al., 2005; Biacchesi et al., 2004b).  The effects of 
SH and G gene deletions on virus growth is further discussed in chapter 6.   
 
1.3.2.7 SH protein  
The SH protein of the pneumovirus subfamily, like the G proteins, vary greatly in length 
from 64 residues for RSV to 183 residues for hMPV (table 1.2) and have no significant 
nucleotide homology or amino acid identity (table 1.11).  The function of the SH protein 
for the pneumoviruses is not well defined.   
 
The RSV SH protein has been shown to be a type 2 integral membrane protein (Collins 
and Mottet, 1993; Feldman et al., 2001; Olmsted and Collins, 1989).  Recombinant 
viruses carrying a deletion in the SH gene have been shown to replicate in vitro and in 
vivo, though a recombinant RSV lacking the SH gene was attenuated (Bukreyev et al., 
1997).  The deletion of the SH and/or G genes from an hMPV cloned virus was also 
carried out and gave the following results: the G deleted virus was not attenuated in vitro, 
but was attenuated in hamsters, the SH deleted virus was not attenuated in vitro or in 
vivo, and the G/SH deleted virus was slightly attenuated in vitro and attenuated in 
hamsters (Biacchesi et al., 2004a; Biacchesi et al., 2004b).   
 
For APV, recombinant viruses has been created which lacks the SH gene or the SH and 
the G gene.  It was found that APV lacking the SH gene showed a syncytial phenotype in 
cell culture.  This virus also had attenuated growth in cell culture and in turkeys (Ling et 
al., 2008; Naylor et al., 2004).  APV recombinant viruses are further discussed in chapter 
6. 
13212013RSV
5242221PVM
5104637hMPV
5103137APV 
subgroup 
C
1271722APV 
subgroup 
A
RSVPVMhMPVAPV 
subgroup 
C
APV 
subgroup 
A
Table 1.11 Percentage nucleotide homology and amino acid identity of the 
pneumovirus SH genes and proteins. The percentage homology of the SH ORFs 
(green boxes) and percentage identity of the proteins (grey boxes) of RSV strain RSS-
2, APV subgroup A isolate CVL141, APV subgroup C, hMPV isolate 001 and PVM 
strain 15 were compared as described in section 2.15.
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1.3.2.8 M protein  
The M proteins of the pneumovirus subfamily do not vary greatly in length (254 to 266 
residues, table 1.2) and the levels of nucleotide homology and amino acid identity for the 
metapneumoviruses are high (67 to 76% and 72 to 84%, respectively, table 1.12).  Little 
is known about the APV M protein, but for RSV the M protein was shown to be the 
matrix protein and to associate with the viral envelope (Peeples and Levine, 1979).  The 
RSV M protein was found to associate with the RNP complex and may inhibit 
transcription via association with the N-terminal 110 amino acids of the M2-1 protein 
(Ghildyal et al., 2002; Li et al., 2008).  The M protein is also required for production of 
infectious virus (Teng and Collins, 1998). 
 
1.3.2.9 NS1 and NS2 proteins  
The NS1 and NS2 genes are found only in PVM and RSV and no homologue has been 
found in the metapneumoviruses.  The NS1 genes are 343 and 420 nucleotides for PVM 
and RSV, respectively, encoding proteins of 113 and 139 amino acids. The NS2 genes 
are 471 and 375 nucleotides (156 and 124 amino acids) respectively for PVM and RSV 
(table 1.2) and there is no detectable nucleotide homology or amino acid identity when 
comparing the NS1 or NS2 genes of RSV and PVM (table 1.13).  For RSV, the NS1 
protein has been shown to bind the M and P proteins in a two-hybrid system, but no 
interaction of NS2 with any other viral protein was found (Evans et al., 1996; Hengst and 
Kiefer, 2000).  The RSV NS1 and NS2 genes can be deleted from cloned virus and result 
in a virus that is attenuated in chimpanzees (Bermingham and Collins, 1999; Jin et al., 
2000b; Teng and Collins, 1999; Whitehead et al., 1999).  Most interestingly, the RSV 
NS1 and NS2 proteins have been shown to act together as mediators of resistance to the 
anti-vial interferon response and as inhibitors of interferon activation (Bossert and 
Conzelmann, 2002; Bossert et al., 2003; Schlender et al., 2000).  As the 
metapneumoviruses have no analogous proteins, it has been speculated that one of the 
other viral proteins might act in a homologous manner; however there has been no report 
of such a function for any of the APV proteins to date.   
 
 
Table 1.12 Percentage nucleotide homology and amino acid identity of the 
pneumovirus M genes and proteins. The percentage homology of the M ORFs (green 
boxes) and percentage identity of the proteins (grey boxes) of RSV strain RSS-2 , APV 
subgroup A isolate CVL141, APV subgroup B, APV subgroup C, hMPV isolate 001 
and PVM strain 15 were compared as described in section 2.15.  
RSVPVMhMPVAPV 
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C
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subgroup 
B
APV 
subgroup 
A
5351475048RSV
4147484948PVM
3737766968hMPV
3737876770APV 
subgroup 
C
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B
3637767684APV 
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A
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Table 1.13 Percentage nucleotide homology and amino acid identity of the 
pneumovirus NS1 and NS2 genes and proteins. The percentage homology of the 
NS1 or NS2 ORFs (green boxes) and percentage identity of the proteins (grey boxes) of 
RSV strain RSS-2 and PVM strain 15 were compared as described in section 2.15. 
PVM
RSV
NS1 homology or 
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16
PVMRSV
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44
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1.4 Virus transcription and replication 
As with other viruses with RNA genomes, the same viral polymerase complex replicates 
the vial genome and transcribes the viral mRNAs.  There is a lack of clarity as to how the 
polymerase complex switches from transcription to replication mode.  For VSV it was 
shown that the extent of terminal complementarity, rather than the terminal sequences, 
determined the levels of replication and transcription.  Replication of DI viruses with 
high complementarity was increased when compared to wildtype VSV (Wertz et al., 
1994).  For RSV the switch may involve several factors, including genome encapsidation, 
speed of processivity of the polymerase, and levels of the M2-2 accessory protein 
(Banerjee et al., 1977; Cowton et al., 2006; Lippincott et al., 2001).     
 
Purified RSV genome RNA is non-infectious and the minimal infectious unit has been 
shown to be the genome RNA together with the N, P and L proteins (Marriott and Easton, 
1999).  The key components in replication and transcription are the signalling sequences 
in the viral genome (the leader, trailer, gene start and gene end sequences), the N protein 
encapsidated negative sense RNA genome, the N protein encapsidated positive sense 
RNA antigenome, and the polymerase complex (consisting of the P and L proteins).  The 
M2-1 and M2-2 proteins are non-essential accessory proteins that may affect 
transcription and replication for some viruses.  
 
1.4.1 Virus transcription 
A model for APV transcription has been developed based on the well studied RSV, VSV 
and SeV models (reviewed in (Cowton et al., 2006))(figure 1.4).  It has been established 
that the negative sense RNA viruses carry out sequential transcription of genes with a 
single point of initiation of transcription, proceeding from the 3’ to 5’ end of the genome 
(Abraham and Banerjee, 1976; Ball and White, 1976).  Transcription by the viral 
polymerase complex of the encapsidated RNA genome produces capped, poly-adenylated 
mRNA transcripts.  These mRNAs are produced in a stop-start process, in which the viral 
polymerase complex starts transcription at the gene start (GS) sequence and transcribes 
the mRNA until it reaches the gene end (GE) sequence.  The mRNA is then 
polyadenylated, transcription is terminated, and the transcript is released (Barik, 1993).  
(A)nCap
Gene start
sequence
Gene end
sequence
Figure 1.4 Model of Paramyxovirus transcription.  In the model of Paramyxovirus 
transcription the viral polymerase complex (blue) binds to the 3’ end of the genome, begins 
transcription of the first gene at the gene start sequence and produces a capped (Cap) 
mRNA with a polyA tail ((A)n) added at the gene end sequence.  The polymerase complex 
then either scans through the intergenic region and transcribes the next gene, or 
disassociates from the genome and starts again at the 3’ end of the genome.  In this way, a 
gradient of mRNA transcripts is produced.  
(A)nCap
(A)nCap
(A)nCap
(A)nCap
(A)nCap
(A)nCap
(A)nCap
(A)nCap
(A)nCap
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The polyadenylation of the mRNA is carried out by the viral polymerase, probably via a 
mechanism of ‘reiterative transcription’ at a series of U residues (Barr and Wertz, 2001).  
How and why the polymerase stops the iteration and releases the transcript is unknown.  
However, termination of the upstream gene must occur before re-initiation of 
transcription of the downstream gene.        
 
The re-initiation of transcription of the polymerase complex at downstream gene start 
sequence is relatively inefficient.  Once the polymerase complex fails to re-initiate at the 
next available gene it disengages from the template and can only re-initiate by binding to 
the 3’ end of the genome RNA where the process begins again. The result is the 
generation of a gradient of transcription where the steepness of the gradient is determined 
by the efficiency of the re-initiation event.  Hence, the genes at the 3’ end of the genome 
are more frequently transcribed than those at the 5’ end of the genome. 
 
1.4.2 Transcriptional regulatory sequences 
When first sequenced, the discrete gene start (GS) and gene end (GE) sequences of 
parainfluenza virus type 3, a member of the Paramyxoviridae family, were said to 
“almost invite foreign gene insertions.” (Brian Murphy, quoted by Schmidt et al., 
(2004)).  Indeed, any gene flanked by the GS and GE signals can be transcribed (when 
present as negative sense RNA that is encapsidated with the viral nucleocapsid protein) 
by the viral polymerase.   
 
The GS sequences of the pneumovirus subfamily are highly conserved sequences of nine 
to thirteen bases (table 1.14).  Each gene of APV subtype A has a GS sequence of    5’ 
GGGACAAGU 3’ (mRNA sense), apart from the L gene that has a GS sequence of  5’ 
AGGACCAAU 3’ (mRNA sense).  The genes of RSV strain RSS-2 have a consensus GS 
sequence of 5’ GGGGCAAAUA 3’ (mRNA sense) that is found upstream of each gene 
apart from the M2 and L genes. PVM stain 15 and hMPV isolate 001 have more variation 
in their GS sequences, but a nine or thirteen base (respectively) sequence is found before 
each gene with no more than three deviations from the consensus sequence.  
 
AGGAyAArUGGGGCAAAUAGGGACAArUAAAAGGGACAAGUconsensus
AGGAUCAAUGGGACAAAAUGGAGACAAAUAACAAGGACCAAUL 
AGGAUGAGUGGGGCAAAUAGGGACAAGUAGUUGGGACAAGUG 
AGGACAAAUGGGGCAAAUAGGGAUAAAUGACAGGGACAAGUSH 
AGGAUAAGUGGGGCAAAUGGGGACAAAUCAUAGGGACAAGUM2 
AGGAUAAAUGGGGCAAAUAGGGACAAAUAAAAGGGACAAGUF 
AGGACAAAUGGGGCAAAUAGGGACAAGUAAAAGGGACAAGUM 
AGGAUAAAUGGGGCAAAUAGGGACAAGUCAAAGGGACAAGUP 
AGGAUAAAUGGGGCAAAUAGGGACAAGUGAAAGGGACAAGUN 
AGGACAAGUGGGGCAAAUAN/AN/ANS2
AGGACAAGUGGGGCAAAUAN/AN/ANS1
PVMRSVhMPVAPV
GS 
sequence
Table 1.14 Pneumovirus gene start (GS) sequences. The source of the sequences by Genbank 
number is detailed in section 2.15.  The non-consensus bases are indicated in bold and in blue.  
‘r’ indicates a purine at this position and ‘y’ indicates a pyrimidine. All sequences are shown 5’
to 3’ mRNA sense.
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For APV, hMPV and RSV, the GS sequences have a series of three G residues at the 5’ 
end (mRNA sense) and are A/G rich.  The first seven bases of the metapneumoviruses 
APV and hMPV GS consensus sequences match exactly, although the pneumoviruses 
PVM and RSV GS sequences have no such degree of conservation.  Mutational analysis 
of the APV GS sequence was carried out and it was shown that any mutation was 
detrimental to transcription, apart from a change of the C at position 5 to a U (Edworthy 
and Easton, 2005).  Kuo et al. (1997) carried out mutational analysis of the RSV GS 
sequence, showing that mutations at positions 1, 3, 6, 7 and 9 resulted in loss of 
expression from the associated gene, whereas mutations to position 5 were well tolerated.  
Interestingly, the RSV vaccine strain candidate cpts248/404 has been shown to have a 
mutation at position 9 (U to C, mRNA sense) of the M2 GS sequence and this mutation 
alone causes virus attenuation in mice (Whitehead et al., 1998).  Taken together, this 
suggests that mutations in GS sequence mutations may attenuate virus in vivo via down 
regulation of viral genes. 
 
The GE sequences of the pneumovirus subfamily are less well conserved than the GS 
sequences (table 1.15), but are functionally important.  For example, for RSV, the GS and 
GE signals of clinical isolates of RSV were compared and, while the GS sequences were 
conserved, the GE sequences varied.  It was speculated changes in the GE sequence of 
the G gene down-regulated F protein expression (Moudy et al., 2003; Wertz and Moudy, 
2004).  Indeed, it has been shown that the GE sequence is necessary to terminate mRNA 
transcription and allow re-initiation at the downstream GS sequence. Loss of the GE 
sequence results in a high level of read-through mRNAs being produced and these read-
through mRNAs do not produce protein efficiently from the second ORF (Kuo et al., 
1996b).       
        
The nucleotides between the GE sequence of one gene and the GS sequence of the next 
gene are termed the intergenic region nucleotides.  For RSV, there is little variation in the 
levels of polymerase that scan through the region although the length of this region varies 
from 1 to 53 nucleotides, (table 1.16)(Kuo et al., 1996a).  The substitution of foreign 
sequence into the intergenic region of RSV had no effect on transcription,  
U
A
G
U
U
A
A
 (n
) 1-
2
(A
) n
U
A
G
U
U
A
 (n
) 2
-4
(A
) n
A
G
U
U
 (n
) 3
-4
 (A
) n
A
G
U
 (n
) 2
-5
 (A
) n
co
ns
en
su
s
U
A
G
U
U
A
A
 C
 A
A
A
A
A
A
U
A
G
U
U
A
 U
U
 A
A
A
A
A
A
G
U
U
 A
A
U
U
 A
A
A
A
A
A
G
U
 U
A
A
U
 A
A
A
A
A
L 
U
A
G
U
U
A
U
A
U
 A
A
A
A
A
A
A
U
A
G
U
U
A
 U
U
U
 A
A
A
A
A
G
U
U
 A
A
C
 A
A
A
A
A
A
A
U
A
 A
U
 A
A
A
A
A
A
A
G
 
U
A
G
U
U
A
A
 U
U
 A
A
A
A
A
U
A
G
U
U
A
 U
A
U
 A
A
A
A
A
G
U
U
 A
U
U
U
 A
A
A
A
A
A
U
U
 U
A
A
U
U
 A
A
A
A
A
SH
 
U
A
G
U
U
A
A
 U
G
 A
A
A
A
U
A
G
U
C
A
 U
U
 A
A
A
A
A
A
G
U
U
 A
G
U
 A
A
A
A
A
A
G
U
 U
A
A
U
U
 A
A
A
A
M
2 
U
A
G
U
U
A
A
 C
 A
A
A
A
A
A
U
A
G
U
U
A
 A
U
U
 A
A
A
A
A
A
G
U
U
 A
A
U
U
 A
A
A
A
A
A
G
U
 U
A
U
U
U
 A
A
A
A
F 
U
A
G
U
U
A
A
 A
U
 A
A
A
A
A
A
G
U
U
A
 A
U
 A
A
A
A
A
A
G
U
U
 A
U
A
U
 A
A
A
A
A
A
G
U
 C
A
A
U
 A
A
A
A
A
A
M
 
U
A
G
U
U
A
A
 U
U
 A
A
A
A
G
A
G
U
U
A
 A
U
 A
A
A
A
A
A
A
A
G
U
U
 U
A
A
U
 A
A
A
A
A
A
G
U
 U
A
U
G
 A
A
A
A
A
A
P 
U
A
U
U
U
A
A
 U
U
 A
A
A
A
G
A
G
U
U
A
 A
U
 A
A
A
A
A
A
A
A
G
U
A
A
U
U
 A
A
A
A
A
A
A
G
U
 A
A
U
U
 A
A
A
A
A
A
N
 
U
A
G
U
U
A
U
A
G
 A
A
A
A
A
U
A
G
U
A
A
 U
U
U
 A
A
A
A
N
/A
N
/A
N
S2
U
A
G
U
U
A
A
 U
U
 A
A
A
A
U
A
G
U
U
A
 A
U
A
U
 A
A
A
A
N
/A
N
/A
N
S1
PV
M
R
SV
hM
PV
A
PV
G
E
 se
qu
en
ce
T
ab
le
 1
.1
5 
Pn
eu
m
ov
ir
us
 g
en
e 
en
d 
(G
E
) s
eq
ue
nc
es
. T
he
 so
ur
ce
 o
f t
he
 se
qu
en
ce
s b
y 
G
en
ba
nk
 n
um
be
r i
s d
et
ai
le
d 
in
 se
ct
io
n 
2.
15
. T
he
 
no
n-
co
ns
en
su
s b
as
es
 a
re
 in
di
ca
te
d 
in
 b
ol
d 
an
d 
in
 b
lu
e.
  ‘
r’
in
di
ca
te
s a
 p
ur
in
e 
at
 th
is
 p
os
iti
on
 a
nd
 ‘y
’i
nd
ic
at
es
 a
 p
yr
im
id
in
e.
 A
ll 
se
qu
en
ce
s 
ar
e 
sh
ow
n 
5’
to
 3
’m
R
N
A
 se
ns
e.
 
35
4645F-M2
1753G-F61260G-L 
244SH-G 1268SH-G 
129M-SH1129M2-SH 
113P-M 412F-M2 
111N-P 342M-F 
426NS1-N 81P-M 
819NS1-NS223N-P 
PVMRSVIR lengthhMPVAPVIR length
Table 1.16 Pneumovirus intergenic region lengths in nucleotides.  The number of 
nucleotides found between the GE and GS sequences of the genes of the pneumoviruses is 
shown.  The source of the sequences by Genbank number is detailed in section 2.15. 
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suggesting that there is a great degree of tolerance of sequence variation in these regions 
of the genome (Kuo et al., 1996a).  The intergenic regions of APV, hMPV and PVM are 
similarly divergent, ranging from 1 to 60 nucleotides for APV, 2 to 189 nucleotides for 
hMPV, and 2 to 56 nucleotides for PVM (table 1.17).     
 
Looking specifically at the Le sequence and initiation of transcription at the 3’ end of the 
genome, two models have been proposed.  The first, supported by work done on SeV and 
other paramyxoviruses, suggests that the viral polymerase complex initiates transcription 
at the 3’ end of the genome, transcribing until the polymerase complex recognizes the 
first GS sequence and then releasing a short leader RNA before beginning transcription 
of the first gene.  The second model, supported by work done on VSV and other 
rhabdoviruses, proposes that the polymerase complex initiates transcription directly at the 
GS sequence, without producing an mRNA from the leader region.  A consistent feature 
of both models is that there are regions of leader sequence that are required for 
transcription and that the polymerase complex binding sequence is contained within the 
first 11 nucleotides of the leader region (Cowton et al., 2006).          
 
1.4.3 Virus replication 
The model for replication of the negative sense RNA virus genome (figure 1.5) utilizes 
the same viral polymerase complex as is used for viral transcription.  However, during 
replication, when the polymerase binds to the 3’ terminus leader region of the genome, 
the polymerase commences transcription of the genome immediately and fails to 
recognize any of the transcription signals.  In this way, an ‘antigenome’ copy of the 
genome is created and immediately encapsidated with N protein (Cowton et al., 2006).  
This antigenome has been shown to be a necessary intermediate to genome replication, as 
the template from which new genomes can be copied (reviewed in (Banerjee et al., 
1977)).   
     
1.4.4 Replication regulatory sequences  
For replication, the extreme 5’ and 3’ terminal sequences contain the signals to direct the 
polymerase complex to replicate the genome.  At the 3’ end of the genome, the leader  
5’ 3’Antigenome RNA
Genomic RNA
3’ 5’
Leader
region
Trailer
region
Figure 1.5 Model of Paramyxovirus replication.  In the model of Paramyxovirus 
genome replication, the viral polymerase complex bind at the 3’ end of the 
genomic RNA and transcribes to the 5’ end, producing an antigenome RNA.  The 
polymerase complex then bind to the 3’ end of the antigenome RNA and 
transcribes a copy of the genomic RNA.  
3’ 5’
Genomic RNA
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Table 1.17 Nucleotide homologies of the pneumovirus Le and Tr 
sequences.  The percentage nucleotide homologies of the Le sequences (blue 
boxes) and Tr sequences (green boxes) of RSV strain RSS-2 , APV subgroup 
A isolate CVL141, hMPV isolate 001 and PVM strain 15 were compared as 
described in section 2.15. 
100325016RSV
691003513PVM
282110022hMPV
535341100APV
RSVPVMhMPVAPVPercentage 
homology 
(%)
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(Le) sequence extends from base 1 to the GS sequence of the first gene.  At the 5’ end of 
the genome, the trailer (Tr) sequence extends from the end of the L gene GE sequence to 
the end of the genome.  As with the GS and GE sequences, these regulatory regions are 
able to direct replication of any sequence they flank.  For the pneumovirus subfamily, the 
Le sequences are most highly conserved between PVM and RSV (69% nucleotide 
identity, table 1.17), but APV, PVM and RSV all have regions of high conservation at the 
ends of the Le region.  The first 11 bases for all three viruses are identical apart from the 
fourth base and a second region of five A nucleotides is conserved for all four viruses at 
the 5’ end of the Le region.  For the Tr regions, there is no more than 50% nucleotide 
identity between any of the pneumoviruses (table 1.17), however the last 12 nucleotides 
are conserved for all four viruses apart from one base in PVM.  This suggests a very well 
conserved process of replication for the various pneumoviruses.      
 
1.5 Reverse genetics systems  
The term ‘reverse genetics systems’ for negative sense RNA viruses refers to systems of 
introducing mutations into the viral genome and determining the resulting phenotype.  In 
order to be able to manipulate the RNA genome of RNA viruses, it is first necessary to 
‘convert’ it into a DNA copy that produces the RNA genome in the presence of a DNA 
dependent-RNA polymerase.  There are three reverse genetics systems- the helper virus 
system, the plasmid rescue system and the full-length rescue system (Theriault et al., 
2004).   
 
The full-length rescue system aims to produce virus entirely from cDNA in vitro.  The 
requirements for the system are a DNA genome plasmid, a DNA dependent RNA 
polymerase, the viral nucleocapsid and polymerase proteins and any additional helper 
proteins (figure 1.6).  This system has been developed for RSV and hMPV (Bukreyev et 
al., 1997; Herfst et al., 2004).  Firstly a method for creating the RNA genome from the 
cDNA clone was required.  By cloning the genome under the control of a T7 DNA 
dependent RNA polymerase promoter, transcription resulted in a copy of the antigenome 
RNA being produced in the cytoplasm of the cell.  The T7 DNA dependent RNA 
polymerase can be provided either by a recombinant vaccinia virus expressing T7 DNA  
M2-1
VVT7
Genome
plasmid
T7 Pro
N
P
L
Assay of 
infectious 
virus
T7 RNA pol
T7 RNA pol
Figure 1.6 Model of the negative sense RNA virus full length rescue system.  The 
components required to create a reverse genetics system for a negative sense RNA viruses 
are show here.  VVT7 (A) is an engineered vaccinia virus used to constitutively express T7 
DNA dependent RNA polymerase (T7 RNA pol) in infected HEp2 cells (B). These cells 
are then transfected with a genome plasmid (C) under the control of a T7 polymerase 
promoter (T7 Pro) that produces an RNA copy of the antigenome upon transcription by the 
T7 RNA polymerase, which is then terminated using a hepatitis ribozyme.  Simultaneously, 
the cells are transfected with expression plasmids for the helper proteins (D).  For RSV, 
these are the N, P, L and M2-1 proteins.  These cells then have all the components 
necessary to form RNP complexes, transcribe and replicate the genome (E).  Transcription 
and replication of the cloned RNA genome result in the production of infectious virus 
which can be assayed (F).
A
C
B
D
E
F
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dependent RNA polymerase (Fuerst et al., 1986) or by using BSR-T7 cells that have been 
engineered to express T7 DNA dependent RNA polymerase (Buchholz et al., 1999). With 
the T7 polymerase present in the cells, expression plasmids for the N, P and L proteins 
(under the control of a T7 promoter) were transfected into cells to provide the helper 
proteins in the cytoplasm of the cell.  In this way, the anti-genome RNA, and the N, P, L 
and M2-1 proteins are able to form a functional unit and the synthetic genome is 
replicated and transcribed.  By using the T7 polymerase, these RNA transcribed in the 
cytoplasm as is seen in natural pneumovirus infection, rather than in the nucleus.  When 
the entire virus genome is used, infectious virus is produced and can be assayed.   
 
This system has the advantage of producing infectious virus that can be assayed in vitro 
and in vivo.  The effect of mutations to the viral genome can be assessed in terms of viral 
fitness, RNA production, and tissue tropism.  However, pneumovirus genomes are 13 to 
16kb and cDNAs are technically difficult to create and manipulate.  Hence historically 
before the creation of a full-length rescue system, a minigenome was used to determine 
the minimal requirements for viral replication and transcription.  This minigenome was 
used to establish helper virus and plasmid rescue systems, as described below.     
 
In the plasmid rescue system, a simpler synthetic ‘minigenome’ (figure 1.7) is used in 
place of the full-length genome clone.  A minigenome has a reporter gene inserted 
between the viral replication and transcription signals and the reporter protein expression 
can be used as a measure of RNP complex function.  This is termed a plasmid rescue 
system (figure 1.8) and has advantages and disadvantages compared to the full-length 
rescue system.  In the plasmid rescue system no virus is produced, whereas full-length 
system produces infectious virus.  However, the plasmid rescue system allows 
manipulation of not only the cis-acting non-translated genome sequences but also of 
the helper proteins.   
       
The helper virus rescue system uses infectious virus to provide the trans-acting proteins 
to replicate and transcribe the minigenome in vitro (figure 1.9).  The difference between 
the helper virus system and the plasmid rescue system is that in the former the helper 
Figure 1.7 Schematic of the APV minigenome and dicistronic minigenome 
constructs. For the minigenome (A), the gene end (GE) signal (5’ UAGUUAAUU 3’, 
mRNA sense), gene start (GS) signal (5’ GGGACAAGU 3’, mRNA sense), leader (Le) 
sequence and trailer (Tr) sequence were cloned flanking the CAT (chloramphenical
acetyl transferase) reporter gene under the control of the T7 RNA polymerase promoter 
(T7) in the pt7.2 plasmid.  The RNA fragment resulting from transcription by the T7 
RNA polymerase and the hepatitis delta virus ribozyme sequence (δ) creates the exact 
viral Le sequence by self cleaving (indicated with the blue arrow).  For the dicistronic 
minigenome (B), an addition reporter gene was added, a luciferase gene.  The APV 
minigenomes were provided by Dr. J. Smith (Marriott et al., 2001).  
T7GS GELe TrCATδ
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Figure 1.8 Model of the negative sense RNA virus plasmid rescue system.  The 
components required to create a reverse genetics system for a negative sense RNA viruses 
are show here.  VVT7 (A) is an engineered vaccinia virus used to constitutively express T7 
DNA dependent RNA polymerase (T7 RNA pol) in infected HEp2 (B) cells.  These cells 
are then transfected with a minigenome plasmid (C) under the control of a T7 polymerase 
promoter (T7 Pro) that produces an RNA copy of the anti-minigenome upon transcription 
by the T7 RNA polymerase, which is then terminated using a hepatitis ribozyme.  
Simultaneously, the cells are transfected with expression plasmids for the helper proteins 
(D).  For RSV, these are the N, P, L and M2-1 proteins.  These cells then have all the 
components necessary to form RNP complexes, transcribe and replicate the genome (E). 
Transcription of the minigenome produces reporter mRNA which, after translated by the 
cell, produces reporter protein  (F).
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Figure 1.9 Model of the negative sense RNA helper virus rescue system.  The 
components required to create a helper virus reverse genetics system for a negative sense 
RNA viruses are show here.  Recombinant BSR-T7 cells (A) are engineered to 
constitutively express T7 DNA dependent RNA polymerase (T7 RNA pol).  These cells 
are then transfected with a minigenome plasmid (B) under the control of a T7 polymerase 
promoter (T7 Pro) that produces an RNA copy of the anti-minigenome upon transcription 
by the T7 RNA polymerase, which is then terminated using a hepatitis ribozyme.  
Simultaneously, the cells are infected with wildtype virus which provides the N, P, L and 
M2-1 helper proteins (C).  These cells then have all the components necessary to form 
RNP complexes, transcribe and replicate the genome (D).  Transcription of the 
minigenome produces reporter mRNA which is then translated by the cell to produce 
reporter protein  (E).
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proteins are provided by infection with ‘helper’ virus and in the latter the helper proteins 
are provided from transfected expression plasmids.  Helper virus rescue and plasmid 
rescue have been used to establish the minimal cis-acting requirements in the viral 
genome to direct transcription and replication.  Helper virus rescue uses live virus and 
can differ from the virus-free systems in its sensitivity to mutations (Fearns et al., 2000; 
Marriott et al., 2001).  From a technical stand point, this technique requires the least 
amount of cloning before experiments can be attempted and hence historically has been 
the first system established for a virus.   
 
The drive for the development of a reverse genetics system for negative sense RNA 
viruses is two-fold.  The creation a virus entirely from cDNA is an excellent tool for 
primary research on virus function, as it allows direct manipulation of the genome using 
standard DNA cloning techniques and hence point mutations, insertions, deletions and 
rearrangements can be introduced and the effects assessed.  The results of this process are 
'rationally designed' viruses that are ideal for vaccination. They can be created to be 
multivalent, safe, effective, and unlikely to revert to virulence.    
 
1.6 Aims 
The aims of this project were to firstly develop the APV plasmid based reverse genetics 
system and then to use the APV reverse genetics systems to: 
- investigate viral protein functions 
- investigate intergenic region mutations 
- quantify RNA levels of gene start sequence mutants 
- create a eGFP tagged APV virus cloned entirely from cDNA in order to 
investigate viral tropism in vitro and in vivo. 
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Chapter 2: 
Materials and Methods 
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2.1 Solutions and buffers 
All chemicals described were of AnalaR grade and supplied by Sigma-Aldrich Co. Ltd. 
or BDH unless otherwise stated.  
 
Glyoxal running buffer pH 7: 10mM NaPO4 buffer, made by combining 5mM NaH2PO4 
and 5mM Na2HPO4 at a ratio (v:v) of 39:61 and adjusted to pH 7 using NaOH or H3PO4 
as necessary. 
 
Hybridization buffer: 50% formamide, 5X SSC, 5X Denhardt’s solution (Sambrook et 
al., 1989), 0.5% SDS, 50µg/ml torula yeast RNA, 0.1mg/ml boiled salmon sperm DNA.  
 
Loading dye (6X): 0.25% bromophenol blue, 0.25% xylene cyanol FF and 30% (w/v) 
glycerol.  
MOPS buffer (X10) pH 7: 0.2M MOPS (3-(N-Morpholino)propanesulfonic acid), 50mM 
anhydrous sodium acetate (NaOAc), 10mM ethylenediamine tetraacetic acid (EDTA). 
 
Phenol/chloroform: A mixture of equal volumes of TE saturated phenol and chloroform.  
 
Phosphate buffered saline (PBS), pH 7.4: 136mM NaCl, 2.7mM KCl, 1.3mM KH2PO4, 
1.4mM Na2HPO4.  
 
SSC (X20) pH 7: 3M NaCl, 0.3M sodium citrate (Na3C6H5O7). 
  
SSPE buffer (X20) pH 7.4: 3M NaCl, 0.2M sodium dihydrogen phosphate (NaH2PO4), 
20mM EDTA. 
 
TAE (50X): 2M Tris, 0.05M EDTA (pH 8.0), 1M acetic acid. 
 
TBE (10X) pH 8.1-8.5: 0.89M Tris, 0.89M Boric acid, 25mM EDTA.  
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TfbI ph 5.8: 30mM Potassium acetate, 100mM rubidium chloride, 10mM calcium 
chloride, 50mM manganese chloride, 15% v/v glycerol, pH adjusted with 0.2M filter 
sterilized acetic acid. 
 
TfbII ph 6.5: 10mM MOPS, 75mM calcium chloride, 10mM rubidium chloride, 15% 
glycerol, pH adjusted with 1.0M filter sterilized potasium hydroxide. 
Tris-EDTA (TE) solution: 10mM Tris (pH 7.5), 1mM EDTA. 
Tris-HCL buffer: Tris (tris(hydroxymethyl)aminomethane), pH adjusted with 10M HCl. 
 
Trypsin: 0.25% (w/v) in PBS pH 7.4 and stored at -20 C.  
 
Versene: 0.002% (w/v) EDTA (disodium salt) and 0.002% (w/v) phenol red. 
 
2.2. Media 
GMEM-NEAA: Glasgow's minimal essential medium supplemented with non-essential 
amino acids and 0.2mM glutamine.  
 
LB (Luria Bertani) medium: 10g/L Bacto tryptone, 5g/L yeast extract and 10g/L NaCl. 
For LB agar, 15g/L of bacto-agar was added. The medium was sterilized by autoclaving 
at 121˚C for 20min.  
 
MEMH: Eagle's minimal essential medium supplemented with 20 mM Hepes/NaOH, pH 
7.2, lacking bicarbonate. 
 
SOB (Super Optimal Broth) medium: 20g/L Bacto tryptone, 5g/L yeast extract, 0.5g/L 
NaCL, 2.5mM KCL (pH 7.0). The medium was sterilized by autoclaving at 121ºC for 
20min. The solution was cooled before the addition of 5ml/L of sterile 2M MgCl2.  
 
SOC medium: SOB medium supplemented with glucose (final concentration 20mM).   
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2.3 Mammalian tissue culture- maintenance of cell lines 
2.3.1 Vero, BSC-1, and HEp-2 cells 
BSC-1, Vero, and HEp2 cells were grown at 37˚C in GMEM-NEAA supplemented with 
either 5% (BSC-1 and Vero cells) or 10% (HEp-2 cells) (v/v) foetal calf serum (FCS).  
Cells were grown at 37˚C in an atmosphere of 5% (v/v) CO2 and passaged when the 
monolayers reached confluence. The cell monolayer was separated from the surface of 
the tissue culture flask by washing briefly with versene solution, adding a mixture of 
versene and trypsin (1:1), and incubation at 37˚C until the cells began to detach. The cell 
suspension was pipetted briefly and a proportion of the cells were resuspended in fresh 
medium, placed in a new flask and returned to an incubator at 37˚C. 
 
2.3.2 BSR-T7 cells 
BSR-T7 cells are BSC-1 cells permanently transformed with a plasmid that constitutively 
expresses bacteriophage T7 DNA dependent RNA polymerase (Buchholz et al., 1999).  
The plasmid was maintained by antibiotic selection with antibiotic G-418 sulphate 
(Promega).  The cell line was kindly provided by Professor K.-K. Conzelmann.  Cells 
were maintained in GMEM-NEAA with10% FCS, 0.2mM glutamine, and 100 units/ml 
penicillin and 100µg/ml of streptomycin added.  1µg/ml of antibiotic G-418 sulphate was 
added every other cell passage. Cells were passed in the same way as described above.  
 
2.4 Bacterial cultures 
2.4.1 Growth of E. coli 
Transformed E. coli (XL1-Blue or DH5α strain) was plated out onto LB agar plates 
containing 100µg/ml ampicillin and grown at 37ºC to obtain single colonies.  One colony 
was then picked and grown up at 37ºC or 30ºC for 8 to 16hr in 5 ml LB medium 
supplemented with 100µg/ml ampicillin.  For larger cultures, 100 ml of LB with 
100µg/ml ampicillin was inoculated with 100µl of a culture grown overnight.      
  
2.4.2 Frozen competent bacteria 
Frozen competent E. coli stocks were generated by adding 1ml of a 5ml culture grown 
from a single colony for 16 hr, to 100ml of warmed LB medium.  Bacteria were grown to 
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an OD600 of 0.39 in a 250ml conical flask at 37˚C with shaking.  Bacteria were then 
chilled on ice for 5min.  Once chilled, the bacteria were pelleted at 2000rpm for 15min at 
4˚C and resuspended in 40ml TfbI buffer.  After chilling on ice for 1hr, the bacteria were 
pelleted as before and resuspended in 4ml TfbII buffer.  After chilling on ice for 2 to 5hr, 
100µl aliquots were snap frozen in liquid nitrogen and stored at -70˚C.  All solutions 
were kept cold and chilled pipettes were used (Dr. P. Gould, personal communication).    
 
2.5 Standard cloning procedures 
2.5.1 Reverse transcription-PCR 
Reverse transcription-PCR (RT-PCR) reactions were carried out using RevertAid™ H 
Minus M-MuLV Reverse Transcriptase (MBI Fermentas) following the manufacturer’s 
instructions. 
 
2.5.2 PCR 
Polymerase chain reactions (PCR) were carried following the individual manufacturer’s 
instructions.  The three most commonly used polymerases were Pfu Turbo DNA 
Polyerase (Stratagene), Elongase Polymerase Mix (Life Technologies) and Pwo DNA 
Polymerase (Roche Applied Science).   
 
A typical Pfu Turbo DNA Polymerase reaction was carried out as follows: 
 
5µl 10X Pfu buffer 
0.4µl dNTP mix (100mM) 
DNA (0.01µg to 1ug) 
10µl forward primer (10pmol/µl) 
10µl reverse primer (10pmol/µl) 
1µl Pfu Turbo DNA Polymerase 
Sterile distilled water (SDW) to 50µl total volume 
 
The solution was then heated for one cycle to 95˚C for 2min; followed by 30 cycles of 
30sec at 95˚C, 30sec at 45˚C and 1min at 72˚C; and one cycle of 10min at 72˚C. 
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A typical Elongase Polymerase Mix reaction was carried out as follows: 
 
Mixture A      Mixture B 
1µl dNTP (10mM)    2µl buffer A 
1µl forward primer (10pmol/µl)  8µl buffer B 
1µl reverse primer (10pmol/µl)  1µl Elongase DNA Polymerase 
DNA (0.01µg to 1ug)    19µl SDW  
SDW to 20µl total volume 
 
Mixtures A and B were combined on ice in pre-chilled PCR eppendorf tubes.  The mix 
was then subjected to PCR consisting of one cycle of 30sec at 94˚C; followed by 30 
cycles of 30sec at 94˚C, 30sec at 50 to 60˚C and 1min at 68˚C; and one cycle of 10min at 
68˚C. 
 
A typical Pwo DNA Polymerase reaction was carried out as follows: 
 
DNA (0.01µg to 1ug) 
0.5µl Pwo DNA polymerase  
2µl forward primer (10pmol/µl) 
2µl reverse primer (10pmol/µl) 
1µl 10X buffer + Mg 
1µl dNTPs (10mM) 
SDW to 50µl total volume  
 
The mix was then subjected to PCR consisting of one cycle of 2min at 94˚C; 30 cycles of 
30sec at 94˚C, 30sec at 60˚C and 1min at 72˚C; and one cycle of 7min at 72˚C. 
 
2.5.3 DNA purification 
2.5.3.1 Gel extraction 
Fragments of DNA were separated on agarose gels and excised using a clean razor blade. 
The DNA was extracted from these gel slices by the use of a QIAquick Gel Extraction 
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Kit (Qiagen) according to the manufacturer’s instructions and the DNA was eluted into 
30 to 50ul of SDW.  Care was taken to expose the DNA to as little UV as possible, 
especially plasmids that were larger than 10kb. 
 
2.5.3.2 Phenol/chloroform extraction 
To purify DNA without gel extraction or the use of a kit, an equal volume of buffer-
saturated phenol: chloroform (1:1) was added to the DNA solution.  After mixing well 
(vortexed for 10sec, except for high molecular weight DNA which were gently rocked), 
the solution was centrifuged for 2 to 3min at 13,000rpm.  The aqueous layer was then 
carefully removed to a new tube, being careful to avoid the interface.  The above process 
was repeated until an interface is no longer visible.  Where necessary, an equal volume of 
EB was added to the phenol/chloroform to remove any remaining DNA, followed by 
mixing, centrifuging and removal of the aqueous layer as before.   
 
2.5.3.3 Ethanol precipitation 
To purify DNA out of a solution, the volume of the DNA sample was measured and the 
salt concentration adjusted by adding 1/10 volume of 3M sodium acetate, pH 5.2.  The 
solution was mixed well and 2 to 2.5 volumes of cold 100% ethanol (calculated after salt 
addition) added. The solution was mix well and placed on ice or at -20ºC for >20 min.  
The solution was then centrifuged at 13,000rpm for 10 to 15min and the supernatant was 
carefully decanted.  1ml of 70% ethanol was added, the solution mixed, and centrifuged 
briefly.  The supernatant was carefully decanted and air dried at 37°C for 10min.  The 
pellet was then resuspended in an appropriate volume of SDW.  
 
2.5.3.4 PCR product fragment purification 
Purification of DNA which did not require gel extraction was also carried out using the 
QIAquick gel extraction kit PCR purification protocol and buffer PB (Qiagen). 
 
2.5.4 Agarose gel electrophoresis 
Purified plasmid DNA, the results of restriction enzyme digests, and PCR products were 
all routinely analyzed by agarose gel electrophoresis. The percentage agarose was 
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determined by the size of the DNA fragments to be differentiated, but usually ranged 
between 0.5 % (w/v) to 1.5 % (w/v) agarose. Agarose was melted in 1X TBE buffer to 
give the appropriate concentration and allowed to cool prior to the addition of a 10mg/ml 
solution of ethidium bromide to give a final concentration of 1µg/ml. Samples containing 
loading dye were subjected to electrophoresis at 180 to 100V until the DNA fragments 
being analyzed had migrated sufficiently to be separated.  The DNA fragments were 
visualized on a UV transilluminator (UV products Inc.).  
 
2.5.5 Urea acrylamide gel electrophoresis 
RNA fragments were purified by urea gel electrophoresis.  The gel was made from 2.5ml 
of 20% acrylamide in 7M urea/1X TBE solution, 9.6ml of 7M urea in 1X TBE, 26.2µl of 
25% APS (Ammonium Persulfate, Sigma) and 11.8µl of TEMED (N,N,N,N -
Tetramethyl-Ethylenediamine, Sigma).  TBE buffer (X1) was used as the running buffer.  
Prior to loading on the gel, the RNA samples were prepared by adding an equal volume 
of loading buffer (RPA kit III, Ambion).  The samples were incubated at 95ºC for 3min 
and loaded onto the gel.  The gel was electrophoresed using a Bio-Rad tank for 
approximately 3hr at 50V.  The RNA in the gel was visualized under UV light     
 
2.5.6 Enzyme digestions 
DNA was digested following the manufacturer’s instructions with restriction 
endonucleases (NEB, Fermentas, or Invitrogen).  The typical volumes of DNA used 
when the concentration was unknown were 10µl of product from alkaline lysis small 
scale DNA preparations and 1µl for DNA from Qiagen Plasmid Mini Kits (Qiagen) and 
GenElute™ Plasmid Mini Kits (Sigma) unless otherwise stated.    
 
2.5.7 Ligations  
DNA was ligated using T4 DNA Ligase (Fermentas) using as close to a ratio (w:w) of 1:3 
vector to insertion fragment DNA as possible, using the manufacturer’s instructions.  
Ligations were carried out for 12 to 16hr at 16ºC or for 48hr at 4ºC.    
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2.5.8 Transformation of bacteria 
Transformation of competent E. coli with DNA was carried out as follows.  200µl 
aliquots of competent bacteria were thawed on ice and 100µl of the bacteria was 
incubated with 10µl of DNA mix for 30 min, on ice.  The samples were transferred to 
42ºC for 30sec and then chilled on ice for 2 min.  900µl of LB medium was added and 
the samples were shaken for at least 45min at 37º C.  50 to 200µl of the suspension was 
then spread on LB agar plates supplemented with 100µg/ml ampicillin and incubated at 
37ºC overnight.  
 
2.5.9 Small scale DNA preparations 
2.5.9.1 Mini-preparations of DNA 
For plasmid DNA pure enough for sequencing reactions to be carried out, either 
QIAGEN Plasmid Mini Kits (Qiagen) or GenElute™ Plasmid Miniprep Kits (Sigma) 
were used.  Aliquots (1 to 5ml) of transformed bacteria in LB medium containing the 
appropriate antibiotics were allowed to grow for 12 to 16hr at 37ºC or 30˚C and the 
plasmid DNA was then purified from it following the manufacturer’s instructions 
 
2.5.9.2 Alkaline lysis 
To screen large numbers of transformed colonies, an alkaline lysis method was utilized as 
detailed in Sambrook et al. (1989) which is a modification of the methods of Birnboim 
(1979) and Ish-Horowicz (1981).  1.5 ml of culture was used, and a phenol chloroform 
purification step was included prior to ethanol precipitation of the DNA.   
 
2.5.10 Large scale DNA preparations 
For large scale preparations, 100 to 400ml of LB medium containing 100µg/ml ampicillin 
was inoculated with transformed E. coli and grown overnight at 37ºC.  The DNA was 
purified using either QIAGEN Plasmid Maxi Kits (Qiagen) or GenElute™ HP Plasmid 
Kits (Sigma) following the manufacturer’s instructions.  The DNA was then dissolved in 
500ul to 3ml sterile distilled water. The concentration of these DNA preparations was 
then determined using a NanoDropTM Spectrophotometer (Thermo Scientific).  
Measurements were taken in duplicate. 
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For low copy number vectors or large plasmids, one colony was picked from a plate and 
added to 2ml LB containing 100µg/ml ampicillin.  The solution was shaken at 30˚C for 
24hr and then all of the mixture added to 400ml LB with containing 100µg/ml ampicillin.  
This was again left to shake at 30˚C, for at least 24hr.  The Sigma maxi prep was then 
used as per manufacturer’s instructions, except that the DNA was eluted with 3ml 70˚C 
EB by centrifuging at 4000rpm for 5 min.  The DNA was then further concentrated by 
EtOH precipitation (section 2.5.3.3) and dissolved in 52µl SDW  
    
2.6 Introduction of site-specific mutations into plasmid DNA 
2.6.1 Modified QuickChange PCR method 
The standard method for introducing mutations into plasmid DNA was by mutagenic 
PCR.  This was used to introduce insertions, deletions or point mutations into plasmid 
DNA and is a modification of the QuikChange® Site-Directed Mutagenesis Kit 
(Stratagen) protocol.  PCR was carried out on 5µl template DNA (0.1µg/µl) combined 
with 1µl forward primer (5.5pmol/µl), 1µl reverse primer (5.5pmol/µl), 1µl dNTP 
(10mM), 5µl 10X PCR buffer, 1µl Pfu turbo (Stratagene) and 37µl SDW.  The solution 
was heated in a PCR block for one cycle at 80˚C for 2min, one cycle at 94˚C for 30sec, 
18 cycles of 94˚C for 30sec followed by 55˚C for 60sec and 68˚C for 30 min.  The PCR 
product was digested with either 2µl Dnp1 (Stratagene) at 37˚C for 8hr or 1µl at 37˚C for 
16 hr.  The enzyme then was inactivated by heating the solution to 75˚C for 15min.  The 
resulting DNA was transformed into BL21-AI One Shot® Chemically Competent E. coli 
(Invitrogen) by adding 3µl of product to one vial of bacteria, incubating for 30min on ice, 
heating to 42˚C for 30sec, and then cooling on ice for 2min.  250µl SOC media 
(Invitrogen) was added to each vial and the vials were incubated at 37˚C for 
approximately 1hr while being shaken at 225rpm.  An aliquot (150µl) of this media was 
spread onto an LB plate with the appropriate antibiotics and incubated at 30˚C for 2 days 
(Clive Naylor, personal communication). 
 
2.6.2 Quick screen method 
Screening of the DNA from the resulting colonies was carried out using the following 
modified DNA mini preparation method (Dr. R. Ling, personal communication).  Here, 
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4.5ml of a 5ml over night culture was centrifuged for 10min at approximately 3000rpm.  
The supernatant was removed and the pellet resuspended with vortexing and pipetting in 
147µl of P1 solution (Qiagen) and transferred to a large eppendorf tube.  To this, 147µl 
P2 solution (Qiagen) was added and the tube inverted 6 times to mix.  206µl N3 solution 
(Qiagen) was then added and the tube inverted 6 times to mix.  After centrifuging the 
mixture for 10min at 13,000rpm, the supernatant was removed, added to a tube 
containing 1ml EtOH, and vortexed.  This mixture was centrifuged for 12min at 
13,000rpm and the supernatant discarded.  To the remaining pellet of DNA, 0.5ml of 
70% EtOH was added and mixed by vortexing.  The tube was then centrifuged for 5min 
at 13,000rpm.  The supernatant was discarded, the tube centrifuged briefly again and any 
remaining liquid removed.  The pellet was then air dried at 37˚C for 10min and 
resuspended in 20µl EB (Qiagen).  The resulting DNA could be screened by restriction 
digestion in the presence of RNase. A typical restriction digest for screening of the full 
length APV subgroup A clones contains: 
 
2µl DNA solution 
0.25µl RNase (0.5mg/µl) 
0.5µl MfeI restriction enzyme 
0.5µl 10X REact buffer 4 
1.75µl SDW 
  
This solution was incubated, as described in the manufacturer’s instructions, at 37˚C for 1 
to 4 hr.   
 
2.6.3 Pre-sequencing purification of DNA from quick screened colonies 
Colonies which gave a correct digestion pattern were then prepared for sequencing as 
follows.  0.25ml of PB (Qiagen) was added to mini prep for screening preparation and 
was then passed through a QIAprep® Spin Miniprep Kit (Qiagen) column into a large 
eppendorf by centrifuging for one min at 13,000rpm.  The column was then washed with 
0.75ml PE solution (Qiagen).  The wash was discarded and the column centrifuged again 
for one min at 13,000rpm.  The column was then removed to a clean eppendorf, and the 
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DNA eluted from it with 50µl EB (Qiagen) preheated to 70˚C.  The DNA from this 
procedure is of good enough quality to be used in sequencing reactions (section 2.7) 
 
2.7 Sequencing reactions with Big-Dye 
Sequencing reactions for the Departmental Sequencing Service prepared as follows: 
5.5pmol of primer was added to the recommended amount of DNA (see below) in a total 
volume of 10µl. The table below shows the recommended amounts of DNA, based on 
template type and size. 
 
Template   Amount DNA 
PCR Products   
100 to 200bp   2ng to 5ng 
200 to 500bp   5ng to 17ng 
500 to 1000bp  8ng to 33ng 
1000 to 2000bp  17ng to 67ng 
>2000bp   33ng to 83ng 
Plasmids  
Up to 15kb  250 to 500ng 
 
For Large templates (over 15kb), at least 1µg of DNA was combined with 1µl of primer 
(5.5pmol/µl) and SDW was added to 6µl.  
 
The mixture was then submitted to the Departmental Sequencing Service, where PCR 
was performed on a Hybaid omnigene PCR machine.  
 
2.8 Rescue systems 
2.8.1 Helper virus rescue system  
The APV helper virus rescue system consisted of the transfection of DNA into BSR-T7 
cells infected with helper virus.  BSR-T7 cells were transfected when 50 to 60% 
confluent. The BSR-T7 cells were infected with APV at an MOI of 1 pfu/cell for 1hr at 
37˚C.  Plasmid DNA was prepared by adding 1µg DNA to 90µl of Opti-MEM 
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(GibcoBRL, Life technologies) to which 3µl of Fugene (GibcoBRL, Life technologies, 
UK) had been added drop-wise, and the mixture incubated at room temperature for 5 to 
15 min. A further 400µl of Opti-MEM was added to the lipid/DNA mix, and this was 
used to overlay BSR-T7 cells in a 12 well plate.  0.5ml of GMEM-NEAA with 5% FCS 
was added to each well. Cells were harvested 48hr later for CAT or luciferase assays.  
 
2.8.2 Plasmid helper rescue system 
The APV plasmid rescue system consisted of the transfection of DNA into HEp2 cells 
infected with recombinant T7 vaccinia virus.  HEp2 cells in a 12 well plate were 
transfected when 50 to 60% confluent. The HEp2 cells were infected with recombinant 
T7 vaccinia virus (VFT7.3) at an MOI of 1 pfu/cell for 1hr at 37˚C.  Plasmid DNA was 
prepared by adding 1µg of DNA to 100µl of Opti-MEM.  A second mixture of 8µl of 
Lipofectin (Invitrogen) added to 100µl of Opti-MEM was incubated at room temperature 
for 30 to 45min.  The DNA was then mixed with the lipid and left at room temperature 
for 15min.  A further 400u l of Opti-MEM was added to the lipid/DNA mix, and this was 
used to overlay the HEp2 cells after the VFT7.3 virus was removed and the cells washed 
with Opti-MEM.  The plate was incubated at 37°C.  0.5 ml of GMEM-NEAA with 20% 
FCS was added to each well after approximately 24hr and cells were harvested 48hr later 
for CAT or luciferase protein.  
 
2.8.3 Full length genome rescue system 
BSR-T7 cells in 6 well (30mm diameter) plates were transfected when 90% confluent.  
The DNA mixture to be transfected consisted of: 0.3µg pCITE N gene plasmid, 0.3µg 
pCITE P gene plasmid, 0.24µg pCITE M2-1 gene plasmid, 0.15µg pCITE L gene 
plasmid and 3.0µg full length genome plasmid.  All APV genes in pCITE vectors were 
provided by Dr. Roger Ling.   Opti-MEM (Invitrogen) was added to the DNA mixture to 
a volume of 250µl/well.  For each well, 10µl of Lipofectamine 2000 was added to 240µl 
of Opti-MEM and left at room temperature for 5min.  The transfection reagent and Opti-
MEM mixture was then added to the DNA and Opti-MEM mixture, vortexed to mix, and 
left at room temperature for 30min.  Meanwhile, the media on the cells was removed and 
replaced with 1.5ml of GMEM-NEAA supplemented with 1% FCS per well.  The DNA, 
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transfection reagent, Opti-MEM mixture was then added to the well in a drop wise 
manner and the transfection returned to 33˚C.  Each well was supplemented with 
2ml/well of GMEM-NEAA with 1% FCS after approximately 24 hr.  Cells were then 
incubated for 5 days or until 90% CPE is visible.  Virus was then harvested as before, 
aliquoted, and stored at -70˚C.    
 
2.9 Preparation of cell lysates for CAT and luciferase assay 
Cells from each well were scraped into the medium with a sterile scraper and the media 
containing the cells transferred to a sterile eppendorf tube. The cells were pelleted by 
centrifugation in a microcentrifuge for 1min at 13,000rpm. The supernatant was 
discarded and the cells were washed with 0.5ml of PBS, resuspended in 150µl of CAT 
lysis buffer (Roche) and incubated at room temperature for 30min. The nuclei were 
removed by centrifugation for 10min at 13,000 rpm and the supernatant either stored at   -
70˚C or analyzed immediately.  
 
2.10 CAT assay 
The reporter CAT protein was assayed with an ELISA technique (Roche).  An aliquot of 
the cell lysate (50ul) was mixed with 150µl of dilution buffer made from 10mg/ml of 
blocking agent (Roche) in PBS and added to a CAT microtitre plate (Roche) coated with 
anti-CAT antibody and incubated at 37˚C for 1hr. The wells were washed five times with 
PBS containing 0.1% (v/v) Tween-20 before the addition of 200µl of anti-CAT- 
digoxigen (DIG) conjugated antibody diluted to 2ug/ml in dilution buffer, to each well.  
The reaction was and incubated at 37˚C for 1hr. The wells were washed as above and 
200ul of anti-DIG-POD (digioxigenin-peroxidase) antibody, diluted to 150units/ml in 
dilution buffer, was added to each well followed by incubation at 37˚C for 1hr. The wells 
were washed again and 200ul of ABTS (2,2'-azino-di-[3-ethylbenzthiazoline sulfonate 
(6)] diammonium salt, Roche) substrate added.  The plate was left to develop color for 
approximately 15min on an ELISA plate reader (Labsystems MultiscanRC, Lifesciences 
international Ltd.) at a wavelength of 405nm. 
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2.11 Luciferase assay 
Cell lysates generated by the method described in section 2.9, were assayed for the 
presence of luciferase by an enzyme reaction that resulted in the production of light.  
10µl of cell lysate was mixed with 50µl of luciferase reagent which was provided in a kit 
to assay for luciferase enzyme activity (Promega) and measured immediately in a 
Labsystems luminoskan luminometer and expressed as relative light units (RLU).  
   
2.12 RNA Quantification 
2.12.1 Northern blot  
Gel Electrophoresis: 
RNA was separated on either a formaldehyde or glyoxal gel.  Formaldehyde gels were 
made of 1X MOPS (v/v) buffer, 1% (w/v) agarose, 1/56 (v/v) formaldehyde and SDW to 
100ml.  Agarose was dissolved in 1X MOPS buffer, cooled slightly and the 
formaldehyde added immediately prior to pouring.  The running buffer consisted of 1X 
MOPS buffer, 1/56 formaldehyde and SDW to 800ml.  Prior to loading on the 
formaldehyde gel, samples were heated to 65˚C for 15min as: 25% of the mRNA from a 
well from a 6 well plate (25µl), 7.5µl formaldehyde, 22.5µl formamide, 6µl 10X MOPS 
buffer, and 0.3µl ethidium bromide (EtBr, 10mg/ml).  The gel was subjected to 80 to 
100V for approximately 1.5hr.  A ladder lane was loaded with 2µl of size ladder 
(Millennium ladder, Ambion), 5µl loading buffer (Promega) and 18µl SDW.  After 
electrophoresis, the gel was washed for 10min in SDW and then for 10min in 10X SSC.    
 
Glyoxal gels were made of 1% (w/v) agarose and SDW and were submersed in glyoxal 
running buffer for electrophoresis at 3 to 4 volts per cm between the electrodes, with the 
buffer circulated using a pump.  Samples were made up of 5µl of 200ng/µl RNA stock 
plus 5µl glyoxal gel load dye (Ambion).  A size ladder lane was loaded with 0.1µl of size 
ladder (Millennium ladder, Ambion), 5µl loading buffer (Promega) and 4.9µl SDW.  
Prior to loading on the gel, samples were heated to 50˚C for 30 to 60min and then chilled 
on ice.  The gel was subjected to 80 to 100V for approximately 1.5hr.  
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Turbo Blot 
A TurboBlotter™ system (Schleicher & Schuell, Inc., Keene, NH) apparatus was used 
following the manufacturer’s instruction for capillary transfer of the RNA from the gel to 
a neutral nylon membrane (Hybond-N membrane, Amersham Biosciences), using 20X 
SSC as transfer buffer for 2 to 3 hr.   
 
Pre-hybridization and hybridization 
The blot was gently dried and baked at 80˚C for 30 to 120min.  The blot was then rinsed 
in 2X SSC or washed in 20mM TrisHCL pH 8 at 68°C for 15min and transferred 
carefully to a small hybridization roller bottle.  After at least 30min of pre-hybridization 
in 5ml of hybridization buffer at 68˚C, the denatured (by boiling) probe was added.  
Hybridization was allowed to proceed overnight.      
 
Blot processing and development 
The blot was then rinsed in 2X SSPE with 0.1% SDS at 68˚C for 15min twice, followed 
by two washes in 0.1X SSPE with 0.1% SDS at 68˚C for 15min each.  The detection 
protocol was then carried out using CSPD (disodium 3-(4-methoxyspiro {l,2-dioxetane-
3,2'-(5'-chloro)tricyclo[3.3.1.13,7]decan}-4-yl) phenyl phosphate, Roche) and the Wash 
and Block Buffer Set (Roche) following the manufacturer’s instructions, except the 
membrane was blocked in blocking buffer for at least 60min and incubated with the 
CSPD for 15min at 37˚C.  Exposures were carried out using professional paper, black-
and-white (Kodak) and developed using either a Curix 60 (AGFA) machine or a 
Universal Hood (Bio-Rad).  Using the Bio-Rad machine and QuantityOne software 
(version 4.6.3, Bio-Rad), digital exposures were taken every 10min for 2hr.   
 
2.13 Growth and harvesting of virus stocks 
2.13.1 Growth of non-recombinant virus stocks 
APV subgroup A virus stocks were generated by infecting sub-confluent monolayers of 
Vero cells in roller bottles at a low multiplicity of infection (0.5 pfu/cell) in 10ml 
GMEM-NEAA with 2% (v/v) FCS, and incubation at 33˚C.  Virus was allowed to absorb 
for 1hr before 10ml of GMEM-NEAA with 1% FCS and CO2 were added.  Bottles were 
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incubated at 33˚C until 90% CPE was observed (usually 11 to 14 days post infection).  
Virus was harvested using glass beads, aliquoted, and stored at -70˚C.       
 
2.13.2 Growth of recombinant virus stocks 
APV recombinant virus stocks were generated by transfection of BSR-T7 cells in 6-well 
plates using Lipofectamine 2000 (Invitrogen, following manufacturer’s instructions) with 
the helper plasmids pCITE N (0.3µg/well), pCITE P (0.3µg/well), pCITE M2-1 
(0.24µg/well), and pCITE L (0.15µg/well), and a cDNA genome plasmid (3µg/well).  
After 4 to 5 days, the virus was harvested and the entire product was overlaid onto a 
confluent large flask of BSC-1 cells.  The cells and virus were incubated at 33˚C for 1hr 
before 10ml of GMEM-NEAA with 1% FCS was added.  The cells and virus were then 
left at 33˚C for approximately 4 days if the virus was expected to form syncytia and 6 to 
12 days if it was not expected to form syncytia.  Once extensive CPE was present, the 
virus was harvested using glass beads and used to infect confluent roller bottles of BSC-1 
cells (about 9.5X108 cells) at approximately 30% of a large cell culture flask (about 
5.4X107 cells per flask) per roller bottle.  The virus was allowed to absorb at 33ºC for 1hr 
before an additional 10ml of GMEM-NEAA supplemented with 1% FCS was added to 
the bottles.  Four and six days p.i, glass beads were used to harvest virus CF2EdSH 56 
and virus CF2SH 11.  The supernatant was cleared of cellular debris by centrifuging the 
media/virus/cell debris mixture for 30min at 4,000g, removing all but 250µl of the 
supernatant to a fresh universal, adding 5ml of PBS, resuspending the cell pellet by 
vortexing, centrifuging the mixture for 30min at 4,000g, and adding the supernatant to the 
supernatant from the first centrifugation step.  Aliquots were the stored at -70°C. 
         
2.14 Determination of virus titre by GFP expression assay 
For recombinant viruses which expressed GFP, a modified protocol for titre 
determination using fluorescent cell-counting was carried out (Philipson, 1961).  BSC-1 
cells were grown to 90% confluency in a 96-well plate.  Virus stocks were serially diluted 
1:10 GMEM-NEAA medium supplemented with 1% FCS with and 100µl of diluted 
solution was overlaid onto cells for 1hr at 33°C.  The virus solution was then removed 
and replaced with 200µl/well of GMEM-NEAA medium supplemented with 1% FCS.  
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Plates were incubated at 33°C for 48 hr.  Cells expressing GFP were then counted and the 
number of cell infecting units (CIF) per ml determined.   
 
2.15 Nucleotide and protein sequence alignments 
Alignments were carried out using the MegAlign program (DNASTAR Ltd.) using the 
alignment function ClustalV, derived from the program ClustalX (Thompson et al., 
1997).  Using GeneDoc (Nicholas et al., 1997), the Blosum 62 scoring table was used to 
determine the percentage homology or identity.  All gene homology calculations were 
carried out used the sequence of the ORF except as indicated.  Unless otherwise stated, 
the nucleotide and protein sequences used were hMPV isolate 00-1 (van den Hoogen et 
al., 2001)(Genbank accession number AF371337), PVM strain 15 (Thorpe and Easton, 
2005)(Genbank accession number AY743910), RSV strain RSS-2 (Tolley et al., 
1996)(Genbank accession number U39662), APV subgroup A, strain CVL14/1 (Li et al., 
1996; Ling et al., 1995; Ling and Pringle, 1988; Randhawa et al., 1996b; Yu et al., 
1992)(Genbank accession numbers U22110, X63408, U65312 and U39295), APV 
subgroup B (Randhawa et al., 1996a)(Genbank accession numbers U37586, AM293283, 
and AM411375), APV subgroup C (Govindarajan and Samal, 2005)(Genbank accession 
number AY590688), APV subgroup D (Bayon-Auboyer et al., 2000)(Genbank accession 
number AJ288946).  It should be noted that when entire genomes were compared, no 
change in the order of the genes was carried out.  This meant that analogous genes were 
not compared, as the gene order of the pneumoviruses differs from that of the 
metapneumoviruses (figure 1.1).       
 
2.16 mRNA and protein simultaneous harvest 
To extract protein and mRNA, tissue culture cells were rinsed once with PBS and 
harvested.  The cells were centrifuged for 1min 13,000g, resuspended in PBS, and then 
divided into two equal aliquots- one to be used for protein extraction and the other for 
mRNA extraction.  The mRNA extraction was carried using the Sigma direct mRNA 
isolation kit (using the protocol for pelleted cells) following the manufacturer’s 
instructions.  Protein extraction was carried out as described in section 2.9.  
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2.17 RNA probes 
RNA probes for northern blots were created as described in 'The DIG System User's 
Guide for Filter Hybridization” (Boehringer Mannheim/Roche).  Alternatively, RNA 
probes were created using 0.2 to 1µg of linearized plasmid DNA as follows.  The DNA 
was combined with 2µl of DIG-NTP mix (Roche), 4µl of 5X polymerase buffer 
(Fermentas), and 10 to 50units T7 or T3 RNA polymerase (Fermentas).  This mixture 
was incubated at 37˚C for 2 hr.  Then 1µl of DNase (Ambion, mixing gently as per 
protocol) was added and the mixture incubated for approximately 15min at room 
temperature.  50µl SDW was added and the RNA purified using a Chromaspin 200 Kit 
(Clontech), including a pre-spin of 700g for 5min.  The RNA was eluted from the 
column, divided into 3 aliquots and stored at -70°C until required.  
 
2.18 RNA standards 
RNA standards were created for northern blot as follows (Dr. R. Ling, personal 
communication).  DNA with the sequence of interest in the correct orientation was 
linearized in RNase-free conditions as follows.  Proteinase K digestion was then carried 
out by combining 50µl of the digested template with 2.9µl of 10X SDS, 0.58µl of 0.5M 
EDTA, and 5µl of Proteinase K (1mg/ml, Sigma). The solution was incubated at 55ºC for 
approximately 2 hr.  The DNA was then purified by phenol/chloroform extraction and 
EtOH precipitation using RNase-free conditions.  The DNA was then examined by 
electrophoresis and the concentration determined using the NanoDropTM 
Spectrophotometer.   
 
RNA fragments were generated from the DNA using a MEGAScript Kit (Ambion) 
following the manufacturer’s instructions.  The RNA was then separated by 
electrophoresis on a urea acrylamide gel (section 2.5.5).  Once separated on the gel, the 
RNA fragments were visualized under UV light using UV shadowing sheets (Ambion).  
The RNA was extracted from the gel by wrapping the gel in cling film, exposing the gel 
to UV light and marking the position of the RNA fragments on the cling film.  The RNA 
fragments were then cut out using a scalpel and put in 1.5ml eppendorf tubes.  350µl of 
pre-warmed Elution solution (RPA III kit, Ambion) was added to the slices and incubated 
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at 37ºC overnight.  The RNA was isolated by removing the liquid to a new tube and 
subjecting the solution to phenol/chloroform extraction followed by EtOH precipitation 
of the RNA.  The RNA pellet was then resuspended in 11µl RNase-free H2O.  The RNA 
was measured as above with the NanoDropTM Spectrophotometer. 
 
2.19 Imaging methods  
GFP expression in cells was captured using a Leica SP2 confocal microscope at 40X 
magnification.  The microscope was connected to a computer that could process the 
images using Leica software.  In this way, it was possible to set the excitation wavelength 
specifically for GFP (488nm) and to capture the resulting emitted light in the appropriate 
range and produce an image digitally.  For sliced tissues, a dye-separation protocol was 
carried out due to the high levels of background florescence seen.  By setting the negative 
control tissues as the background and removing this light from the captured image of 
GFP expressing tissues, the cells expressing GFP could be clearly seen.  Protocols for 
image capture and background substitution were provided by Leica.  
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3.1 Introduction  
The sub-family Pneumovirinae consists of the pneumoviruses avian pneumovirus (APV), 
respiratory syncytial virus (RSV), pneumonia virus of mice (PVM), and human 
metapneumovirus (hMPV).  By analogy to RSV, the three proteins likely to be required 
for replication and transcription of the APV genome are the nucleocapsid (N) protein, the 
phosphoprotein (P) and the large polymerase subunit (L) protein.  In addition, for RSV, 
the presence of the M2-1 protein has been found to increase viral transcription (Fearns 
and Collins, 1999).  APV, like all viruses with a non-segmented negative-sense RNA 
genome, cannot produce infectious virus from the genome alone.  In pneumoviruses, the 
minimal unit of infectivity is the RNP complex made up of the negative sense RNA 
genome encapsidated by N protein and associated with the L and P proteins.  Reverse 
genetics systems that reconstitute this RNP complex using cloned components have been 
used to determine the role of the viral proteins, the functional regions of the proteins, and 
the function of conserved non-translated regions of the genome (section 1.3 and 1.4).   
 
An APV reverse genetics system was developed by creating an APV sub-genomic mini-
replicon plasmid expressing either CAT or CAT and LUC protein under the control of 
authentic APV replication and transcription signals (Marriott et al., 2001; Smith, 2001) 
(section 1.4).  These ‘minigenomes’ were used to investigate the sequence requirements 
for transcription and replication of the minigenome in the presence of APV.   This rescue 
system was useful for investigating the role of specific non-translated regions of the 
genome, but it could not be used to look at the effect of mutations in APV genes.  The 
development of a plasmid-based rescue system (PRS) (section 1.5) would allow 
investigation of the role of the N, P and L proteins.  The pneumoviruses also express a 
unique M2 mRNA, which contains two ORFs (M2-1 and M2-2, figure 3.1) for which 
there are no homologous or analogous genes in other Paramyxoviruses.   
 
In the case of RSV, the M2-1 protein expressed in a PRS has been shown to greatly 
enhance mRNA production by acting as an elongation and anti-termination factor 
(Collins et al., 1999a; Cuesta et al., 2000; Fearns and Collins, 1999; Hardy and Wertz, 
1998; Teng and Collins, 1998), while the M2-2 protein inhibited viral RNA 
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replication and transcription (Collins et al., 1999a; Collins et al., 1996; Hardy and Wertz, 
1998; Teng and Collins, 1998).  In the case of PVM, the M2-1 protein has been shown to 
greatly (more than 10-fold) to enhance reporter protein expression when present at low 
levels and to inhibit RNA synthesis when present at higher levels in the PRS (Dibben, 
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M2-1 ORF (561bp)                                                                                 
       M2-2 ORF (222bp)                         
                                                   M2-1/M2-2 overlap (44bp) 
A 
B 
 
5’ GGGACAAGTGAAGATGTCTAGGCGAAATCCCTGCAGATATGAAAT 
AGGGGCAAATGCAACAGGGGATCATCCTGTACATTTAACCATAATTA
TTGGTCCTGGCCTGATCATGTGCTCTTAGTCAGAGCAAACTACATGCT
TAACCAATTATTGAGAAACACAGACAGGACAGATGGCCTATCCTTGA
TATCAGGGGCAGGACGAGAAGATAGAACCCAGGATTTTGTTCTAGGA
TCTGCCAATGTTGTACAGAATTATATAGAAGGGAACACAACAATCAC
CAAATCAGCAGCCTGCTACAGCCTGTACAACATTATAAAACAGCTCC
AGGAAAATGATGTGAAAACATCCAGAGATTCAATGCTTGAAGACCCT
AAACATGTGGCGCTACACAATCTGATACTATCTTATGTTGATATGAGT
AAAAATCCGGCAAGTTTGATCAACAGCCTCAAGCGGCTTCCCAGAGA
AAAACTCAAAAAGCTTGCCAAGATCATACTACAGCTATCTGCAGGGC
CAGAGAGTGACAATGCCAATGGTAATACCCTGCAGAAGGGTGACAGC
AATAATTAAGTGCAATGCACTTGGATTGTGTATGGTTCGTAGGATATA
TGATTATAGTATTGCGAGCTGGAGTGATTTAATAGAGGAAGTAGCCA
ATATGGTCCTAATAGATCACATCAATAGGAAACAATGTGTGGAGTGT
CGAAAAGATTTTGAGTTTATAGCTATATATACCTCATATAATTAGTTA
ATTAAAACCAATTAAGCTATAAGTCCAAAAAAGGGT  3’                           
Figure 3.1 Sequence of the APV subgroup A (isolate CVL-14/1) M2-1 and M2-2 
ORFs.  The M2 mRNA contains two overlapping ORFs, M2-1 and M2-2 (A).  The 
nucleotide sequence of the M2-2 ORF is shown here, with the M2-1 ORF shown in 
blue and purple and the nucleotides of the proposed M2-2 ORF shown in purple and 
red. The purple sequence is the overlapping sequence found at the end of the M2-1 
ORF and the proposed start of the M2-2 ORF.  The transcriptional gene start and gene 
ended sequences (in bold) are found and the 5’ and 3’ ends respectively of the M2 
gene. Translational stop and start codons (in italics) flank each ORF, with the M2-2 
ORF starting from either the first or third codon in the M2-2 ORF (Gould & Easton,  
2007)(B).  
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2006; Dibben and Easton, 2007).  HMPV recombinant virus lacking the M2-1 or M2-2 
ORFs grew to good levels in vitro, but could not replicate in vivo without the M2-1 ORF 
present.  Virus lacking the M2-2 ORF grew to very low levels in vivo but protected 
hamsters from challenge with hMPV, suggesting it would make a good vaccine candidate 
(Buchholz et al., 2005).  APV lacking the M2-2 ORF replicated normally in vitro but 
showed impaired replication and a reduced antibody response in turkeys (Ling et al., 
2008).   
 
The aim of this section of the project was to develop a functional APV subgroup A 
(isolate CVL14/1) PRS, to optimize the PRS, and to use the PRS to investigate the role of 
the M2-1 and M2-2 proteins on protein production from minigenome constructs.   
 
3.2 Development of the plasmid rescue system for APV 
It was hypothesized, based on the established RSV PRS (Yu et al., 1995), that the APV 
RNA-dependent RNA polymerase (consisting of the L, N and P proteins) could be 
reconstituted in cell culture from cDNA plasmids and would recognize a synthetic APV 
genome or minigenome (also referred to in the literature as a genome analog).  Activity 
of the polymerase could be measured by assaying for a reporter gene expressed in place 
of the APV genes from the minigenome.  Here, two APV minigenomes were used: a 
CAT protein expressing minigenome (pCAT minigenome) and a CAT and LUC protein 
expressing dicistronic minigenome (pCATLUC).  The levels of protein expressed from 
these minigenomes were used to measure the functionality of the N, P, and L expressing 
helper plasmids.    
 
The pCAT minigenome and pCATLUC have been described (Marriott et al., 2001; 
Randhawa et al., 1997; Smith, 2001).  The L helper plasmid (pCITE L) was provided by 
Dr. R. Ling and the M2-1 and M2 plasmids were provided by Dr. H. Stokes.  It was 
therefore necessary to clone the APV N, P and M2-2 ORFs into a pTM1 or pT7.2 vectors 
in order to have a full set of the proposed plasmid rescue system components.  These 
protein expression vectors have a multi-cloning site flanked by a T7 polymerase 
promoter/IRES sequence and a T7 terminator sequence.   
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3.2.1 Cloning of the APV N gene helper plasmid 
RT-PCR was used to clone the APV N gene from RNA into the pT7.2 vector (Novagen) 
as follows.  Cellular RNA was extracted from APV subgroup A (isolate CVL-14/1) 
infected cells (courtesy of Prof. A. J. Easton), and a reverse transcriptase reaction was 
carried out using approximately 0.2µg of RNA, primers APVNTOPOF and 
APVNTOPOR (appendix A), and RevertAid H minus M-MuLV reverse transcriptase 
(Section 2.5.1).  This was followed by performing PCRs using Pfu polymerase with 
primers APVNTOPOF and APVNTOPOR (figure 3.2) and confirmed to produce a DNA 
fragment of the expected size by gel electrophoresis (sections 2.5.2 and 2.5.4).   
 
The product of this reaction was then purified (section 2.5.3) and digested with restriction 
enzymes SalI and NcoI.  The produce was ligated into a pT7.2 vector that had been 
similarly digested and then treated with shrimp alkaline phosphatase (Fermentas Life 
Sciences) to prevent re-ligation of the ends of the DNA as per the manufactures 
Figure 3.2 Cloning of the N10 plasmid. Following RT-PCR, an approximately 
1170bp N gene DNA fragment was visualized on an agarose gel (A).  Ligation of this 
fragment into the pT7.2 vector resulted in three clones: N10 and N11 gave the 
expected 3592bp and 1178bp fragment restriction digestion pattern whereas N12 
lacked the 1178bp fragment that denotes N gene insertion (B).  
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instructions.  Following transformation (section 2.5.8) of the ligation product into DH5α 
E.coli competent cells and small scale plasmid purification (section 2.5.9.1), the DNA 
from three colonies (N10-N12) was digested with the restriction enzymes NcoI and SalI  
and separated by gel electrophoresis as before to check for ligation of the N gene into the 
pT7.2 vector (figure 3.2).  Samples N10 and N11 were found to produce fragments of the 
expected sizes (3592 and 1178bp) and were sequenced (section 2.7).  Plasmid pN10 had 
the expected sequence and the DNA subjected to large scale plasmid purification. 
 
3.2.2 Cloning of the APV P gene helper plasmid 
The APV P gene was cloned into the pPTM 1 expression vector (Moss et al., 1990).  PCR 
was carried out on an APV P gene clone (pBSII SK+ P plasmid, provided by Dr. Joanne 
Smith) using Pwo DNA polymerase (example in section 2.5.2) with primers TRTP4 and 
TRTP2 (appendix A).  A fragment of the desired length (approximately 850bp) was 
detected following gel electrophoresis (figure 3.3).   
 
The PCR product was purified by phenol/chloroform extraction followed by ethanol 
precipitation and then digested with the restriction enzymes NcoI and BamHI followed by 
A B
Figure 3.3 Cloning of P9 plasmid.  Visualization of P gene PCR product of 
approximately 850bp (A) and results of restriction digestion of plasmid P1, P3, P6, and 
9 with NcoI and BamHI by agarose gel electrophoresis.  Here, the P1, P3 and P9 
clones give the expected digestion pattern of 836bp and 5.4kb fragments (B). 
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fragment separation in an agarose gel.  The approximately 850bp fragment was excised 
from the agarose gel and ligated into a PTM1 vector which had been digested previously 
with NcoI and BamHI enzymes.  The ligation reaction was transformed into XL-1 Blue 
competent bacteria and nine colonies were subjected to small-scale plasmid purification 
as above.  The resulting samples were digested with the restriction enzymes NcoI and 
BamHI and examined by gel electrophoresis.  The clones with the correct insert produced 
two fragments of 5.4kb and 836bp.  As can be seen in figure 3.2, samples 1, 3, 6 and 9 
had the correct insertion.  E. coli transformed with samples 1 and 9 was then subjected to 
large-scale plasmid purification as above.  The clones were sequenced as above and clone 
P9 was shown to contain the correct sequence. 
 
3.2.3 Cloning of the APV M2-2 ORF helper plasmid 
The APV M2-2 ORF was cloned from the existing APV subgroup A (isolate CVL-14/1) 
M2 plasmid.  A PCR reaction was carried out on this plasmid with Elongase DNA 
polymerase (section 2.5.2) and primers APVAM2-2FOR and APVAM2-2REV (appendix 
A).  The M2-2 fragment was visualized on an agarose gel (figure 3.4), extracted, and was 
digested with restriction enzymes NcoI and EcoRI.  The fragment was then purified and 
ligated into the pT7.2 vector which had been subjected to restriction digestion as above.  
Colonies were screened for correct insertion (section 2.6.2) using restriction enzymes 
NcoI and EcoRI and colonies 16, 17, 22, 24 and 33 were found to have the correct 
digestion pattern of fragments of 231bp and 3651bp (figure 3.5) on an agarose gel.  The 
DNA from these colonies was then sequenced.  Preparations 16-18, 22, 24 and 33 were 
found to have gained a base in the non-coding region of the vector at base 3424 and 
preparation 16 to have an additional change of a G→A at base 3557.  Preparation M2-2 
24 was arbitrarily chosen out of the preparations with a base insertion (which should have 
no effect on protein production) to be use in all future experiments. 
 
3.3 Establishment and optimization of the APV plasmid rescue system                                               
Initial attempts to establish an APV PRS were carried out using the APV pCAT or 
pCATLUC minigenomes and APV helper and M2-1 plasmids described above based on 
the existing RSV PRS (Marriott et al., 1999).  Plasmid rescue system attempts were 
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carried out by transfecting sub-confluent monolayers of HEp2 cells (approximately 106 
cells/well) which had been infected with vTF7-3 recombinant vaccinia virus expressing 
T7 polymerase (Fuerst et al., 1986) at an multiplicity of infection (MOI) of 1 pfu/cell.  
The DNA for all replicate samples was combined with an appropriate amount of 
Lipofectin (Invitrogen) and Opti-MEM medium, measured into aliquots and transfected 
into HEp2 cells as described in section 2.8.2.  After 48hrs, the cells were harvested 
(section 2.9), pelleted, and lysed using 150ul of CAT lysis buffer to isolate the reporter 
proteins.  The cell lysates were then assayed (sections 2.10 and 2.11) and the total amount 
of CAT protein per well calculated.  Each sample was repeated 2-3 times within each 
assay and the whole procedure was repeated on at least two separate occasions.  Means 
were calculated for occasion the whole experiment was performed and these were used as 
the independent replicates for calculation of the standard error. 
 
Figure 3.4 Cloning of pM2-2: PCR for M2-2 fragment and restriction digest of 
M2-2 fragment and vector.   PCR was carried out on the pM2 using primers M2-2 
FOR and APV A M2-2 REV pT7.2 and the approximately 250bp fragment was 
visualized on an agarose gel (A).  The M2-2 PCR fragment and Pt7.2 vector were 
subjected to restriction digestion and visualized: a 3650 and 6bp fragments for Pt7.2 
and an approximately 220bp fragment for M2-2. 
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Initial testing resulted in a PRS able to produce levels of CAT protein at least 100-fold 
above background using 0.2µg per well N10 plasmid, 0.1µg per well P9 plasmid, 0.1µg 
per well pCITE L plasmid, 0.01µg per well M2-1 plasmid, 0.2µg per well pCAT 
29 30 31   L   32  33  34  35 36   L  37  38  39 40
17 18  19  20  21 22   L   23  24 25 26  27  28   L  
Figure 3.5 Screen of M2-2 plasmid clones for correct inserts.  DNA isolated from 
M2-2 colonies 7-40 (1-6 data not shown, all without inserts) was subjected to 
restriction digestion with EcoRI and NcoI.  Colonies with the M2-2 ORF inserted 
would be expected to show fragments of 3650 and 231bp (circled) whereas the vector 
alone would be 3650bp.  Colonies 16 (A), 17, 22, 24 (B), and 33 (C) gave the expected 
pattern and were fully sequenced. 
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minigenome or pCATLUC plasmid and enough pT7.2 vector plasmid to make the total 
DNA amount up to 1µg per well.  Optimization of the plasmid rescue system was carried 
out by varying each of the helper plasmids in turn, while keeping the rest of the plasmids 
at the concentrations listed above.   
 
3.3.1 Optimization of the amount of N10, P9, and pCITE L plasmid 
Varying the amounts of N10 helper plasmid from 0.01 to 0.4µg per well resulted in a 
range of activity from 572 to 4392pg per well at 0.4 and 0.05µg per well of N10 plasmid, 
respectively.  The negative controls of 0µg per well of N10 plasmid and APV (-) (no L 
plasmid included) gave 39 and 4pg per well, respectively, of CAT protein.  Cat protein 
expression at 0.05 to 0.2µg per well of plasmid was over 1000-fold above the 0µg N10 
plasmid control. Further increase in the amount of N10 plasmid, 0.3 and 0.4µg per well, 
resulted in a decrease in CAT protein production by 62 and 86%, respectively (figure 
3.6).  This indicated that the use of 0.05 to 0.2µg of plasmid per well should be used for 
maximum reporter protein expression.  
 
The P9 helper plasmid was added from 0.05 to 0.4µg per well, resulting in a range of 
activity from 1444 to 4969pg per well at 0.1 and 0.2µg per well of P9 plasmid, 
respectively.  The negative controls of 0µg per well of P9 plasmid and APV (-) gave 7 
and 13pg per well, respectively, of CAT protein.  A higher level of plasmid, 0.4µg per 
well, resulted in a decrease in CAT protein production by 41% (figure 3.7).  Hence, the 
use of 0.1 or 0.2µg of plasmid per well should be used for maximum reporter protein 
expression.  
 
The effect of variation of the pCITE L helper plasmid from 0.0001µg per well to 0.4µg 
per well was similar to that seen for the N and P plasmids.  Variation resulted in a range 
of activity from 1908 to 7441pg per well at 0.01 and 0.2µg per well of pCITE L plasmid, 
respectively.  The negative control of 0µg per well of pCITE L plasmid gave 26pg per 
well of CAT protein.  Cat protein expression at 0.05 to 0.4µg per well of plasmid was 
over 2000-fold above the 0µg pCITE L plasmid control (figure 3.8).  This indicated 
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Figure 3.6 Effect of APV N plasmid concentration on CAT protein expression in the 
APV A PRS. The amount of N plasmid added to the transfection was varied from 0 to 
0.4ug/well.  The results are the average of at least three independent experiments (except 
for 0.5ug/well which was determined on two days) and the bars show the standard error 
of the means.  
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Figure 3.7 Effect of P plasmid variation on CAT protein expression in the APV 
PRS.  The amount of P plasmid added to the transfection was varied from 0 to 
0.4µg/well. The results are the average of at least three independent experiments and the 
bars show the standard error of the means. 
0 
1000
2000
3000
4000
5000
6000
7000
APV (-) 0 0.05 0.1 0.2 0.4 
Amount P plasmid (ug/well)
 A
m
ou
nt
 C
A
T 
pr
ot
ei
n 
(p
g/
w
el
l) 
 78
that the use of 0.05 to 0.4µg of plasmid per well should be used for maximum reporter 
protein expression.  
 
The development of a PRS produced a set of plasmids that could be used in either the 
PRS with a minigenome or in full-length genome rescue system with a full-length cloned 
genome.  All subsequent transfections were performed with 0.1 to 0.2µg per well of N10 
plasmid, 0.1µg per well of P9 plasmid and 0.1µg per well of pCITE L plasmid.   
 
3.3.2 Effect of varying the amount of pM2-1 and pM2-2 plasmid on reporter gene 
expression 
As discussed in section 3.1, the APV M2 gene contains two ORFs (M2-1 and M2-2) that 
are coupled via an overlapping region.  Here, the M2-1 and M2-2 ORF were investigated 
separately and together for their effect on production of reporter protein from the 
pCATLUC dicistronic minigenome  (section 1.5).  Having a second reporter gene in the 
Figure 3.8 Effect of APV L plasmid concentration on CAT protein expression in 
the APV A PRS.  The amount of L plasmid added to the transfection was varied from 
0 to 0.4µg/well. The results are the average of at least three independent experiments 
and the bars show the standard error of the means. 
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minigenome provides the opportunity to investigate the effect of the M2 proteins on 
sequential genes expression.  
 
Variation of the M2-1 plasmid from 0µg per well to 0.4µg per well increased the amount 
of CAT protein production from 3224pg per well to a maximum of 15222pg per well at 
0.025µg per well of M2-1 plasmid.  There was a plateau of CAT production from 
0.005µg per well to 0.1µg per well of M2-1 plasmid.  M2-1 plasmid amounts greater than 
0.1µg per well decreased CAT protein production by approximately 26% (figure 3.9).    
 
For APV, the effect of the addition of 0 to 100ng of M2-2 plasmid to the PRS, with and 
without 10ng of M2-1 plasmid, was a gradual increase in inhibition of CAT and LUC 
protein production.  At levels of 1ng/well M2-2 plasmid, CAT protein was still detected 
at more than 1000pg per well.  However, the addition of M2-1 plasmid to the transfection 
mixture increased the CAT protein expression 2-3 fold.  Interestingly, when more than 
1ng of M2-2 plasmid was added, CAT expression decreased to almost zero, even with an 
equal amount of M2-1 plasmid present.  For LUC protein, the protein expression pattern 
was identical to that seen for CAT protein in the presence of M2-2 plasmid with and 
without M2-1 plasmid present (figure 3.10). 
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A 
B 
Figure 3.9 Effect of APV M2-1 plasmid concentration on CAT and LUC protein 
expression in the APV A PRS.  The amount of M2-1 plasmid added to the 
transfection was varied from 0 to 0.4µg/well.  The results are the average of at least 
three independent experiments (except for APV (-) which was determined on one day) 
and the bars show the standard error of the means.  
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3.4 Discussion 
3.4.1 The APV plasmid rescue system 
This work describes the development and optimization of a robust APV PRS.  The effect 
of varying the N, P, L and M2-1 plasmids was measured and it was shown that there was 
a range of acceptable concentrations for all four plasmids.  This suggested that the N, P, 
L and M2-1 proteins were not required in exact ratios, but that there was a minimum and 
a maximum amount of each protein (relative to a fixed amount of minigenome plasmid) 
required for the PRS to function.  For the N, P and L helper plasmids, a minimum of 
0.1µg of plasmid out of a total reaction containing 1µg input DNA was ideal for 
Figure 3.10 Effect of APV M2-2 plasmid concentration with and without M2-1 
plasmid present on CAT protein expression in the APV A PRS.  The amount of M2-2 
plasmid added to the transfection was varied from 0 to 100ng/well with no M2-1 plasmid 
added (blue) and with 0.01µg/well of M2-1 plasmid added (red).  The results are the 
average of at least two independent experiments and the bars show the standard error of 
the means.  
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maximum efficiency and more than 0.4µg per well of any of the helper plasmids 
appeared to be detrimental to reporter protein expression.  For the M2-1 plasmid, any 
concentration above 5ng/well enhanced reporter protein expression.  Similarly, the 
maximum PVM PRS reporter protein production was achieved using a range of ratio of 
reporter plasmids (Dibben, 2006; Dibben and Easton, 2007).  For RSV, it was found that 
maximum production of genomic RNA was achieved with N, P and L genes transfected 
at a 12:5:1 molar ratio  (Yu et al., 1995).   
 
3.4.2 M2-1 and M2-2 in the APV plasmid rescue system  
With the establishment of the APV PRS, it was possible to investigate the role of the M2-
1 and M2-2 proteins in viral transcription.  The PRS was the appropriate rescue system 
with which to investigating the minimal requirements for production of a fully functional 
RNP complex as Collins et al. (1999a) showed that M2-1 protein could be produced from 
the anti-genomic plasmid or helper virus in the full-length or helper virus rescue systems, 
respectively, by promiscuous transcription by the vaccinia virus polymerase.  It was 
shown that M2-1 protein could be produced in sufficient amounts to have an 
enhancement effect on transcription in the absence of any M2-1 expression plasmid being 
present (Collins et al., 1999a).   
 
For RSV, the components of the RNP complex were found to be the N, P, L proteins and 
viral (-) RNA, with the M2-1 protein acting as an anti-termination and elongation factor 
necessary for transcription of more than one gene from a minigenome or full length 
cloned genome (Collins et al., 1999a; Collins et al., 1996; Fearns and Collins, 1999; 
Hardy and Wertz, 1998).  The RSV M2-1 protein was shown to enhance synthesis of full-
length mRNA of long (1,212 or 1,780nt) genes (up to a 615-fold increase) more than a 
short (274nt) gene (less than a 2-fold increase) (Fearns and Collins, 1999).  The N, P, and 
L proteins along with RNA genome were also found to be the minimal requirements for 
protein production from a minigenome in the PVM PRS (Dibben and Easton, 2007).  A 
PRS for APV was developed here whereby the N, P and L proteins were able to produce 
reporter protein from an APV minigenome in the absence of any source of M2-1 protein.  
The APV M2-1 protein was found to enhance reporter protein production 2 to 5-fold 
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only.  Hence, unlike RSV but similar to PVM, the M2-1 protein was not necessary for 
multiple gene transcription.    
 
The addition of M2-2 plasmid to the APV PRS had a marked effect on reporter protein 
production.  This suggests that the M2-2 protein is likely to be produced by the virus, 
although it has not been detected as a protein expressed during APV infection by western 
blot (Ahmadian et al., 1999).  The effect of the M2-2 plasmid on protein expression was 
modulated by the presence of the M2-1 plasmid. Gould and Easton (2007) showed that 
the overlapping region of the M2-1 and M2-2 ORF can direct coupled translation of the 
second ORF following translation of the first ORF.  However, they found that the APV 
M2-1/M2-2 overlapping region was 64-times less efficient at directing coupled 
translation than the M2-1/M2-2 overlapping regions of PVM or RSV.  This suggests that 
if the M2-2 protein is produced, it is a very low level.  Hence, the work here supports the 
theory, based on RSV and PVM, that APV does express an M2-2 protein that it is a down 
regulatory protein that balances the enhancing effect the M2-1 protein.     
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Chapter 4:  
Effect of mutation of the GS and GE 
signals on mRNA and protein expression 
in the APV plasmid rescue system 
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4.1 Introduction 
With the establishment of a robust plasmid rescue system (PRS) for APV (chapter 3), the 
minimal requirements for protein production from the APV minigenome were found to 
be the N, P and L proteins though this was enhanced by the presence of the M2-1 gene.  
The functionality of the minigenome demonstrated that the non-translated cis-acting 
leader (Le), trailer (TR), consensus gene start (GS), and consensus gene end (GE) 
sequences are sufficient to direct transcription by the viral polymerase complex.  These 
findings are consistent with the current model of pneumovirus transcription (section 1.4), 
whereby the polymerase complex transcribes mRNAs by travelling in a progressive stop–
start manner from the 3' to the 5' end of the genome directed by the GS and GE sequences 
which flank each gene (Dickens et al., 1984; Randhawa et al., 1997).  Dicistronic 
minigenomes have been used for mutational analysis of the gene junction regions in 
hRSV (Kuo et al., 1997; Kuo et al., 1996b).  By mutating the gene start sequence 
between the reporter genes (5’ GS-CAT-GE-IR-GS-Luc-GE 3’, antigenome sense, 
appendix B), the effect on transcription of the LUC gene can be compared to the 
transcription of the CAT gene, which should be unaffected by the mutation.  Similarly, 
the effect of mutation to the GE sequence of the CAT gene on termination or re-initiation 
should be reflected in changes in the amounts of CAT and LUC mRNAs produced.   
 
For APV, the conserved GS sequence is identical for all genes except for that preceding 
the L gene.  The APV consensus GS sequence is GGGACAAGU (antigenome sense) (Li 
et al., 1996; Ling et al., 1995; Ling et al., 1992; Randhawa et al., 1996b; Yu et al., 1991; 
Yu et al., 1992), whereas the L GS sequence has three differences (underlined), giving a 
sequence of AGGACCAAU (Randhawa et al., 1996b) (section 1.4).  The gene end 
sequences are more varied, with a consensus sequence of uAGUtAnnn(An), and the 
intergenic regions vary in length from one to 60nt.  The APV pCATLUC minigenome 
contains the conserved GS sequence before both the CAT and the LUC genes.  It has the 
P gene end sequence (UAGUUAUGAAAAAA, antigenome sense) following the CAT 
gene and the L gene end sequence (UAGUUAAUAAAAA, antigenome sense) following 
the LUC gene.  A five nucleotide intergenic region, introducing a ClaI site for cloning 
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purposes (A/UCGAU, antigenome sense), separates the CAT GE sequence and the LUC 
GS sequence.  
It has been previously shown that mutations introduced into specific nucleotide positions 
of the GS sequence have different effects on LUC reporter gene expression (Edworthy 
and Easton, 2005).  The aim of this section was to use the pCATLUC minigenome to 
determine the effect of a set of naturally occurring mutations to the gene junction (GJ) 
sequence.  The GJ consists of nucleotides found between the genes, including the 
upstream gene GE sequence, the intergenic region (IR) sequence and the downstream 
gene GS sequence.  The level of correlation between mRNA production and protein 
production following transcriptional signal mutation to the pCATLUC minigenome was 
first examined by comparing reporter gene mRNA levels and reporter protein levels.   
4.2 Comparison of mRNA and protein expression levels from GS sequence mutants 
Based on previous studies in the RSV PRS (Marriott et al., 1999), it was hypothesized for 
the APV PRS that reporter proteins were produced in the same ratios as reporter gene 
mRNAs though this was not directly confirmed.  In order to test this, GS sequence 
mutations that were known to decrease LUC protein production from the pCATLUC 
minigenome in the APV PRS (Edworthy and Easton, 2005) were examined to determine 
if this decrease was due to a loss of mRNA production.  CAT protein or mRNA 
production was used as the control for each sample, as CAT production should be 
unaffected by mutations to the LUC GS sequence.  Mutant plasmids were named to 
indicate the base of original nucleotide and the mutant base.  For example, mutant 
plasmid G1A has the first base of the LUC GS sequence changed from a G to an A.    
 
The first sets of mutants investigated altered the first base and fifth base of the GS 
sequence (table 4.1).  These four mutants represented those with the least (C5U), greatest 
(G1C and G1U), and a modest (G1A), effect on reporter gene expression (figure 
4.1)(Edworthy and Easton, 2005).  The second set of mutations used to investigate 
mRNA and protein production included mutant A7U, G2U, G3A, A4C, and G8A.  The 
GS mutant plasmid A7U has a change of an A at base seven of the consensus GS 
sequence to a U.  The mutation introduced an AUG into the GS sequence (5’ 
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GGGACAUGU 3’, mRNA sense, start codon in bold), creating an alternate start codon 
and alternate ORF out of frame with the LUC ORF.  Mutants G2U and A7U were  
selected due to their low level of LUC protein production, mutants G3A and A4C for 
their middle level LUC protein production and mutant G8A for its high level of LUC 
protein production (figure 4.1, taken from Edworthy and Easton, 2005).   
 
By carrying out a standard PRS transfection experiment (section 2.8.2), reporter protein 
and mRNA were collected in sufficient quantities to visualize on northern blots and to 
measure in protein assays using the same transfection sample.  This was done by using 
the mRNA and protein simultaneous harvest protocol as described in section 2.16.  The 
northern blot membranes were incubated with a RNA probe specific for CAT and LUC 
mRNA (section 2.17) and all blots were repeated to confirm initial findings.  
 
All constructs showed similar levels of CAT protein expression, apart from mutant A4C 
that produced approximately 2.8-fold more CAT protein seen from transfection of the 
pCATLUC minigenome (figures 4.2 and 4.3).  Levels of CAT mRNA expression were 
similarly consistent, with mutant A4C having a darker band that the other samples.   
 
The level of LUC protein produced from these constructs ranged from 408 RLU/106 cells 
for the unmutated pCATLUC plasmid (labelled ‘Wildtype’, figure 4.2) to no signal  
GS mutant     GS sequence      
Wildtype GGGACAAGU 
G1A     AGGACAAGU 
G1C      CGGACAAGU 
G1U     UGGACAAGU 
G2U     GUGACAAGU 
G3A     GGAACAAGU 
A4C      GGGCCAAGU 
C5U      GGGAUAAGU 
A7U     GGGACAUGU 
G8A   GGGACAAAU 
Table 4.1 Sequences of the mutant GS signals.  ‘Wildtype’ indicates the consensus 
APV gene start sequence.  All sequences are shown 5’ to 3’, mRNA sense. 
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for mutants G1C (figure 4.2) and G2U (figure 4.3).  The plasmids that directed synthesis 
only of low levels of reporter protein showed no LUC mRNA production (mutants G1C, 
G1U, G2U, and A7U).  Plasmids G1A, G3A and A4C gave moderate levels of LUC 
protein and had moderate levels of LUC mRNA production.  The highest levels of LUC 
protein production were produced by the plasmids C5U and G8A (figures 4.2 and 4.3).   
 
For the GS sequence mutants investigated, the levels of reporter protein expressed from 
pCATLUC minigenome constructs correlated well to levels of mRNA expressed from the  
Figure 4.1 Effect of mutation of the dicistronic minigenome plasmid LUC GS 
sequence on percentage activity. Edworthy and Easton (2005) determined the 
percentage activity of 27 single point mutations to the nine nucleotide APV 
consensus gene start sequence (5’ GGGACAAGU 3’, mRNA sense) of the LUC 
gene of the APV pCATLUC minigenome.  Each mutation is named after the base to 
be mutated, the position (1-9, mRNA sense) and the base after mutation.  The ‘L’ 
mutant has the L gene start sequence (5’ AGGACCAAU 3’, mRNA sense) prior to 
the LUC gene.  The ‘G1A/G8A’ mutant has two of the three L non-consensus GS 
sequence (5’ AGGACAAAU 3’, mRNA sense).  The ‘wildtype’ plasmid is the 
unmutated pCATLUC minigenome. 
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Figure 4.2 CAT protein and LUC protein levels of selected GS sequence 
mutants.  Protein production from GS sequence mutants (A) was compared to 
mRNA production as measured by northern blot using a RNA probe specific for 
the LUC and CAT genes (B). The CAT gene is 66obp and the LUC gene is 
1650bp.  ‘Wildtype’ is the unmutated pCATLUC dicistronic minigenome and ‘no 
MG’ is the negative control of no minigenome included in the PRS experiment.
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Figure 4.3 CAT protein and LUC protein levels of selected GS sequence 
mutants.  Protein production from GS sequence mutants (A) was compared to 
mRNA production as measured by northern blot using a RNA probe specific for 
the LUC and CAT genes (B). The CAT gene is 66obp and the LUC gene is 
1650bp. ‘Wildtype’ is the unmutated pCATLUC dicistronic minigenome.  Both 
lanes of the left part of panel B derive from the same exposure of a single blot; 
background levels across the blot were uneven.  ‘No MG’ is the negative control 
of no minigenome included in the PRS experiment.
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constructs.  The faint upper band seen in both northern blots is consistent with the mRNA 
products of read-through transcription.  This does not appear to change significantly in 
intensity, suggesting that the GS sequence mutations did not affect mRNA termination at 
the gene junction.  This would agree with the discontinuous model of transcription where 
an intact downstream gene start signal is not required for termination and polyadenylation 
of the upstream mRNA.   
 
4.3 Activity of transcriptional signal mutations in the APV plasmid rescue system 
4.3.1 Gene junction mutations  
Reverse genetics systems have played a major role in the analysis and development of 
protective, non-pathogenic, APV vaccine strains.  APV A field strain #8544, an actual 
vaccine strain isolated from an outbreak in northern England in 1985, was found to 
protect turkeys from challenge with APV.  However, it was also shown to produce post-
vaccination disease in some cases, even following passage in Vero cells (Williams et al., 
1991a; Williams et al., 1991b).  Naylor & Jones (1994) and Naylor et al. (2007) 
determined that this was due to the presence of a sub-population of virulent virus.  Plaque 
purification produced 12 viruses that were free of the disease-causing sub-populations.  
These isolates had varying degrees of sequence conservation and differing abilities to 
induce protective immunity.  Complete sequencing of the original isolate (field strain 
#8544), of the attenuated (virus P20), and of selected plaque-purified isolates (viruses C, 
K, F, H, and L) revealed a set of point mutations which produced four phenotypes for the 
virus:  protective against APV challenge but severely pathogenic (isolate #8544), 
protective but some pathogenicity (virus P20), protective and non-pathogenic (viruses C 
and K), or non-protective and non-pathogenic (viruses F, H and L).  Briefly, compared to 
the pathogenic progenitor strain isolate #8544, the P20 virus had nine base changes: one 
change in the F gene start sequence, two in the F gene itself (coding), one in the M2-1 
gene (coding), one in the SH-G gene junction, one in the G gene (non-coding), and two in 
the L gene (non-coding).  The protective viruses C and K were found to have the same 
sequence as the P20 virus.  Virus L differed in sequence from P20 in having two bases 
that matched isolate #8544 (F gene start and L gene) and extensive mutation to the G 
gene (55 A to G mutations in the coding region).  Viruses F and H differed from P20 by 
 92
one mutation each to the SH-G gene end sequence.  The four SH-G gene junctions found 
upon sequencing the progenitor strain 8544 (IR mutant 1), the protective virus C (IR 
mutant 2), and the two non-protective viruses H and F (IR mutant 3 and IR mutant 4, 
respectively) are shown in figure 4.4.   The IR mutant 1 represents the naturally occurring 
SH-G gene junction for virus strain 8544 and does not represent a sequence that is a 
mutation of the ‘wt’ virus.  All other viruses were sequenced only across the 11 regions 
of mutation found between isolate #8544 and P20 and were found to have identical 
sequence to virus P20 (Naylor et al., 2007).  
 
pCATLUC minigenome gene junction (GJ): 
UAAUAGUUAUGAAAAAAUCGAUGGGACAAGUAACCAUG 
 
IR mutant 1 (pathogenic, protective strain #8544 GJ): 
UAAUGAAUUUUGACAACACUAGUGCCAAAUAAUAGGCAACAG 
UAUUAUUUAAUUAAAAAGAAAGGUCGGGACAAGUAUCUCUAUG 
 
IR mutant 2 (non-pathogenic, protective viruses C, K and P20 GJ): 
UAAUGAAUUUUGACAACACUAGUGCCAAAUGAUAGGCAACAG 
UAUUAUUUAAUUAAAAAGAAAGGUCGGGACAAGUAUCUCUAUG 
 
IR mutant 3 (non-pathogenic, non-protective virus H GJ): 
UAAUGAAUUUUGACAACACUAGUGCCAAAUGAUAGGCAACAG 
UAUUAUUUUAUUAAAAAGAAAGGUCGGGACAAGUAUCUCUAUG 
 
IR mutant 4 (non-pathogenic, non-protective virus F GJ): 
UAAUGAAUUUUGACAACACUAGUGCCAAAUGAUAGGCAACAG 
UAUUAAUUAAUUAAAAAGAAAGGUCGGGACAAGUAUCUCUAUG 
Gene Junction Mutations
   GS         CAT gene        GE      IR      GS           LUC gene           GE   
Figure 4.4 Dicistronic minigenome (mRNA sense) gene junction mutants.  
Shown here are the IR mutant 1-4 gene junction sequences (antigenome sense), 
with stop and start codons shown in blue, point mutation position in red, and the 
GE and GS sequences underlined. 
 
Pt7.2 backbone 
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As the only mutations in common in the non-protective (viruses F and H) and the 
protective (viruses C, K and P20) genomes were single base changes in the SH-G gene 
junction, it was hypothesized that the differences in the ability of these viruses to elicit 
protection to APV challenge may be due to changes in the amounts of SH and G proteins 
expressed by the virus.  The effect of the mutations on gene expression was investigated 
by replacing the existing dicistronic pCATLUC minigenome gene junction with the SH-
G gene junction and carrying out point mutations to create the four desired gene junction 
sequences. 
 
4.3.1.1 Generation of IR mutant 1 
The mutation of the pCATLUC minigenome gene junction to the SH-G gene junction 
was carried out using a series of overlapping primers.  As described in section 2.6.1, it is 
possible to insert large fragment into plasmid using a modified QuickChange site directed 
mutagenesis protocol.  The first step was to create a large fragment that contained the 
desired SH-G gene junction of 150-200 nucleotides that matched the start of the LUC 
gene and the end of the CAT gene.  To create the insertion fragment, a series of PCRs 
were carried out (shown diagrammatically in figures 4.5 to 4.7) using primers ranging 
from 19 to 84 bases (appendix A).  PCRs 1 and 2 were carried out using the pCATLUC 
minigenome as the template DNA.  A 20 base forward primer (primer DSMG IR F) 
which bound from 200bp upstream of the end of the CAT gene stop codon was used with 
a reverse primer (primer IntMut/DSMG R) containing the final 15 bases of the CAT gene 
sequence followed by a non-binding region of 69 bases.  This PCR gave a fragment of 
269bp which was named fragment A.  For fragment B, a PCR was carried out using a 40 
base forward primer (primer IntMut/DSMG F) which contained the final 31 bases of the 
replacement gene junction followed by the first 19 bases of the LUC gene, and a 19 base 
reverse primer (primer DSMG IR R) that complimented the LUC gene 186 bases 
downstream of the LUC gene start codon (figure 4.5).  PCR for fragment C was carried 
out using fragments A and B and the full length cloned APV CASA genome) (Naylor et 
al., 2004) as the template (figure 4.6).  Fragment C contained the desired progenitor gene 
junction flanked by sequence complementary to the CAT and LUC genes.   
Figure 4.5 Generation of fragments A and B. A) Using the pCATLUC 
minigenome as the template for PCR, primers DSMG IR F and IntMut/DSMG R 
were used to introduce 69bp (in green) of SH-G gene junction sequence to the 3’
end of a 200bp fragment (in light green) of the pCATLUC plasmid (fragment A).   
For fragment B, the pCATLUC plasmid was again used as the template for PCR 
and primers IntMut/DSMG F and Primer DSMG IR R were used to introduce 
31bp (in green) of SH-G gene junction region sequence to the 5’ end of an 179bp 
fragment (in light blue) of the pCATLUC minigenome.  B) PCR product 
fragments A (269bp) and B (210bp) were visualized on an agarose gel. 
5’ TAATAGTTATGAAAAAATCGATGGGACAAGTAACCATG 3’
GS           CAT gene        GE      IR      GS        LUC gene       GE  
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GS            SH Gene             GE    IR   GS           G gene                 GE  
APV CASA
Product: Fragment C
Figure 4.6 Generation of fragment C. A) Fragments A and B were used in PCR 
with the APV full length cloned genome (APV CASA) to create fragment C.  
Fragment C has the SH-G intergenic flanked by pCATLUC minigenome 
sequence. B) PCR product fragment C (458bp) was visualized on an agarose gel. 
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TAATGAATTTTGACAACACTAGTGCCAAATAATAGGCAACAG
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
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TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
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Fragment C was then used in the modified QuickChange site directed mutagenesis 
protocol (section 2.6.1), with the pCATLUC minigenome construct as template (figure 
4.7).  Twenty-four colonies were selected and used for small-scale DNA purification.  
The resulting plasmid DNA was screened for the presence of the insertion by digestion 
with Cla1 and Sph1 enzymes.  The presence of the desired insertion into the plasmid 
resulted in a single band of 5383bp, whereas the plasmid without insertion gave bands of 
675bp and 4661bp.  As seen in figure 4.8, samples 7, 9, 11, 16-20, 22, 24, 26, 28-30 had 
the desired restriction digest fragment pattern and samples 7, 9, 11, 16-20, 22, 24 were 
Primer: 
Fragment C
Pt7.2 backbone  Product: IR mutant 1
5’ TAATAGTTATGAAAAAATCGATGGGACAAGTAACCATG 3’ 
GS           CAT gene        GE      IR      GS           LUC gene         GE   
FL quick-change PCR template: 
pCATLUC minigenome  
Figure 4.7 Generation of IR mutant 1.  Fragment C was used in the modified 
quick change protocol PCR to introduce the modified IR mutant 1 intergenic region 
into the pCATLUC minigenome, resulting in the desired IR mutant 1 plasmid.  
 
FL quick-
change 
PCR 
TAATGAATTTTGACAACACTAGTGCCAAATAATAGGCAACAG 
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG 
Pt7.2 backbone 
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sequenced using primers DSMG check 5 and DSMG check 6.  All samples were found to 
have a G→A change at base 4480 in the CAT gene that was non-coding.  Sequencing of 
samples 7, 11, 16-18, and 19 confirmed insertion of the desired gene junction.  Sample 18 
was chosen to be used for IR mutant 1 plasmid in all further experiments. 
 
4.3.1.2 Generation of IR mutant 2 
In order to generate the second set of mutations to the gene junction to create IR mutant 2 
(figure 4.4, A to G change at base 28 of the IR mutant 1 gene junction), QuickChange site 
directed mutagenesis was utilized as above.  It had been observed that, even for point 
mutations, primers or DNA fragments in excess of 40 bases were necessary when using 
Figure 4.8 Agarose gels examining of restriction digestion products for IR mutant 
1 cloning.  Thirty samples were digested with Cla1 and Sph1 enzymes for loss of the 
Cla1 site found in the unmutated pCATLUC minigenome intergenic region.  
Introduction of the desired intergenic region should result in a single band of 5383bp, 
whereas digestion of the pCATLUC minigenome gives two bands (4661 and 675bp).  
Samples 7, 9, 11, 16-20, 22, 24, 26 and 28-30 gave the desired bands and samples 7, 
11, 16 to 19 were sequenced with primers check 5 and 6.  Based on the results of this 
sequencing, sample 18 was fully sequenced and used in all further experiments. 
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this protocol (Dr. O. Dibbin, personal communication).  Two 80 base primers, IRmut2 
FOR long and IRmut2 REV long (appendix A), were prepared (figure 4.9).  These primer 
pairs were used in the method for full-length clone modification protocol (section 2.6) 
with IR mutant 1 plasmid as the template in the PCR.  This protocol resulted in one 
sample, sample 7, with the desired gene junction mutations for IR mutant 2.  This 
plasmid was fully sequenced and used in all further experiments. 
  
 
 
 
Pt7.2 backbone 
FL quick-change PCR template: 
IR mutant 1 plasmid 
Figure 4.9 Generation of IR mutant 2.  IRmut2 REV long and IRmut2 FOR long 
are complementary primers which match the gene junction region of the IR mutant 2 
plasmid apart from the A->G mutation at base 28 of the gene junction sequence 
(antigenome sense).  Primers IRmut2 REV long and IRmut2 FOR long were used in 
the modified QuickChange site-directed mutagenesis PCR to introduce the IR 
mutant 2 intergenic region into the IR mutant 1 plasmid (in yellow), resulting in the 
desired IR mutant 2 plasmid with an A to G mutation at base 28 of the gene junction 
(antigenome sense).  
Primer: 
IRmut2 FOR 
long 
 Product: IR mutant 2
TAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG 
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG 
Primer: 
IRmut2 REV 
long
Quick- 
Change 
PCR 
Pt7.2 backbone 
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4.3.1.3 Generation of IR mutant 3 
The strategy used to generate the IR mutant 3 plasmid was to create a large fragment 
containing the desired gene junction and to use this fragment in QuickChange site 
directed mutagenesis PCR.  PCR was carried out using DSMG IRF with IR3 REV LONG 
as primer pairs and IR mutant 2 DNA as the template and resulted in the generation of 
fragment D (figure 4.10).  Using fragment D with the IR mutant 2 plasmid as the 
template in QuickChange site directed mutagenesis PCR (as above), the IR mutant 3 
plasmid was generated (figure 4.11).  The resulting product was transformed, the DNA 
isolated, and sixteen colonies were screened by sequencing with the primer DSMG check 
5.  IR mutant 3 sample 66 was fully sequenced and used as the IR mutant 3 plasmid in all 
further experiments.  
 
Figure 4.10 Generation of fragment D.  A) Using the IR mutant 2 plasmid as 
the template for PCR, primers DSMG IR F and IR mut 3 REV LONG were used 
to introduce 67bp (in orange) of IR mutant 3 intergenic region sequence to the 3’ 
end of a 200bp fragment (in light green) of the CAT gene (Fragment D).  B) PCR 
product fragment D (267bp) was visualized on an agarose gel. 
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TAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG 
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG 
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5’ TAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG 3’
GS           CAT gene        GE      IR      GS           LUC gene         GE  
FL quick-change PCR template: 
IR mutant 2 plasmid
Figure 4.11 Generation of IR mutant 3. Fragment F was used in the modified 
QuickChange site-directed mutagenesis PCR to introduce the IR mutant 3 gene 
junction sequence into the IR mutant 2 plasmid, resulting in the desired IR mutant 
3 plasmid.
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4.3.1.4 Generation of IR mutant 4 
The strategy attempted to create IR mutant 4 was to PCR very long fragments which 
spanned the IR and could be used full-length quick-change mutagenesis.  PCR to 
generate the desired fragments was carried out using Elongase polymerase (as above) 
with primers DSMG IR F and IR mut 4 REV LONG and the IR mutant 1 plasmid as the 
template (figure 4.12).  PCR resulted in the desired fragments (fragments E and F) which 
were then used to generate a very long fragment (fragment G) using PCR (figures 4.13).  
Fragment G was purified as above and used in FL quick-change mutagenesis PCR (figure 
4.14) to create the IR mutant 4 plasmid.   
 
Transfection as above resulted in approximately 200 colonies per plate, of which 12 were 
selected for small scale DNA preparation.  The preparations were then sequenced using 
the primer DSMG check 5.  Sequencing showed IR mutant 4 sample 22 to have the 
desired mutations, although this sample also contained a coding change to base 4055 in 
the LUC gene.  By subjecting both sample 22 and the pCATLUC plasmid to restriction 
digestion and ligation it was possible to replace the coding mutation at base 4055 and 
produce a correct plasmid (figure 4.15).   
 
Both plasmids were subjected to sequential restriction digest with BstB1 and Sph1 and 
the desired fragments purified (figure 4.15).  Ligation resulted in 24 clones that were 
screened by sequencing using primer DSMG check 5.  IR mutant 4 sample 23 was chosen 
to be used in future experiments as the IR mutant 4 plasmid. 
  
 
 
 
 
 
 
 
 
Figure 4.12 Generation of fragments E and F. Using the IR mutant 1 plasmid 
as the template for PCR, primers DSMG IR F and IR4 REV LONG were used to 
introduce 67bp (in dark blue) of IR mutant 4 gene junction sequence to the 3’ end 
of a 200bp fragment (in light green) of the CAT gene (fragment E).  For fragment 
F, the IR mutant 1 plasmid was again used as the template for PCR and primers 
IR mut 4 FOR LONG and primer DSMG IR R were used to introduce 79bp (in
dark blue) of IR mutant 4 gene junction sequence between an 179bp fragment (in 
light blue) of the LUC gene and a 13bp fragment of the CAT gene (in light 
green). B) PCR products fragment E (left, 267bp) and fragment F (right, 271bp) 
were visualized on an agarose gels. 
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Figure 4.13 Generation of fragment G. Fragments E and F were used in PCR 
with the IR mutant 1 plasmid to create fragment G.  Fragment G has the IR 
mutant 4 gene junction sequence flanked by IR mutant 1 sequence, with changes 
of an A to G change at base 28 and an A to a T at base 48 (antigenome sense). 
PCR 7 template:
IR mutant 1 plasmid
TAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG
TATTATTTTATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
PCR 7 Primer:
Fragment F
Pt7.2 backbone
TAATGAATTTTGACAACACTAGTGCCAAATAATAGGCAACAG
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
Primer:
Fragment E
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Primer:
Fragment G
Pt7.2 backboneProduct: IR mutant 4*
GS           CAT gene        GE    IR   GS           LUC gene   GE  
FL quick-change PCR template:
IR mutant 2 plasmid
Figure 4.14 Generation of IR mutant 4*. Fragment I was used in the modified 
QuickChange site-directed mutagenesis PCR to introduce the IR mutant 4 gene 
junction into the IR mutant 2 plasmid, resulting in the IR mutant 4 plasmid.  
Sequencing of plasmid IR mutant 4 showed a point mutation of a C to a T at base 
4055 (antigenome sense) in the LUC gene, which would change the amino acid 
for that codon from a proline to an serine. 
Quick-
Change 
PCR
TAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG
TATTAATTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
Pt7.2 backbone
TAATGAATTTTGACAACACTAGTGCCAAATAATAGGCAACAG
TATTATTTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
*
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IR mutant 4* plasmid
*
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pCATLUC minigenome
* *
Pt7.2 backbone
BstBI and SphI digestion
Pt7.2 backbone
* * * *
Pt7.2 backboneProduct: IR mutant 4
TAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG
TATTAATTAATTAAAAAGAAAGGTCGGGACAAGTATCTCTATG
ligation
Figure 4.15 Generation of IR mutant 4. A) Plasmid IR mutant 4* was found to 
contain a mutation in the LUC gene at base 4055 (antigenome sense).  In order to 
correct the mutation, the IR mutant 4 plasmid and the pCATLUC minigenome 
were digested with enzymes BstBI and SphI to give 488 and 4895bp fragments.  
The 488bp fragment from pCATLUC was ligated with the 4895bp fragment from 
the IR mutant 4* plasmid, producing an IR mutant 4 plasmid with an unmutated 
LUC gene.  B) Digestion products were visualized on an agarose gels, with the IR 
mutant 4* as the vector (left) and the pCATLUC minigenome as the insert.  The 
insert fragment was visible only when larger volumes were added to the gel 
(right, indicated with an arrow).
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4.3.2 Determination of effect of mutation of the pCATLUC minigenome gene 
junction 
Plasmids IR mutant 1, IR mutant 2, IR mutant 3 and IR mutant 4 were transfected into 
HEp2 cells with the APV PRS helper plasmids and cell lysates were assayed for reporter 
protein (sections 2.8.2, 2.9, 2.10 and 2.11).  The mean of the three independent 
experiments was determined and standard error calculated and is shown in figure 4.16.    
 
When introduced into the PRS, all minigenomes produced levels of CAT protein similar 
to that of minigenome IR mutant 1 (p-values of 0.4319 to 0.7032, figure 4.17), although 
the mean values for IR mutants 3 and 4 are lower than those seen for IR mutants 1 and 2 
(30.0 and 31.5ng verses 27.5 and 26.6ng, respectively).  Luc protein production from the 
set of IR mutants ranged from 40.4 to 103.2 RLU per well, with IR mutant 1 producing 
the highest levels of protein.  IR mutant 2 and IR mutant 3 produced similar levels of 
LUC protein (98.2 and 74.0 RLU per well on average).  The lowest levels of LUC protein 
production were seen for IR mutant 4, at an average of 40.6 RLU per well.  IR mutants 1 
had significantly higher levels of LUC protein production than either IR mutant 3 
(p=0.0197) or IR mutant 4 (p=0.0067).  IR mutant 4 produced significantly less LUC 
protein than all other mutants (p-values from 0.0067 to 0.0140, figure 4.17).   
Figure 4.16 Determination of effect of mutation of the pCATLUC minigenome 
gene junction on CAT and LUC protein expression.  The mean of three 
independent experiments and standard error were taken.  IR1 to 4 are minigenome 
plasmids IR mutants 1 to 4.  ‘APV (-)’ indicated the control (no L plasmid added). 
IR1 IR2 IR3 IR4 APV (-) 
IR mutant
CAT 
(ng/well) 
0 
20 
40 
60 
80 
100 
120 
A
m
ou
nt
 p
ro
te
in
 p
er
 w
el
l 
LUC 
(RLU/well)
 107
 
The levels of CAT protein production from IR mutants 1 to 4 were also compared to 
CAT protein production from the pCATLUC minigenome that was included as the 
positive control.  Modification of the CAT-LUC gene junction in this plasmid to be the 
longer SH-G gene junction found in IR mutant 1 (figure 4.4) resulted in consistently 
higher levels of CAT production (data not shown, 23.7ng for the pCATLUC minigenome 
verses 30.0ng for IR mutant 1 plasmid), indicating that production of protein from the 
first ORF of the dicistronic minigenome was affected by mutation of the gene junction.  
Levels of LUC protein production from the IR mutant 1 were, conversely, consistently 
lower than the levels produced from the pCATLUC minigenome (95.5 verses 171.3 RLU 
per well, respectively).  The control experiments (no L plasmid added to the PRS) gave 
an average of 0.0ng of CAT protein per well and an average 0.6 RLU of LUC protein per 
well.   
Figure 4.17 P values determined using the Paired T Test for significance 
between the IR mutants 1 to 4 for CAT and LUC protein values.   Using the 
Paired T Test of significance, the CAT protein (top) and LUC protein (bottom) p-
values for IR mutants 1 to 4 were compared (labelled 1 to 4).  The pairs that are 
significantly different (based on a 0.05 p-value significance level) are in bold. 
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 4.3.3 Generation of dual GS sequence point mutations  
The L GS sequence is the only non-consensus APV GS sequence and differs by three 
nucleotides from the consensus GS sequence (AGGACCAAU, differences underlined).  
Edworthy and Easton (2005) showed that the introduction of the L GS sequence in place 
of the consensus GS sequence before the LUC ORF in a dicistronic minigenome resulted 
in 47% of the activity seen for the consensus GS sequence.  Interestingly, when each 
mutation was introduced individually into the consensus GS sequence (mutants G1A, 
A6C, and G8A), the percentage activities of the constructs were similar (mutant G1A was 
46%, A6C was 52%, G8A was 59% activity), as was the combination of the first and last 
mutations together (mutant G1A/G8A, 40% activity). These experiments showed that the 
effect of the mutations was not cumulative (Edworthy and Easton, 2005) and also 
indicated that the L gene expression is determined by the GS sequence as well as the 5’ 
proximal location of the L gene in the genome RNA.   
 
The potential role of the GS in pathogenicity was raised following analysis of a naturally 
occurring mutation in a pathogenic isolate of the APVA CVL-14 virus (Dr. R. Ling, 
personal communication).  This pathogenic isolate was generated by passaging the non-
pathogenic APVA CVL-14 virus through turkeys until infection caused disease.  This 
pathogenic isolate was fully sequenced and three regions of mutation were found, 
including a mutation to the L GS sequence.  This mutation resulted in the L gene having 
the GS sequence 5’ GGGACCAAU 3’, which has only two changes compared to the 
standard consensus GS sequence (changes in bold).  No differences in transcription levels 
were seen in northern blot experiments of the pathogenic strain mRNA compared to the 
wildtype virus mRNA, suggesting that the mutation to the L GS sequence did not affect L 
gene transcription.  The L GS mutation was introduced into the CASA APV full-length 
genome and the virus rescued from this was used to infect turkeys.  However, none of the 
viruses produced with the CASA backbone were viable (Prof. A. Easton, personal 
communication). 
 
In order to determine the potential effect of these mutations on gene expression, two 
mutants were created containing two out of the three possible L GS sequence changes.  
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They were named G1A/A6C (GS sequence AGGACCAGU) and A6C/G8A (GS 
sequence GGGACCAAU), indicating the original nucleotide, its position in the GS 
sequence and the mutant nucleotide.   
 
The construction of the A6C/G8A and G1C/A6C dual GS sequence mutants was carried 
out as follows.  PCR was performed using Pfu DNA polymerase (Stratagene) following 
the manufacturer’s instructions. The mutagenic forward primers for each reaction and 
different dicistronic minigenome templates are listed in table 4.2.  The reverse primer for 
all these PCRs was the T7prom primer (appendix A).  The PCR products were used to 
create mutated fragments for ligation into the APV pCATLUC minigenome.  The 
products of PCR were sized on an agarose gel, as shown in figure 4.18.  PCR products 
were then purified by gel extraction to remove template DNA, as described in section 
2.5.3.1.  The purified PCR product was then digested with Cla1 and SphI enzymes, the 
products separated on an agarose gel, and the 675bp band extracted.  The vector was 
obtained by digesting the pCATLUC minigenome with Cla1 and Sph1 enzymes and 
purified as for the insertion fragments.  Ligation of the mutated insertion fragments into 
the vector fragment was then carried out and the ligation mixture was transformed into 
competent E. coli DH5α.  Plasmid DNA was prepared and screened by sequencing of the 
insert region.  Samples with the correct insertion were subjected to large-scale 
preparation and fully sequenced. 
 
 
PCR name:  DNA template: Forward primer:           
G1A/A6C PCR 1 G1A   ADM G1A/A6C 
G1A/A6C PCR 2 A6C   ADM G1A/A6C 
A6C/G8A PCR 3 A6C   ADM A6C/G8A 
A6C/G8A PCR 4 G8A   ADM A6C/G8A 
G1A/A6C PCR 5 DSMG   ADM G1A/A6C 
A6C/G8A PCR 6 DSMG ADM A6C/G8A
Table 4.2 Primers and template pairs used for generation of dual GS 
sequence mutants.  For each PCR, a DNA template was selected that was either 
unmutated (the DSMG plasmid) or had been mutated at the LUC GS sequence.  
Primers were designed to introduce one or two point mutations into the LUC GS 
sequence.  Full primer sequence can be found in appendix A. 
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4.3.4 Effect of dual GS sequence point mutation 
The effect of the introduction of two of the three non-consensus GS sequence bases to the 
LUC gene GS sequence on LUC protein production was calculated as ‘percentage 
activity’ (i.e. the LUC:CAT protein ratio for the mutant plasmid divided by the 
LUC:CAT protein ratio for the wildtype plasmid, multiplied by 100) as described 
previously (Edworthy and Easton, 2005)(figure 4.19).  The effect of dual mutation for 
mutant G1A/A6C was to reduce the activity of the dicistronic minigenome to 25% of the 
wildtype pCATLUC minigenome.  Mutant A6C/G8A gave 40% the activity of the 
unmutated wildtype pCATLUC minigenome.  The low level of activity seen for mutant 
G1A/A6C, even lower than that for the L GS sequence, suggests that the third change 
(G8A) may compensate for the effect of the first two.  The activity of the mutant G8A 
alone was the highest of the L GS single point mutations with 59% activity.  For all of the 
dual and triple mutants, the resultant effect on gene expression was not an average or an 
addition of the effects seen with the single mutations.  However, the two point mutations 
with lowest levels of activity (G1A with 46% and A6C with 52%) when present in 
combination did result in the dual mutant with the lowest activity levels (G1A/A6C with 
25%).     
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Figure 4.18 Agarose gel examining PCR products for cloning of L GS sequence 
dual mutants.  G1A/A6C PCR 1 (PCR 1), G1A/A6C PCR 2 (PCR 2), A6C/G8A 
PCR 3 (PCR 3), A6C/G8A PCR 4 (PCR 4), G1A/A6C PCR 5 (PCR 5), and 
A6C/G8A PCR 6 (PCR 6) all produced the desired approximately 1960bp band (as 
indicated by the arrow) using the template and forward primer combination listed in 
table 4.3.  The reverse primer for all reactions was the T7prom primer.    
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4.4 Conclusions  
The value of the minigenome system as a fast and reliable way to measure the effect of 
mutation of the cis- and trans- acting signals of the APV genome was investigated by 
examining the effect of GS sequence mutations on mRNA and protein production 
simultaneously.  Northern blot analysis to detect LUC mRNA showed a strong 
correlation between mutation of the GS sequence, a change in its ability to act as a 
transcriptional promoter, and a change in the levels of protein detected from the reporter 
genes.  Of particular interest was mutant A7U, whereby mutation of the A at position 
seven of the GS sequence resulted in an alternative start codon being introduced upstream 
of the LUC gene start codon. It was possible that some of the loss of functional protein 
Figure 4.19 Effect of dual GS point mutation on reporter protein expression.  
Mutants G1A/A6C and A6C/G8A were cloned (chequered bars). The average and 
standard error of the percentage activity was taken from the means of two or three 
independent experiments of PRS experiments.  Error bars indicate standard error.  
Data for mutants G1A, A6C, G8A, G1A/G8A, and ‘L GS’ (having the L non-
consensus GS sequence before the LUC gene) is reproduced here from Edworthy 
and Easton (2005) for comparison, all mutations being either single or dual point 
mutations found in the non-consensus L GS sequence.  ‘Wildtype’ is the 
unmutated pCATLUC minigenome.    
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observed for this mutant was due to use of the introduced codon for translation.  
However, Northern blot analysis showed that the mutation resulted in a loss of LUC 
mRNA production.  For all the GS sequence mutants examined, the loss of LUC protein 
correlated directly with a loss of LUC mRNA production.  The GS sequence mutations 
appeared to directly affect transcription of mRNAs rather than producing read-through or 
truncated transcripts.  This result agrees with similar analysis done for the PVM and RSV 
where the gene start sequences mutations that affected levels of reporter protein also 
affected mRNA production (Dibben and Easton, 2007; Kuo et al., 1996b).    
 
The L GS non-consensus sequence has been shown to down-regulate mRNA production 
(Edworthy and Easton, 2005).  It was hypothesized that the APV L gene start sequence 
contained changes which in groups of two out of the three would also reduce mRNA, and 
hence protein, production in an additive manner.  Here, L GS sequence dual mutants 
showed a non-additive effect.   
 
The plasmid rescue system was used to investigate the effect of naturally occurring gene 
junction mutations on upstream and downstream protein expression.  The mutations were 
observed when an APV strain (field stain #8544) was found to be both protective and 
have some post vaccine virulence.  From this virus strain, a less virulent virus (virus P20) 
was purified, as well as non-protective/non-virulent virus stains (viruses H and F) and 
protective/non-virulent virus stains (viruses A-E, G, J, K and M).  Sequence changes in 
the SH-G gene junction were found to be the sole differences between some of the 
protective and non-protective viruses.  By cloning these gene junction mutations into the 
dicistronic minigenome used in the APV PRS, a number of conclusions can be drawn.  IR 
mutants 2-4 all have an A to G change at base 4377.  This is the only difference between 
the pathogenic strain #8544 virus SH-G gene junction and the non-pathogenic virus SH-
G gene junctions.  This suggested that the base change may contribute to the non-
pathogenic phenotype.  However, no effect on protein production due solely to the 
mutation was seen.  Looking at the SH-G gene junction of the non-protective, non-
pathogenic viruses (IR mutant 3 and 4), the gene junction sequence differs by one base in 
the GE sequence from the non-pathogenic but protective viruses.  However, only in the 
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case of IR mutant 4 does the GE sequence mutation affect mRNA levels of the 
downstream gene. The down-regulation of the downstream gene via mutation of the GE 
sequence in the case of IR mutant 4 may contribute to the non-protective phenotype.  
However, this effect on downstream gene expression was found only with the two IR 
mutant 4 mutations.  Thus, down-regulation of G gene expression may be one mechanism 
by which the virus becomes non-protective.    
 
The dicistronic minigenome gene junction mutation results presented here were found to 
agree well with analysis of identical gene junction mutations introduced into the SH-G 
gene junction of the cloned APV CASA genome (Naylor et al., 2007).  Naylor et al. 
(2007) mutated the APV CASA genome SH-G gene junction to be identical to the gene 
junction of IR mutants 2 to 4 (cloned viral genomes rC, rH, and rF, respectively).  The 
recombinant genomes rC, rH and rF were uses in the full-length rescue system to create 
recombinant viruses. Unfortunately, it was not possible to directly determine the amounts 
of SH and G protein produced from these viruses, as no antibodies were available.  
However, the SH and G gene mRNA levels were determined for theses viruses by 
quantitative northern blot.  The SH and G gene mRNA levels from the original viruses 
#8544, C, and F (virus H was unavailable for analysis) were also determined and the 
effect of the mutations compared to the effect of the IR mutant gene junctions on CAT 
and luc protein expression.  The ‘activity’ of each of the gene junction mutants was 
determined comparing the expression of the upstream protein (CAT) or mRNA (SH RNA 
and SH-G read-through mRNA) to the downstream protein (LUC) or mRNA (G gene 
RNA)(Naylor et al., 2007).  The ‘percentage activity’ was determined as described for the 
GS mutants previously (Edworthy and Easton, 2005) by dividing the mutant activity level 
by the relevant wild-type activity level (virus #8544 for all viruses and minigenome IR 
mutant 1 for IR mutants 1 to 4) and multiplying by 100 (Edworthy and Easton, 
2005)(figure 4.20).  The average CAT and LUC protein level ratios from the IR mutants 
3 and 4 were all within the range of the two recombinant viruses examined.  The activity 
level of IR mutant 2 was closer to that of the virus C than the recombinate virus rC, but 
for all measures of activiy, the GE found in IR mutant 4 gave the lowest activity. 
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For RSV, deletion of the GE sequence from a CAT minigenome in the RSV PRS reduced 
CAT protein expression to 1.6% of wildtype production. Northern blots of the mutant 
showed a loss of the CAT mRNA.  Kuo et al. (1996) hypothesized that this loss of 
expression from the GE sequence deletion mutant was likely to be due to a disruption of 
the polyadenylation of RNA transcripts.  Using a RSV dicistronic minigenome, deletion 
of the CAT GE sequence resulted in 16% CAT expression and 0.9% LUC protein 
expression.  Northern blotting showed that CAT-LUC read-through mRNA was being 
produced primarily, with only a small amount of LUC mRNA.  They concluded that the 
viral polymerase could not recognize the downstream GS sequence if the upstream GE 
sequence was deleted (Kuo et al., 1996b).        
 
Determining the effect of a mutation on viral gene expression and the effect of the change 
in gene expression on phenotype is not always straightforward.  The PRS can be used for 
rapid screening of gene junction mutants for their effect on upstream and downstream 
Figure 4.20 Percentage activity of gene junction mutation in vitro and in vivo.  
The percentage activity was calculated as described by Edworthy and Easton (2005) 
for the IR mutant genomes 1-4.  The percentage activity for the same gene junction 
mutations in naturally occurring APV virus mutants (virus #8544, virus C and virus 
F) and recombinant APV viruses (virus rC, rH and rF)(Naylor et al., 2007).  For the 
in vivo experiments with the IR mutant genomes, the mean of three independent 
experiments was calculated and the standard error determined.    
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gene expression.  These mutations can then be used in the production rationally designed 
vaccine candidates that are protective and attenuated.   
 116
 
 
 
Chapter 5: 
Heterologous and chimeric protein 
function in the  
APV plasmid rescue system 
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5.1 Introduction 
The development of a plasmid-based rescue system (PRS) for APV, described in chapter 
3, provided a direct way to investigate the function of the trans-acting N, P, L and M2-1 
proteins as well as the cis-acting leader, trailer, and gene junction non-translated genomic 
sequences.  The substitution of functionally, or genetically, equivalent proteins from 
related viruses in place of one or more of the helper plasmids (heterologous rescue) has 
been used to investigate the role of conserved residues in protein function.  The result of 
transfection of a set of homologous helper plasmids together with the genome or 
minigenome of a related virus can also provide information about the importance of 
conservation of cis-acting non-translated sequences.  Heterologous rescue attempts using 
reverse genetics have been used to show the close functional relationship of the cis-acting 
and trans-acting signals of the metapneumoviruses APV subgroup C and human 
metapneumovirus (Govindarajan et al., 2006) and to generate candidate vaccine viruses 
(Pham et al., 2005).  For RSV, rescue of a bovine RSV (bRSV) minigenome was 
achieved using ovine and human RS helper virus, showing that the bRSV cis-acting 
signals can be recognized by ovine RSV and human RSV polymerase complex proteins 
(Yunus et al., 1999).  A similar approach has been described for parainfluenza virus types 
1 and 3, which were shown to be able to rescue a Sendai virus DI genome when the RNA 
template was encapsidated by parainfluenza virus NP protein.  The inability of either 
parainfluenza virus to rescue the Sendai virus genome when encapsidated with Sendai 
virus NP protein suggested that the NP:polymerase interaction was virus specific (Curran 
and Kolakofsky, 1991).  Using the established APV plasmid-based rescue system, 
heterologous rescue of the RSV, PVM and hMPV minigenome by APV N, P, L and M2 
proteins was attempted.  
 
Heterologous rescue attempts to determine the level of functional homology between 
viruses.  The other basic way of predicting functional homology is by comparing protein 
identity levels.  As described in chapter 1, but using the clone sequences from chapter 3, 
the percentage of amino acid identity of the pneumovirus N, P, and L and M2-1 proteins 
was carried out as described in section 1.15 and is presented in table 5.1.  Amino acid 
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identity here refers to the number of residues that match exactly between the two 
sequences.  It was also useful to consider conserved substitutions in a percentage identity 
calculation (here referred to as percentage identity with conserved substitutions).  This 
calculation includes residues whose comparison yields a greater than zero score in the 
Blosum 62 scoring table using GeneDoc software.  For the purposes of this discussion, 
levels of amino acid identity that are 60% or above will be termed ‘high’, levels between 
60 and 35% ‘low’, and levels of 34% and below ‘very low’. 
 
Comparing the N, P, L and M2-1 proteins of these pneumoviruses, overall APV has the 
highest levels of homology with hMPV, followed by PVM and RSV.  Previously, it was 
shown that the APV helper plasmids were unable to functionally replace the RSV helper 
plasmids in the RSV PRS (Stokes, 2003), as might be expected from the low levels of 
homology between these proteins.  The APV subgroup A N protein was 391 residues in 
length (Li et al., 1996) and has a high (68%) level of amino acid identity with the 394 
residue hMPV N protein (van den Hoogen et al., 2001), rising to 86% when conservative 
substitutions are included.  A region of 98% identity was found in the carboxyl-terminal 
half of the APV N protein, from residues 238-290.  The APV N protein was found to 
have low levels of homology to the 393 residue PVM N protein and 391 residue RSV N 
protein (Thorpe and Easton, 2005; Tolley et al., 1996) with 42 and 39% amino acid 
identity, respectively.   
Table 5.1 Amino acid identities of the APV N, P, L and M2-1 protein sequences 
with the homologous proteins of hMPV, PVM and RSV.  The percentage amino acid 
identity, calculated as described in section 2.15, is shown here in pair-wise comparisons 
of the APV N, P, L or M2-1 protein with the equivalent hMPV, PVM or RSV protein.  
For comparison of the APV and hMPV proteins, included in parenthesis is a percentage 
identity calculation including similar amino acid substitutions based on a Blosum 65 
amino acid similarity matrix.   
                            hMPV                   PVM          RSV 
APV N                68% (86%)            42%            39% 
APV P          55% (69%)            25%            24% 
APV L         63% (79%)            50%            43% 
APV M2-1          71% (84%)            35%            39%
 119
The APV P protein, at 287 residues (Ling et al., 1995; Ling and Pringle, 1988), was 
shorter than the hMPV and PVM P proteins which are 294 and 295 residues in length, 
respectively (Thorpe and Easton, 2005; van den Hoogen et al., 2001), but longer than the 
RSV 241 residue protein (Tolley et al., 1996).  Overall, the APV P protein has lower 
homology with the hMPV, PVM, and RSV P proteins than was seen for the N proteins.  
APV P has 55% identity with hMPV (69% with similar residue substitution), but the first 
28 residues are 75% identical and the carboxyl-terminus half of the protein (residues 139 
to 278) are 72% identical.  The carboxyl-terminus has two regions of 94% and 83% 
identity (residues 168 to 203 and 227 to 256, respectively).  The APV P protein has 25% 
and 24% amino acid identity with PVM and RSV, respectively, but the region spanning 
residues 168 to 203 shows a 61% amino acid identity across the pneumovirus sub-family.   
 
The APV L protein was 2004 residues long (Randhawa et al., 1996b), which was similar 
to the hMPV L protein (2005 residues; (van den Hoogen et al., 2001), but shorter than the 
PVM and RSV L proteins (2040 and 2165 residues, respectively)(Thorpe and Easton, 
2005; Tolley et al., 1996).  The APV L protein has 63% amino acid identity with the 
hMPV L protein, rising to 79% when including similar residue substitutions.  When 
compared to PVM or RSV, the APV L protein has 50% and 43% amino acid identity, 
respectively.  However, regions of 100% conservation exist of up to 11 consecutive 
residues (for example, APV residues 1185 to 1195) that are conserved in all four viruses .  
 
The APV M2-1 protein was 186 residues in length (Ling et al., 1992) and has high level 
(71%) of amino acid identity with the 187 residue hMPV M2-1 protein (van den Hoogen 
et al., 2001).  The level of homology rises to 84% when including similar residue 
substitutions.  The APV and hMPV M2-1 have eight regions of 6 to 17 consecutive 
residues that are conserved.  The levels of amino acid identity between the APV M2-1 
protein and the RSV or PVM M2-1 proteins are lower, at 39% or 35% identity, 
respectively.        
 
The minigenomes used in the PRS contain only non-translated nucleotides from the viral 
genomes (section 1.5).  Considering the non-translated regions of the pneumovirus 
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genomes, comparisons of the leader sequences (section 1.4.4) showed that APV has low 
levels of nucleotide identity with either hMPV (41%), PVM (53%) or RSV (53%), 
however 10 of the first 11 nucleotides from the viral 3’ end are identical for APV, RSV 
and PVM.  The trailer region of APV (section 1.4) has less nucleotide identity with the 
other pneumoviruses- hMPV (22%), RSV (16%), and PVM (13%)- but all four viruses 
have identical sequence for 11 out of the 12 nucleotides at the viral 5’ end.  All four virus 
genomes have a similar gene start (GS) sequence for their first gene, with hMPV and 
APV containing identical motifs of 5’GGGACAAUG 3’(mRNA sense).  The PVM and 
the RSV first (NS1) gene start sequences contain one and two base differences each, with 
sequences of 5’AGGACAAGU 3’ and 5’GGGGCAAAU 3,’ respectively (table 1.14).  
From mutational analysis of the APV consensus gene start sequence which was found 
before the first (N) gene, it has been shown that mutation of the first position from a G to 
an A residue decreases activity of the GS sequence by approximately 50%, as does 
mutation of position 4 from an A to a C residue or mutation of position 8 from an G to an 
A residue (figure 4.1) (Edworthy and Easton, 2005).  However, as shown in figure 4.19, 
the effect of multiple mutations to the APV gene start sequence was not an additive effect 
(section 4.3.4).  The gene end (GE) sequences of pneumoviruses are poorly conserved but 
have the consensus sequence of uAGUuA(n)2-3(A)4-6 (table 5.2).  Kuo et al. (1997) 
showed that the diverse RSV-A2 GE sequences were equally able to facilitate mRNA 
production except for the NS1 and NS2 GE sequences (60% as efficient).  The RSV-S2 
GE sequences are identical to those found for RSV-A2 (Kuo et al., 1997) except for the 
N and P GE sequences which have an additional A at the 3’ end, the M GE sequence 
which has one fewer A at the 3’ end, and the G GS sequence which has sequence 
AGUCAUUAAAAA instead of the A2 G GE sequence of  AGUUACUUAAAAA (5’ to 
3’, (+) sense, differences in bold).  The intergenic regions of pneumoviruses vary greatly 
in length and content and for RSV-A2 it was shown that the intergenic region did not 
play a role in transcription (Kuo et al., 1996a).     
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Previously, Stokes (2003) used the RSV PRS to investigate the functioning of chimeric N 
and M2-1 proteins with the aim to isolate functional regions of the RSV N and M2-1 
proteins.  It was shown that the PVM M2-1 protein, although 40% identical to the RSV 
M2-1 and retaining a conserved Cys3-His1 motif, could not functionally replace the RSV 
M2-1 protein in a RSV PRS using lacZ as the reporter protein.  Chimeras were created 
with RSV and APV M2-1 protein and used to identify two functional regions that 
separately affected production of the first (CAT) gene (the N-terminal 44 residues) and 
both the first and second (LUC) genes (residues 93-152) from the RSV pCATLUC 
minigenome (Stokes, 2003) (Dr. A. Marriott, personal communication).  Similarly, it was 
shown that the APV N protein could not replace the RSV N protein in the RSV PRS.  
Truncated versions of the RSV N proteins were non-viable in the RSV PRS and hence 
chimeric RSV/PVM N proteins were created to examine the RSV N protein functional 
regions.  Using these chimeras, it was showed that residues 352-369 are essential for 
function of the N protein and binding to the P protein (Stokes, 2003; Stokes et al., 2003). 
 
The aim of this section of the project was to determine the level of functionality of each 
of the RSV, PVM and hMPV N, P, L and M2-1 proteins in the APV PRS.  For hMPV, 
the APV N, P, L and M2-1 proteins were substituted individually into the hMPV PRS to 
determine their ability to functionally replace the equivalent hMPV protein and the 
hMPV N, P, L and M2-1 proteins were tested collectively for their ability to rescue the 
APV minigenome.  The ability of the APV N, P, L and M2-1 proteins to collectively 
Table 5.2 Pneumovirus consensus gene start and gene end sequences.  Positions 
that have only a purine (r) or pyrimidine (y) are marked.    
ashown here 5’ to 3’, (+) sense  
uAGUuAnnn(An)GGGGCAAUaRSV 
UAGUUAanu(An)AGGAyAArUPVM 
uAGUUA(n)2-3(A)4-6GGGACAArUhMPV 
nAGUtAnnn(An)GGGACAAGUAPV 
Consensus GE 
sequencea 
Consensus GS 
sequencea  
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rescue the RSV, PVM and hMPV mini-genomes was also investigated.  The APV M2-1 
protein hypothesised functional domains were also investigated utilizing a set of 
RSV/APV M2-1 protein chimeras.  
5.2 Effect of APV/PVM and APV/RSV heterologous helper plasmid sets on protein 
expression in the APV plasmid rescue system 
Plasmids containing the RSV or PVM N, P, L or M2-1 genes (provided by Dr. H. Stokes, 
Dr. A. Marriott and Dr. O. Dibben) were individually substituted into the APV PRS and 
the effect on protein production from the pCAT APV minigenome assessed.  The RSV 
helper plasmids have been successfully used to rescue RSV minigenome (Marriott and 
Easton, 1999) and were provided by Dr. A. Marriott for use in these experiments.  The 
PVM helper plasmids have also been fully assessed and found to be functional in the 
PVM plasmid rescue system (Dibben, 2006; Dibben and Easton, 2007) and were 
provided by Dr. O. Dibben for use in these experiments.  Experiments were carried out as 
described in section 3.3, with substitutions and variations in amount of heterologous 
plasmid transfected as indicated.  
 
The RSV helper plasmids were investigated for their ability to functionally replace the 
equivalent APV helper plasmids.  As can be seen in figure 5.1, the RSV N plasmid at 
concentrations of 0.05, 0.1, or 0.4µg/well failed to support minigenome rescue at levels 
significantly above the control containing no RSV N plasmid.  Substitution of RSV P and 
L plasmids at 0.2 and 0.4 or 0.1 and 0.3µg/well, respectively, gave levels of CAT protein 
production that were not significantly higher than the respective negative controls (i.e. 
when of no P or no L plasmid was added).  The RSV minigenome was found to have 
some activity in the APV PRS, however the level was only 0.27% of that measured using 
the APV minigenome.  As the M2-1 protein was not absolutely required for APV 
transcription (section 3.3.2), the high levels of protein production in the absence of M2-1 
protein were expected and substitution of the RSV M2-1 plasmid at either 0.01 or 
0.025µg/well gave levels of CAT protein production that were not significantly above 
those seen in the absence of any M2-1 protein. 
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Figure 5.1 Effect of heterologous substitution of RSV plasmids. The RSV N, P, L, 
RSV pCAT minigenome plasmid (A) or the M2-1 plasmid (B) was substituted for the 
APV analogue in the APV plasmid rescue system and compared to the levels of CAT 
protein achieved using a homologous set of helper plasmids and the APV pCAT 
minigenome plasmid.  The CAT protein levels for the positive control (‘All APV 
plasmids’) that has no RSV plasmid substitution and negative controls of no plasmid 
for each of the helper plasmids were measured. The mean and standard error of two 
to four independent experiments was taken and plus or minus one standard error 
utilized for error bars. 
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The PVM helper plasmids were also investigated for their ability to functionally replace 
the equivalent APV helper plasmids.  As can be seen in figure 5.2, the addition of the 
PVM N plasmid at concentrations of 0.05, 0.1, or 0.4µg/well failed to support 
minigenome rescue.  Substitution of PVM P and L plasmids at 0.2 and 0.4 or 0.1 and 
0.3µg/well, respectively, gave levels of CAT protein production that were not 
significantly higher than the negative controls.  The PVM minigenome was found to have 
some activity in the APV PRS, however the level was only 1.7% of that measured using 
the APV minigenome.  As the M2-1 protein was not essential for APV transcription, the 
high levels of protein production in the absence of M2-1 protein were expected and 
substitution of the PVM M2-1 plasmid at either 0.01 or 0.025µg/well gave levels of CAT 
protein production which were not significantly above those seen in the absence of any 
M2-1 protein.   
 
Thus, none of the PVM or RSV helper proteins were found to be similar enough in 
protein or RNA binding ability to be able to functionally replace the equivalent APV 
proteins in the APV PRS.  Interestingly, both PVM and RSV minigenomes showed very 
low levels of activity, supporting previous findings that nucleocapsid complexes of 
related viruses can support replication and transcription of another virus in the same 
genus (Buchholz et al., 1999; Curran and Kolakofsky, 1991; Govindarajan et al., 2006; 
Halpin et al., 2004; Pelet et al., 1996; Theriault et al., 2004; Yunus et al., 1999).        
5.3 Effect of APV and hMPV heterologous helper plasmid sets on protein expression 
in the hMPV plasmid rescue system and APV plasmid rescue system 
The ability of the closely related APV and hMPV plasmid rescue system components to 
functionally replace each other was assessed by substituting the heterologous N, P, L, 
M2-1 or pCAT minigenome plasmid into the APV or hMPV plasmid rescue system.  The 
hMPV plasmid rescue has previously been established (Herfst et al., 2004) and the 
hMPV pN, pP, pL and pCAT minigenome were the generous gift of Prof. A. Osterhaus.  
Plasmid rescue experiments were carried out as described in section 3.3, using 0.2µg/well  
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Figure 5.2 Effect of heterologous substitution of PVM plasmids. The PVM N, P, 
L (A), M2-1 plasmid or the PVM pCAT minigenome plasmid (B) was substituted 
into the APV plasmid rescue system and compared to the levels of CAT protein 
achieved using a homologous set of helper plasmids and the APV pCAT 
minigenome plasmid.  The mean and standard error of two to four independent 
experiments was taken. 
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pN and pCAT minigenome plasmids, 0.1µg/well pP and pL plasmids and 0.01µg/well 
pM2-1 plasmids with substitutions of heterologous plasmid as indicated.  
 
The result of exchanging the N, P or L plasmids is shown in figure 5.3.  As can be seen, 
heterologous substitution of the N or L plasmids into either the APV or hMPV PRS did 
not result in CAT protein production significantly above the negative control samples, 
labelled as either ‘Plasmid absent from hMPV PRS’ or ‘Plasmid absent from APV PRS.’  
Interestingly, the hMPV P protein did show activity in the APV PRS, although at a level 
0.6% of that seen using the APV P plasmid (‘All APV… plasmids’ column, figure 5.4).   
This level of activity was also unexpected as the P proteins of APV and hMPV have the 
lowest levels of amino acid identity of all the helper proteins, at 55%.  Also, experiments 
with hMPV and APV subgroup C showed that an hMPV full-length cloned genome could 
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Figure 5.3 Effect of heterologous substitution of APV and hMPV N, P or L 
plasmids.  APV and hMPV heterologous substitution of N, P or L gene plasmids 
was carried out.  The average and standard error three independent experiments 
for each sample were taken.  A negative control was included for each sample set, 
labelled as ‘Plasmid absent from hMPV PRS’ or ‘Plasmid absent from APV 
PRS’. 
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be rescued with one substitution in the helper plasmid set at 23%, 5%, and 6% with APV 
subgroup C L, N, and P plasmids, respectively.  Conversely, a cloned APV subgroup C 
full-length genome could be rescued to 28%, 10%, and 12% using hMPV L, N, and P 
plasmids, respectively (Govindarajan et al., 2006).  In both cases the heterologous P 
plasmid was least able to function in the full-length rescue system, unlike the APV 
subgroup A P plasmid used here in the PRS.  This may be due to the high level of amino 
acid identity between the APV subgroup C P protein and the hMPV P protein (67%) 
(Govindarajan et al., 2006). 
 
Rescue of the hMPV pCAT minigenome plasmid using APV helper plasmids and rescue 
the APV pCAT minigenome plasmid using hMPV helper plasmids was also carried out.  
As can be seen in figure 5.4, CAT protein production was obtained.  Although not able to 
fully replace the equivalent minigenome, rescue using the hMPV and APV heterologous 
minigenome plasmids generated 29% (18000ng of CAT for heterologous rescue verses 
62000pg for homologous rescue) and 26% of the CAT protein of the homologous 
plasmid rescue experiments (4000ng of CAT for heterologous rescue verses 15000pg for 
homologous rescue).  This was not surprising given the high level of homology of the cis-
acting sequences in the APV subgroup A and hMPV genomes and the finding that an 
hMPV full-length cloned genome was rescued by a set of APV subgroup C helper 
plasmids to 52% virus recovery. Conversely, rescue of an APV subgroup C full-length 
cloned genome was recovered with hMPV helper plasmids at 47% of homologous virus 
recovery (Govindarajan et al., 2006). 
 
The action of the heterologous M2-1 plasmid was tested in the hMPV and APV plasmid 
rescue systems.  As shown in figure 5.4, the M2-1 plasmid was not able to functionally 
replace the homologous plasmids as not significantly more CAT protein was produced 
from these samples than in the absence of any M2-1 protein in the system.  This result 
was consistent with the results of experiments using the full-length rescue system where 
virus was rescued using a heterologous M2-1 plasmid (Govindarajan et al., 2006). 
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5.4 Functionality of M2-1 APV/RSV chimeras in the APV plasmid rescue system 
It was not expected that the RSV helper plasmids could replace the APV plasmids, as the 
percentage identity between their N, P, L and M2-1 genes was low (24 to 43%, section 
5.1).  This property was utilized to create chimeric RSV/APV N protein and chimeric 
 
RSV/APV M2-1 proteins which were used to assess the functionality of a sub-section of 
the RSV proteins (Stokes, 2003; Stokes et al., 2003; Zhou et al., 2003).  This strategy 
was found to be useful as truncated protein can lack the structure of a complete protein 
and be mis-folded even if they have retained essential residues.   
hMPV homologous 
rescue 
 
APV homologous 
rescue 
Figure 5.4 Effect of heterologous substitution of APV and hMPV minigenome or 
M2-1 plasmids.  APV and hMPV heterologous substitution of M2-1 gene and 
minigenome plasmids was carried out.  The average and standard error were taken 
from three independent experiments.  A positive (no substitution) and a no M2-1 
plasmid control were included in each plate. 
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Investigation of the function of regions of the RSV M2-1 protein was initially carried out 
by excluding the M2-1 protein from the RSV PRS or by deleting the M2-1 gene start 
signal from full-length cloned genomes (Collins et al., 1995; Fearns and Collins, 1999; 
Mason et al., 2003).  These studies established the M2-1 protein as a transcriptional 
elongation and anti-termination factor that was necessary for efficient transcription of 
mRNAs downstream of the first ORF of either the RSV mini-genome or full-length 
genome.  The RSV M2-1 protein has also been shown to bind P protein, RNA and to 
activate Rel A (of the NFκβ family) (Cartee and Wertz, 2001; Mason et al., 2003; 
Reimers et al., 2005).  Stokes (2003) carried out an initial investigation of the functional 
regions of the RSV M2-1 gene by creating three deletion mutants of the M2-1 expression 
plasmid which were truncated at amino acid 44, 92 or 153 (figure 5.5).  In summary, the 
resulting truncated M2-1 proteins were tested for their ability to enhance mRNA 
production in the RSV PRS and it was found that these mutants had lost all ability to 
enhance mRNA production in the PRS.  Additionally, it was shown that the APV M2-1 
protein was not able to functionally replace the RSV M2-1 protein in the RSV PRS.   
 
A chimeric protein strategy was also attempted (Stokes, 2003; Stokes et al., 2003), 
whereby sections of the RSV gene sequence were replaced with the equivalent APV M2-
1 sequence, as shown in figure 5.6.  Regions of conserved sequence (three consecutive 
 
RSV M2-1 
 
 
RSV∆150 
 
 
RSVΔ102 
 
 
RSVΔ41 
1                                                                                        194      
Figure 5.5 RSV M2-1 protein deletion mutants.  Shown here is a diagrammatic 
representation of RSV M2-1 deletion mutant proteins.  Amino acids were deleted 
from the carboxyl terminus and numbers represent amino at the start and end of 
the protein. 
1                     44 
1                                           92
1                                                                  153
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residues) between the APV and RSV M2-1 protein sequences were utilized to divide the 
protein into four sections.  Six chimeric APV/RSV M2-1 protein expression plasmids 
were created, as shown in figure 5.6, and shown to produce proteins of the expected size 
(Stokes, 2003)(Dr. A. Marriott, personal communication).     
    
In this study, the APV/RSV M2-1 chimeras were tested in the APV PRS to determine if 
sub-sections of the APV M2-1 sequence could enhance protein production from the APV 
pCATLUC minigenome.  The RSV M2-1 protein was shown to be unable to functionally 
APV
M2-1 chimera 1
M2-1 chimera 2
M2-1 chimera 3
M2-1 chimera 4
M2-1 chimera 5
M2-1 chimera 6
RSV
B 
M2-1            Section composition: 
Chimera:   RSV residues   APV residues   I          II         III          IV      
1         1-44   45-186            1-44      45-91    92-151   152-186 
2         1-92  92-186  1-44    45-92    92-151   152-186 
3         1-153   152-186 1-44     45-92    93-153   152-186 
4         45-194   1-44   1-44      45-92    93-153   154-194 
5         93-194   1-91  1-44      45-91    93-153   154-194  
6         154-194   1-151 1-44      45-91    92-151   154-194 
Section  I       Section II      Section III    Section IV 
Figure 5.6 Composition of APV/RSV chimeric M2-1 proteins.  A: Diagrammatic 
representation of APV/RSV M2-1 chimeric proteins.  Blue sections represent amino 
acids derived from the RSV M2-1 protein and gray sections represent amino acids 
derived from the APV M2-1 protein. B: The protein residue composition of each 
chimera is shown.  The residues from either the APV (in bold) or RSV M2-1 proteins 
which comprise Sections I-IV are presented under ‘Section composition’.  
A 
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replace the APV M2-1 protein in the APV PRS (section 5.2, figure 5.1).    Introduction of 
chimeras 1 to 6 into the PRS at 0.01µg/well as described in section 3.3 was carried out 
and the levels of CAT and LUC protein measured as described in section 2.9 to 2.11.  
Controls of APV M2-1 plasmid, RSV M2-1 plasmid and no M2-1 plasmid were included, 
as the APV PRS produces high levels of reporter protein even in the absence of the M2-1 
plasmid.  For each independent experiment, the protein values were calibrated against the 
control of the levels of CAT and LUC activity seen in the absence of the M2-1 plasmid 
and this value was set at 100%.  The standard error of the means of five independent 
experiments was utilized for the error bars and a negative control of transfection lacking 
the L plasmid was included for each experiment (figure 5.7).      
 
As can be seen in figure 5.1 and 5.8, the control experiment of addition of the RSV M2-1 
plasmid in place of the APV M2-1 plasmid in the APV PRS was unable to enhance 
reporter protein expression.  The APV M2-1 protein was also confirmed to be non-
essential in the APV PRS.  The addition of 0.01µg/well of APV M2-1 plasmid increased 
CAT protein production by more than four-fold and LUC relative light activity levels by 
more than three-fold above no M2-1 levels, confirming the results of the experiments in 
section 3.3.2.  Substitution of chimeric M2-1 plasmids 2, 3, 4 failed to produce levels of  
CAT protein significantly above the levels seen in the absence of any M2-1 plasmid.  
Substitution of chimeric M2-1 plasmids 5 and 6 produced low (6-20% over no M2-1 
control) levels of CAT protein.  Chimera 1, however, showed enhancement of both CAT 
and LUC protein production, with two-fold and 3.5 fold increases, respectively.  
Substitution of chimeric M2-1 plasmids 2, 3 and 6 produced low (6-20% over no M2-1 
control) levels of LUC protein and substitution of M2-1 chimeras 4 and 5 failed to 
produce levels of LUC protein significantly above the levels seen in the absence of any 
M2-1 plasmid.  Hence, while none of the M2-1 chimeric plasmids was able to fully 
replace the APV M2-1 plasmid in terms of the 3’ genome proximal gene (the CAT gene) 
transcription enhancement, the addition of 0.01µg/well of a M2-1 gene that has the first  
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Figure 5.7 The effect of APV/RSV M2-1 chimeric protein on CAT reporter protein 
expression in the APV PRS.  Each well was transfected with 0.2µg of pN10 and 
pCATLUC, 0.1µg of pP9 and pCITE L.  For chimeric substitutions, 0.01µg/well of 
chimeric M2-1 plasmid was added.  ‘RSV M2-1’ indicates that the RSV M2-1 
expression plasmid was added to the transfection mixture in place of the APV M2-1 
plasmid.  The APV (+), a positive control, had 0.01µg of APV pM2-1 added to the 
transfection mixture.  APV (-), a negative control, included the pN10, pP9 and pM2-1 in 
the transfection mixture but lacked the pCITE L plasmid.  All transfection mixtures were 
made up to 1µg/well with pT7.2 vector plasmid.  CAT protein expression (A) and LUC 
protein expression (B) were measured 48hr post-transfection.  The standard error was 
determined from three to five independent replicates.  
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44 residues substituted with RSV M2-1 sequence was able to enhance the second (LUC) 
gene transcription to wildtype levels.    
 
The high level of activity of chimera 1 but not the other chimeras suggests that section II 
along with either section III and/or section IV (figure 5.6) of the M2-1 protein are 
necessary for transcriptional enhancement.  This was supported by the data obtained 
using chimera 4, which contains section I but not sections II, III or IV, and which was the 
only chimera to give no enhancement of transcription of either the CAT or the LUC gene.  
No chimera was constructed which contained sections II and IV, however chimera 6 
contained both sections II and III; this chimera gave low levels of both CAT and LUC 
protein expression.   
 
Chimera 5, with sections I and II, stimulated a very low level of CAT production (110% 
+/-9%), but not significantly more than chimera 4 (100% +/-4) and neither gave 
significant LUC production.  This suggests that sections I or sections I and II are not 
sufficient to enhance protein production in the APV PRS.  Chimeras 2 and 3 did not 
produce enhancement of CAT production, but did (at low levels) enhance LUC 
production, suggesting that section IV may have a small role in second gene transcription 
enhancement.   
5.5 Discussion 
Heterologous substitution, the substitution of genes from other viruses, into reverse 
genetics systems has been used extensively to determine the level of functional 
relatedness between viruses, to create vaccine candidate viruses and to study the 
functional regions of the proteins essential to virus genome transcription and replication  
(Bailly et al., 2000; Biacchesi et al., 2005; Buchholz et al., 2000; Clements-Mann et al., 
2001; Curran and Kolakofsky, 1991; Dimock and Collins, 1993; Durbin et al., 2000; 
Govindarajan et al., 2006; Halpin et al., 2004; Muhlberger et al., 1999; Newman et al., 
2002; Pelet et al., 1996; Pham et al., 2005; Schmidt et al., 2000; Schmidt et al., 2001; 
Skiadopoulos et al., 2003; Stokes, 2003; Stokes et al., 2003; Theriault et al., 2004; Yunus 
et al., 1999).  The ability of proteins to functionally substitute between viruses would be 
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most expected between closely related viruses.  For example, full-length rescue of hMPV 
was achieved using a set of APV subgroup C helper plasmids and an APV subgroup C 
synthetic genome was rescued by a set of hMPV helper plasmids (Govindarajan et al., 
2006).  The authors showed that the polymerase complex of either virus could recognize 
the cis-acting signals in the heterologous genome, indicating a close functional 
relationship between these viruses.  However, while hMPV and APV subgroup C have a 
high level of identity between their leader regions (65% nucleotide identity), trailer 
regions (72% nucleotide identity) and  N, P, L and M2-1 proteins (N proteins 89% amino 
acid identity, P proteins 68%, M2-1 proteins 85%, L proteins 80%) (Govindarajan et al., 
2006; Govindarajan and Samal, 2005), APV subgroup A has less identity with hMPV 
both in the amino acid identity of its protein or in the nucleotide identity of its non-
translated regions (section 5.1).   
 
Based on a  ‘Jennerian’ vaccination approach, heterologous substitution of closely related 
virus proteins could introduce a level of attenuation of replication to the virus without 
loss of protection (Bailly et al., 2000).  A similar approach was used to create a live-
attenuated vaccine candidate for hMPV by substituting the APV P gene into a hMPV 
genome.  This resulted in a virus with the unique and desirable phenotype of having 
increased growth in cell culture but being attenuated in vivo (Pham et al., 2005). 
 
The results presented here show that substitution of the hMPV pP or pN plasmids into an 
APV subgroup A background retained only very low levels of ability to support 
minigenome protein expression (figure 5.3), as did the hMPV minigenome plasmid 
(figure 5.4).  Interestingly, while the APV minigenome plasmid could also function in the 
hMPV PRS, none of the other APV helper plasmids gave levels of activity in the hMPV 
PRS significantly above the negative controls.  This could be due to greater fidelity of the 
APV RNP complex proteins, such that a change to the N, P or L proteins interferes with 
the protein:protein binding required to form the RNP complex.  Compared to experiments 
using the rescue systems where a hMPV full-length genome was shown to be rescued to 
varying degrees by sets of hMPV and APV subgroup C RNP complex proteins 
(Govindarajan et al., 2006) and to produce viable virus with substitutions in the genome 
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of the APV subgroup C N or P genes (Pham et al., 2005), the APV subgroup A was less 
able to functionally replace sequence from hMPV.  Generally however, it follows that if 
heterologous substitution in PRS experiments results in a lower level of functionality, it 
may be a useful substitution to consider when creating a live attenuated vaccine strain of 
a virus.  However, as this may result in over-attenuation, it was useful to have a selection 
of mutations of known effect to choose from.     
 
Heterologous substitutions in rescue systems have been used extensively to investigate 
virus relatedness and protein function.  Heterologous rescue of the human parainfluenza 
virus type 1 strain Washington/20993/1964 (HPIV1 WASH/64) cloned genome was 
successfully carried out using HPIV3 helper plasmids or a mixture of HPIV1 and HPIV3 
helper plasmids.  The amino acid identity between these helper proteins varies from 62% 
and 61% for the N and L proteins, respectively, to only 29% for the P proteins.  These 
viruses also have extensive nucleotide homology between their cis-acting sequences.  
This indicates a high level of functional activity between these proteins- the HPIV3 N can 
recognize the HPIV1 genome and the HPIV3 L:P polymerase complex can act on this 
template to produce functional RNP complex and anti-genome RNA.  More interestingly, 
the data shows that the HPIV3 L protein can recognize a template bound with HPIV1 N 
and P protein.  Newman et al. (2002) used heterologous rescue to confirm that the well 
conserved sequences in P proposed to be  responsible for L:P binding can act in the 
context of an otherwise poorly conserved protein.  Rescue of a Sendai virus (SeV) 
minigenome cDNA by PIV3 N, P and L proteins was also shown to be possible, 
confirming that with an N protein which was from the same virus as the polymerase 
complex (L:P)  recovery was possible of a heterologous RNA genome.  This suggests 
that protein: protein binding (ie P:N) was virus specific whereas protein:RNA binding 
(N:RNA) can be heterologous for PIV3 and SeV (Curran and Kolakofsky, 1991; Pelet et 
al., 1996).  Similar results were achieved using the Zaire Ebola virus full-length rescue 
system with heterologous helper plasmids from the closely related Reston Ebola virus 
(71-89% overall amino acid identity) or the more distantly related filovirus Marburg virus 
(46-58% amino acid identity).  This showed again the importance of protein:protein 
interactions over protein:RNA interactions in the RNP complex (Theriault et al., 2004).     
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Chimeric proteins have been used to evaluate the functional regions of the RSV helper 
proteins in the RSV PRS.  Stokes (2003) and Marriot (personal communication) 
substituted the APV/RSV chimeras into the RSV PRS at 0.025, 0.05, 0.1, 0.2, 0.4 and 
0.8µg/well.  As shown in figure 5.7, none of the chimeras restored reporter protein 
production to the level seen when RSV M2-1 was included at 0.05µg/well.  APV/RSV 
chimera 3 gave the highest levels of both reporter proteins, with a high (>60%) amount of 
CAT protein production when 0.4 and 0.8µg/well of chimeric plasmid were used.  
APV/RSV chimeras 1 and 2 showed moderate levels of CAT expression (40-59% of 
wildtype) at 0.8µg/well of chimeric plasmid.  Chimeras 4 and 5 gave low levels of CAT 
production (20-39% of wildtype) at 0.2, 0.4 and 0.8µg/well.  Chimera 6, with only the 
final 154-194 bases from the RSV M2-1 protein, showed no activity above the negative 
control in which no M2-1 plasmid was added to the transfection.  Luciferase activity in 
the presence of these chimeras was even lower than that seen with CAT assay, with the 
greatest enhancement being 20% of that seen with RSV M2-1 protein for chimera 3 at 
0.8µg/well plasmid; however, enhancement was seen across the range of concentrations 
added.  Chimera 5 gave moderate (3-19%) levels of LUC protein production, reaching 
7% at 0.8µg/well added.  Chimeras 2 and 4 gave low (<5%) levels of LUC expression, 
even at 0.8µg/well of plasmid added.  Chimeras 1 and 6 gave no enhancement of LUC 
expression above the negative control of no M2-1 plasmid added.  From this data, it was 
proposed that the RSV M2-1 protein had two functional domains, one that enhanced 
production of the leader proximal gene (here the CAT gene) between residues 1-44 and a 
second transcriptional enhancer for both genes between residues 93-152 (Stokes, 
2003)(Dr. A. Marriott, personal communication).  It would be expected that the chimera 
proteins might show sections that were important for both the APV M2-1 and the RSV 
M2-1 protein: protein interactions.  However, as the proteins are different lengths and 
have low levels of amino acid identity (39%), it is not surprising that different regions 
will be important for different virus protein interactions.    
 
Protein functionality studies on the bRSV N protein have shown any amino acid deletion 
to be very detrimental to N protein activity and deletion of certain residues in the C- and 
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N-termini also obliterated N protein function (Khattar et al., 2000).  Further studies 
utilizing RSV/PVM N chimera proteins showed that only six residues at the C-term end 
of the protein were essential for viral replication and N-P protein binding (Stokes et al., 
2003).  With the APV M2-1 protein, initial studies of heterologous substitution into the 
RSV PRS found that the APV M2-1 protein could not functionally replace the RSV M2-1 
protein.  It was also shown that truncated versions of the RSV M2-1 protein did not 
enhance reporter protein production in the RSV PRS.  Subsequently, the APV M2-1 
 
protein sequence was utilized to create a chimeric protein which could be used to 
investigate the functionality of regions of the RSV M2-1 protein.  The functionality of 
APV/RSV M2-1 chimeras 1 to 6 (figure 5.6 and 5.7) in the RSV PRS was determined by 
Dr. H. Stokes and Dr. A. Marriott.  They found that the APV/RSV M2-1 chimera 3 
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Figure 5.8 The effect of APV/RSV M2-1 chimeric protein on CAT and LUC 
reporter protein expression in the RSV PRS.  The ability of the chimeric 
proteins to direct transcription was measured by calculating the level of CAT or 
LUC protein production in the presence of 0.025 to 0.8µg/well of chimeric M2-1 
protein as a percentage of the levels of protein produced with 0.05µg/well of the 
RSV M2-1 plasmid.  Shown here is the maximum value achieved when adding 
chimeric plasmids at 0.025 to 0.8µg/well (adapted from Stokes, 2003)(Dr. A. 
Marriott, personal communication).   
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retained the ability to produce both CAT and LUC reporter proteins from a RSV 
pCATLUC mini-genome.  Chimeras 1 and 2 enhanced CAT protein production but failed 
to enhance LUC production.  Chimeras 4 and 5 gave increased levels of both reporter 
proteins, but not to the extent seen for chimera 3.  Chimera 5, which has only the final 
154-194 bases from RSV, failed to enhance expression of either reporter protein.  Hence 
two functional regions were identified, the N-terminal 44 residues for production of the 
leader-proximal gene (the CAT gene) and residues 93-152 for expression of both genes in 
the RSV pCATLUC minigenome (Stokes, 2003).    
 
Using the same chimeras in the APV PRS, only chimera 1 gave any level of 
functionality. This was surprising, as chimera 1 lacks the first 44 residues that were 
shown to be important function in the RSV PRS.  Chimera 1 contained the first 1-44 
residues derived from the RSV M2-1 protein and the rest from the APV M2-1 protein.  If 
the first 1-44 residues were essential for APV transcription enhancement, chimeras 4-6 
should have some function, but not chimeras 1-3.  The functionality of chimera 1 but not 
chimeras 2 or 3 implies that section II was essential for M2-1 protein transcriptional 
enhancement activity; however chimeras 5 and 6 that retain this section are non-
functional.  Non-functionality of chimeras 4-6 suggests that section IV was essential for 
efficient transcription from the minigenome.  However as chimeras 2 and 3 (which retain 
this section) are non-functional, the data suggest that both sections II and IV are needed 
for M2-1 protein transcriptional enhancement activity.  The limited functionality of any 
of the chimeras apart from chimera 1 suggests that APV M2-1 has different functional 
regions than the RSV M2-1 protein and that these regions may be non-consecutive.  Also, 
although the amount of M2-1 chimera was appropriate for the APV PRS, it may be that 
over-expression of the protein would result in higher levels of activity and this would be 
interesting to investigate.    
 
This work lays the foundation for future experiments investigating the functionality of the 
N, P, L and M2-1 by creating chimeric proteins with hMPV, PVM, or RSV.  By using 
sequence comparison, possible functional regions can be identified and chimeras created 
to test mutations which might result in complete loss of function if just deleted from the 
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gene sequence.  Also, as has been show for hMPV and APV subgroup C, the substitution 
of APV subgroup A genes into the hMPV full-length genome might result in viable 
vaccine candidates and increase the options available for varying the levels of attenuation 
of a vaccine candidate.   
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Chapter 6: 
Rescue of APV from cDNA clones 
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6.1 Introduction 
The ability to create a virus entirely from cDNA is a powerful tool and is the ultimate 
goal of reverse genetics studies.  Using a cloned copy of the viral genome and helper 
plasmids, it is possible to produce a virus entirely from cDNA (section 1.5).  For the 
pneumovirus subfamily, viruses created from cloned DNA have been created for APV 
(Govindarajan et al., 2006; Naylor et al., 2004; Naylor et al., 2007), RSV (Buchholz et 
al., 1999; Collins et al., 1995), PVM (Krempl et al., 2007) and hMPV (Biacchesi et al., 
2004a; Biacchesi et al., 2004b; Herfst et al., 2004).  At least one virus from most of the 
families of non-segmented negative sense RNA viruses have been created from cloned 
DNA.  Viruses have been created for many of the members of the Paramyxoviridae 
family (in addition to the pneumoviruses above) including Sendai virus (Garcin et al., 
1995), measles virus (Radecke et al., 1995), rinderpest virus (Baron and Barrett, 1997), 
human parainfluenza virus type 3 (Durbin et al., 1997; Hoffman and Banerjee, 1997), 
simian virus 5 (Karron et al., 1997), Nipah virus (Yoneda et al., 2006), canine distemper 
virus (Gassen et al., 2000), and Newcastle disease virus (Krishnamurthy et al., 2000).  
Amongst the Rhabdoviridae family viruses, rescue systems have been described for 
rabies virus (Schnell et al., 1994) and vesicular stomatitis virus (Lawson et al., 1995; 
Whelan et al., 1995).  Full length rescue systems (FLRS) in which infectious virus is 
recovered have been developed for Marburg virus (Enterlein et al., 2006) and Zaire 
ebolavirus of the Filoviridae family (Theriault et al., 2004), as well as for the 
Bornaviridae family virus borna disease virus (Perez et al., 2003).  The ability to create a 
virus entirely from cloned cDNA has become an essential instrument for the study of 
negative sense RNA viruses. 
 
FLRS are being used for a wide range of studies of viruses, including creation of 
rationally designed vaccine candidates (Biacchesi et al., 2005; Biacchesi et al., 2004b; 
Buchholz et al., 2005; Cheng et al., 2005; Cheng et al., 2001; Collins et al., 1995; 
Hoffman and Banerjee, 1997; Jin et al., 1998; Skiadopoulos et al., 2004), determination 
of the function of naturally occurring mutations isolated from field strains (Naylor et al., 
2007), investigation of protein function (Bermingham and Collins, 1999; Buchholz et al., 
2005; Buchholz et al., 1999; Bukreyev et al., 1997; Cheng et al., 2005; Cheng et al., 
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2001; Collins et al., 1995; Jin et al., 2000a; Jin et al., 2000b; Naylor et al., 2007; 
Skiadopoulos et al., 2004; Techaarpornkul et al., 2001; Teng et al., 2000; Theriault et al., 
2004), and determination of the ability of the virus to be used as a vector (Govindarajan 
et al., 2006; Karron et al., 1997; Skiadopoulos et al., 2004).  The goal of rational vaccine 
design is to create vaccines by introducing a small number of attenuating mutations in 
order to fine-tune the balance of attenuation and protection of a candidate-vaccine strain 
(Buchholz et al., 2006; Collins and Murphy, 2005; Collins et al., 1999b).  The individual 
point mutations found to produce cold-passaged, temperature sensitive, or naturally 
occurring mutations have been analysed for their ability to attenuate the virus (Firestone 
et al., 1996; Karron et al., 1997; Naylor et al., 2007; Patnayak and Goyal, 2004; Patnayak 
and Goyal, 2006; Patnayak et al., 2003).  Deletion mutations have also been generated 
which would not be likely to occur naturally- such as whole gene deletions- and hence 
would be unlikely to revert to virulence (Biacchesi et al., 2005; Biacchesi et al., 2004b; 
Bukreyev et al., 1997; Karron et al., 1997; Ling et al., 2008; Naylor et al., 2004; 
Whitehead et al., 1999).  The addition of foreign genes to a virus genome has also 
allowed multivalent vaccine-candidate strains to be produced (Buchholz et al., 2006; 
Collins and Murphy, 2005; Durbin et al., 2000; Schmidt et al., 2001).  Insertion of a 
reporter gene, such as green florescent protein (GFP), into the viral genome can serve as 
a marker of recombinant virus production and expression of GFP by a recombinant virus 
also allows visualization of virus in vitro and in vivo, thereby increasing the speed of 
analysis and production of slow growing viruses (Govindarajan et al., 2006; 
Techaarpornkul et al., 2001). 
 
By analogy to RSV, APV has three glycoproteins expressed on its surface; the F (fusion) 
protein, the G (glycoprotein) protein and the SH (small hydrophobic) protein.  While the 
roles of the F and G proteins have been well defined (sections 1.3.2.5 and 1.3.2.6), the 
function of SH protein is unknown.  Full-length cloned RSV, hMPV and APV viruses 
have been created which lack one or more of the viral glycoproteins (Biacchesi et al., 
2005; Biacchesi et al., 2004b; Bukreyev et al., 1997; Karron et al., 1997; Ling et al., 
2008; Naylor et al., 2004; Techaarpornkul et al., 2001; Whitehead et al., 1999).  For 
RSV, deletion of the SH gene from the genome resulted in no change in phenotype and 
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showed that the SH protein was not required for viral infectivity (Techaarpornkul et al., 
2001).  Teng and Collins (1998) showed that the F gene was required for the production 
of infectious particles and production of infections virus from an F-deleted genome has 
only been possible by complementing the genome with a F protein producing cell line 
(Oomens and Wertz, 2004b) or substituting an analogous glycoprotein gene in place of 
the F gene (Buchholz et al., 1999; Cartee et al., 2003; Oomens and Wertz, 2004a; Stope 
et al., 2001).  The RSV G gene was not required for the production of infectious virus 
(Teng and Collins, 1998; Wertz and Moudy, 2004).  The deletion of the hMPV SH gene 
from the genome also showed the SH protein to be non-essential in vitro and in vitro 
(Biacchesi et al., 2004a; Biacchesi et al., 2004b).  However, for APV, an SH gene deleted 
virus produced a syncytial plaque phenotype, suggesting a role in regulation of the cell-
cell fusion process.  Recombinant APV lacking an SH or G gene were also shown to 
replicate poorly in turkeys compared to wildtype APV (Ling et al., 2008).   
 
Green florescent protein (GFP), derived from the Aequorea Victoria jellyfish, is a 
frequently used reporter gene in reverse genetics studies.  Enhanced GFP (eGFP) has 
been developed to give greater fluorescence and increased expression in mammalian cells 
(Chalfie et al., 1994; Inouye and Tsuji, 1994; Prasher et al., 1992).  The initial aim of the 
work described in this chapter was to insert an eGFP ORF either in place of the SH gene 
or after the SH gene in the CF2 APV cloned genome (Naylor et al., 2007).  These 
recombinant viruses would then be used to determine sites of replication in vivo and to 
follow virus replication in vitro.   
 
6.2 Production of GFP-expressing APV 
The APV clones described here were based on those constructed by Dr. R. Ling (Ling et 
al., 2008).  A modified version of this genome, the CF2 genome, was later constructed as 
a semi-cassetted APV subgroup A cloned genome.  The CF2 APV genome construct 
differs from the APV subgroup A isolate CVL14/1 virus by the insertion of restriction 
enzyme sites into the intergenic regions between the genes (all gene junctions except the 
M-F and F-M2 junctions) in order to facilitate cloning (appendix B) as this modification 
was found to increase the recombinant virus growth rate compared to the fully cassetted 
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genome (Dr. R. Ling, personal communication).   The CF2 APV genome was utilized to 
create a recombinant APV genome containing an eGFP gene inserted before the SH gene.  
In this way, the virus could be visualised in cell culture and in turkey organs (figure 6.1).    
 
6.2.1 Cloning of the eGFP full-length genome 
In order to create a cloned APV virus that expressed GFP, the GFP ORF was cloned into 
the CF2 genome.  The cloning strategy used for inserting the GFP gene into the M2-SH 
gene junction was carried out as described below.  The CF2 genome containing the 
inserted eGFP gene was named CF2ESH.  Due to the placement of restriction sites in the 
genome, the cloning of the CF2ESH genome was done via an intermediate genome that 
Figure 6.1 Full length APV cloned genomes.  The APV full-length cloned genome pCF2 
(first, top to bottom) was modified such that a gene encoding eGFP was additional gene 
inserted between the M2 and SH genes (second) or substituted for the SH gene (third and 
fourth).  G* indicated that this gene may not be expressed, as the eGFP GE sequence was 
deleted during cloning (third). 
 
Mutant genome CF2EdSH 34
eGFP
3' 5' 
N M F L M2P G
APV full length genome CF2
3' 5' 
N M F L M2P SH G
Mutant genome CF2ESH 11 
eGFP
3' 5' 
N M F L M2P GSH
Mutant genome CF2EdSH(dG) 56
5' 
eGFP
3' 
N M F L M2P G*
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lacked the SH ORF (named genome CF2EdSH) (figure 6.2).  Also shown in figure 6.2, 
and discussed later in section 6.3, is a genome created whist attempting to create the  
 
 
CF2EdSH genome which lacks a functional G gene, called genome CF2EdSH(dG).   The 
mutant genome CF2EdSH 34 was created first by removing the SH gene and replacing it 
Figure 6.2 Generation of pCF2 mutants- overview of cloning strategy.  The CF2 
genome (A) was digested with restriction enzymes AgeI and EagI (as indicated with 
yellow and red stars) and ligated with a PCR generated eGFP fragment (B) that had 
been similarly digested.  The ligation produced the CF2EdSH genome (C), which 
was then digested with restriction enzymes EagI and SmaI (as indicated with red and 
green stars) and ligated with a PCR generated SH fragment (D) that had been 
similarly digested.  This ligation produced the CF2ESH genome (F).  
eGFP N M F L M2 P GC 
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digestion with 
EagI and SmaI 
ligation 
5’ GGCCG 3’ 
3’            C 5’    
5’ CCC 3’ 
3’ GGG 5’   
SH  
ORF 
(525bp) 
D 
eGFP N M F L M2 P GSHF 
5’   CCGGT 3’ 
3’              A 5’  
5’ C             3’
3’ GCCGG  5’ 
eGFP 
ORF 
(717bp) 
B 
restriction 
digestion with 
AgeI and EagI 
ligation 
A 
N M F L MP SH G
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with the eGFP gene fragment.  To insert a copy of the eGFP gene in place of the SH gene 
whilst retaining the SH transcription signals, primers containing AgeI and EagI enzyme 
restriction sites along with the SH gene start and gene end sequences were used to create 
an eGFP fragment.  The plasmid pEGFP-C1 (BD Biosciences Clontech, GenBank 
Accession #: U55763) was used in a PCR (section 2.5.2) with primers FPSHP and 
FPSHMES (appendix A).  The product (figure 6.3) was purified (section 2.5.3.1) and the 
DNA digested with AgeI enzyme.  Following purification, the fragment was digested 
with the enzyme EagI and the fragment purified (figure 6.3).   
 
This fragment was then ligated into the similarly digested and purified CF2 genome DNA 
(figure 6.4).  The ligation product was transformed into E. coli, producing 70 colonies.  
The recombinant bacteria were grown at 30°C over night, plasmid DNA was purified 
from all 70 colonies (section 2.6.2), and digested with EcoRV and EagI enzymes to 
provide an initial screen for the presence of the eGFP insert.  Preparations 34-36, 47-49, 
56 gave the expected fragments of 1409 and 15118bp, whereas the vector plasmid alone 
produced a single fragment of approximately 15kbp (figure 6.5).  These preparations 
were further purified, sequenced with primer TRT22K2 (appendix A), and preparations 
56 and 34 were found to contain the eGFP insert.  The insertion regions of preparations 
CF2EdSH 56 and CF2EdSH 34 were fully sequenced and found to have the following 
unexpected mutations:  
 
Mutant  Bases  Mutation Location 
CF2EdSH 34  8104  deletion eGFP-G intergenic region 
CF2EdSH(dG) 56 8073 to 8080 deletion eGFP GE sequence 
CF2EdSH(dG) 56 8085 to 8240 deletion eGFP GE sequence 
CF2EdSH(dG) 56 8870  A→C  M2-eGFP intergenic region 
CF2EdSH(dG) 56 8894  A→C  M2-eGFP intergenic region 
 
The CF2ESH genome was created by inserting the SH gene into the eGFP-G intergenic 
region of the CF2EdSH 34 genome.  The SH gene was amplified by PCR from the 
cassetted APV genome using the primers SHSmaIU and GEagIL, as above.  The SH PCR  
ApEGFP C1
FPSHP        FPSHMES
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AgeI and EagI
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ladder     1
4,000
2,000
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ladder 
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B
C
Figure 6.3 Generation of eGFP fragment for insertion into the CF2 genome.  
PCR was carried out on the plasmid pEGFP C1 (Clontech) using primers FPSHP 
and FPSHMES (A).  PCR produced an eGFP fragment flanked by AgeI and EagI 
restriction digest sites, as well as the SH GE and GS sequences. The product was 
examined on an agarose gel (B) and the 846bp eGFP gene fragment (lane 1, 
arrow) was purified. The eGFP fragment was then digested with enzymes AgeI 
and EagI to produce an 832bp fragment (C, lane 1, arrow).
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Figure 6.4 Generation of genome vector for insertion of the eGFP gene into 
the CF2 genome.  The genome CF2 (A) was digested with AgeI and EagI 
enzymes.  The digestion product (B) was examined on an agarose gel (C, lane 1).  
As indicated with an arrow in lane 1, sequential restriction digestion and 
purification produced a single fragment larger than 10kbp.
purification
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product was purified and digested with restriction enzymes SmaI and EagI (figure 6.6).  
The CF2EdSH 34 vector DNA was similarly digested and purified (figure 6.7), ligated 
with the SH insertion fragment and transformed into E. coli.  Small-scale preparation of 
plasmid DNA was carried out from 32 colonies and the DNA was digested with EcoRV 
and EagI, as above (figure 6.8).  Preparation CF2ESH 11 was shown to have the correct 
digestion pattern and the insertion region of this plasmid was fully sequenced.  This 
region matched the desired sequence, except for the following deletions in the eGFP-SH 
intergenic region (genome sense of CF2ESH 11 genome): a T was deleted at base 8724 
and an A was deleted from between bases 8714 and 8715.  All mutant virus genome 
plasmids were amplified poorly in E. coli, so DNA from small scale preparations was 
Figure 6.5 Screening of clones by restriction digestion for substitution of the 
eGFP gene for the SH gene to create the CF2EdSH genome.  Small scale plasmid 
preparation was carried out on clones 34 to 59 and these samples were subjected to 
restriction digestion with EcoRV and EagI enzymes.  Preparations with the desired 
substitution (eGFP gene in place of the SH gene) should have a 1409bp DNA 
fragment.  Preparations 34, 35, 47-49, 56, and 59 (in red) were selected as possible 
candidates.  
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amplified using the Illustra™ TempliPhi 100 Amplification Kit (GE Healthcare) 
following the manufacturer’s protocol.   
 
Figure 6.6 Generation of SH fragment for insertion into the CF2ESH 
genome.  PCR was carried out on the CASA genome plasmid using primers 
SHSmaIU and GEagIL (provided by Dr. R. Ling) (A).  PCR produced a SH ORF 
fragment flanked by EagI and SmaI restriction digest sites, as well as the SH GE 
and GS sequences.  The product was examined on an agarose gel (B) and the 
681bp SH gene fragment (lane 1, arrow) was purified. This fragment was then 
digested with enzymes AgeI and EagI to produce a 629bp fragment (C, lane 1, 
arrow).  
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Figure 6.7 Generation of genome vector for insertion of the SH gene into the 
CF2EdSH genome.  The genome CF2EdSH (A) was digested with SmaI and EagI 
enzymes.  The digestion product (B) was examined on an agarose gel (C, lane 1).  This 
fragment was then purified to produce a single DNA fragment larger than 10kbp (C, lane 
3).
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6.2.3 Growth and eGFP expression in cell culture of virus CF2ESH 11   
Full-length rescue was carried out as described in section 2.8.3 by transfection of the 
required plasmids into 6-well plates of BSR-T7 cells (Ling et al., 2008).   Transfected 
cells were examined for eGFP expression after 2 days to check for the production of 
recombinant virus (figure 6.9).  Virus infected cells were harvested (section 2.13.2) at 4 
to 6 days post inoculation (p.i.).  A 2ml aliquot of this supernatant was then used to infect 
a small flask of confluent BSC-1 cells at 33ºC and the virus was then harvested by 
freeze/thawing when 80% CPE was present (6 to 12 days p.i.).  The virus was ultimately 
amplified to prepare stocks as described in section 2.13.2.  The titre of the virus was 
determined by examination of GFP expression in infected cells from 10-fold serial 
ladder  1      2       3      4       5       6  ladder   7       8       10     11     12   13  
10,000 
8,000 
4,000 
3,000 
2,500 
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1,500 
5,000 
DNA 
ladder 
(bp) 
Figure 6.8 Screening of clones by restriction digestion for insertion of the SH 
gene to create the CF2ESH genome. Small scale preparation was carried out on 
clones 1 to 8 and 10 to 25 and these preparations were subjected to restriction 
digestion with EcoRV and EagI enzymes.  Preparations with the desired 
substitution (eGFP gene in place of the SH gene) should have 2,029bp and 
15,118bp DNA fragments.  Preparations 3, 11, 13, 19, and 20 (in red) were 
selected as possible candidates.  
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dilution of virus stock in 96 well plates of BSC-1 cells (section 2.14).  The titre for virus 
CFESH 11 was determined to be 6.5x106 CIU/ml.   
  
 
 
 
Examination of the eGFP expression of virus CF2ESH 11 was carried out by 
photographing infected BSC-1 cells using confocal microscopy.  BSC-1 cells were grown 
to confluency in 35mm glass-bottom dishes (IWAKI brand, Asahi techno glass) and were 
infected with 1ml of virus (MOI of 2.17 cell infecting units (CIU) per cell) for 1hr at 
33ºC, the medium removed, and the cells overlaid with Leibovitz’s L-15 medium 
(Invitrogen).  Photographs were taken between  5hr and 33hr 20min p.i. every 10min in a 
heated chamber (33°C) with the 489nm Argon Laser line (figure 6.10).  Infection was 
monitored over 2300min, with the majority of eGFP expression occurring between 300 
and 2000min (5hr and 33hr 20min).  The expression of eGFP increased in intensity and 
number of cells infected increased until cell death started to occur (1900 and 2000min, 
figure 6.10 part III, appendix C).   
 
 
Figure 6.9 eGFP expression of virus CF2ESH 11 in BSR-T7 cells.  BSR-T7 cells 
were grown to a confluent monolayer and transfected with genome CF2ESH 11, pCite 
L, pCite M2-1, pCite N and pCite P plasmids.  After 48hrs, the cells were examined 
by microscopy under white light (A) and UV (B) microscope for eGFP expression.  
A B 
Figure 6.10 part I: Time lapse photography of infection of cells with virus CF2ESH 
11, 300 to 800min. Confluent monolayers of BSC-1 cells were infected with virus 
CF2ESH 11 at 2.17 CIU per cell. eGFP expression was visualized using confocal 
microscopy.
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Figure 6.10 part II: Time lapse photography of infection of cells with virus CF2ESH 
11, 900 to 1400min.
900min
1000min
1100min
1200min
1300min
1400min
155
Figure 6.10 part III: Time lapse photography of infection of cells with virus CF2ESH 
11, 1500 to 2000min.
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6.2.4 CF2ESH 11 virus expression of SH, G and eGFP mRNAs  
In order to determine the levels of SH, G and eGFP mRNA being produced from mutant 
virus CF2ESH 11, northern blots were carried out (section 2.12).  Total RNA was 
extracted from infected BSC-1 cells using a RNeasy® mini kit (Qiagen) following the 
manufacturer’s instructions 4-6 day p.i. and 1µg of RNA was added to each of the sample 
lanes.  The SH and G gene probes and standards were provided by Dr. R. Ling.  The 
eGFP RNA probe and standards were created (section 2.17 and 2.18) from p(-)GFP and 
p(+)GFP expression plasmids, respectively, provided by Dr. A. Marriot.  The RNA size 
markers (RNA Millennium Markers, Ambion) were probed with a complementary RNA 
probe provided by Dr. R. Ling. 
 
As can be seen in figure 6.11 (A), G gene mRNA was expressed from mutant virus 
CF2ESH 11 and non-mutated virus CF2.  Using the G gene standards, virus CF2ESH 11 
produced approximately 1x108.5 molecules of G mRNA from 1µg of total RNA and virus 
CF2 produced between 1x108.5 and 1x108 molecules of G mRNA from 1µg of total RNA.  
Expression SH RNA was examined (figure 6.11, B) and mutant virus CF2ESH 11 and 
non-mutated virus CF2 showed detectable levels of production.  Using the SH gene 
standards, both virus produced between 1x108.5 and 1x108 molecules of SH mRNA from 
1µg of total.  Examining eGFP RNA (figure 6.11, C), as expected virus CF2ESH 11 
alone showed expression.  The eGFP standards were larger than the viral eGFP 
transcripts as they were produced from a DNA template that did not terminate at the end 
of the eGFP gene.  On the basis of the quantity of the standards, the amount of eGFP 
mRNA produced in 1µg of total RNA from virus CF2ESH 11 was between 1x109.5 and 
1x109 molecules of eGFP mRNA.     
 
6.2.5 CF2ESH 11 virus replication in turkeys 
Mutant virus CF2ESH 11 was used to infect turkeys.  These experiments were conducted 
by Dr. N. Eterradossi and Dr. D. Toquin at the Agence Française de Securite Sanitaire 
des Aliments (AFSSA) in France.  Specific pathogen free (SPF) turkeys were hatched 
and kept in isolators, blood samples taken, and one group of nine birds with one control 
group of six birds were established.  The experimental group was then infected via intra  
Figure 6.11 Northern blot of CF2ESH 11 virus RNA with G, SH or eGFP specific 
probes. Total RNA was extracted from BSC-1 cells infected with virus CF2ESH 11 
(lanes labelled 11), virus CF2 (lane labelled C), and mock infected cells (lane labelled (-)).  
Lanes labelled 109.5 to 107 are standards (number of molecules of relevant gene RNA).  A) 
The membrane was probed with G gene specific RNA.  The mRNA transcript of the G 
gene is predicted to be 1.2kb.  The blot was exposed for 1hr and 12min.  B) The membrane 
was probed with SH gene specific RNA. The mRNA transcript of the SH gene is predicted 
to be 0.5kb. The blot was exposed for 20min.  C) The membrane was probed with eGFP 
gene specific RNA. The mRNA transcript of the eGFP gene is predicted to be 0.7kb.  The 
blot was exposed for 1hr and 53min.  The ladder for all blots is an RNA ladder with 
markers from 0.5 to 9.0kb.
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nasal inoculation with 0.1ml CF2ESH 11 virus per bird, and the SPF birds with 0.1ml of 
MEMH medium as the mock-inoculated controls.  At three and five days post inoculation 
two birds from each group were culled and organs taken for histology and quantitative 
real-time PCR experiments.  These tissues were stored in 10% paraformladehyde.  The 
organs taken were: sinuses, upper trachea, lower trachea (with bronchi), lung, oviduct (in 
females), spleen, liver, thymus, bursa of Fabricus, and M. pectoralis.  The remaining 
birds were culled at 21 days p.i., with blood samples taken for serological tests (see 
below).   Samples were passed back to Warwick for analysis. 
 
The respiratory tissue samples (sinuses, lung, upper trachea, and lower trachea) were 
examined for eGFP expression.  One fourth of each organ sample was removed from 
paraformladehyde and soaked for at least 24hours in PBS before being snap frozen in 
Tissue-Tek O.C.T.™ compound (Sakura Finetek).  The embedded tissues were then 
sliced using a freezing microtome (OTF 5000, Bright) and 5µm sections were mounted 
with Gel Mount™ Aqueous Mounting Medium (Sigma-Aldrich) on slides.  The slide 
cover slips were immediately sealed and examined for eGFP fluorescence using a 
confocal microscope.  Four or more slices were examined for each bird for all respiratory 
organs.  The fixed tissue had a high level of auto-fluorescence, but it was possible to 
separate this signal from the eGFP signal using the dye separation protocol in the Leica 
confocal software, which labelled auto-fluorescence red and eGFP fluorescence green.  
As can be seen in figures 6.12 and 6.13, sinus tissues from birds infected with virus 
CF2ESH 11 showed clear eGFP expressing cells from both birds on day 3 and from one 
of the birds on day 5.  Sinus from birds mock infected showed no GFP expression and no 
other organ showed any eGFP expression (figure 6.14). 
 
 
 
 
 
 
Figure 6.12 Confocal microscopy of CF2ESH infected turkey sinus 3 days p.i. Sinus 
tissues were removed from turkeys 3 days p.i. with virus CF2ESH 11 and 
paraformladehyde fixed.  Confocal microscopy was used to separate the auto florescence 
signal from the eGFP signals (A), with samples no. 5 (top) and no. 6 (bottom) representing 
two independently treated birds.  
No. 5: CF2ESH infected sinus tissue, 3 days p.i  
No. 6: CF2ESH infected sinus tissue, 3 days p.i  
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Figure 6.13 Confocal microscopy of CF2ESH infected turkey sinus 5 days p.i.  Sinus 
tissues were removed from turkeys 5 days p.i. with virus CF2ESH 11 and 
paraformladehyde fixed.  Confocal microscopy was used to separate the auto florescence 
signal from the eGFP signals (sample no. 7).  
No. 7: CF2ESH infected sinus tissue, 5 days p.i  
No. 34 No. 40
No. 41 No. 42
Figure 6.14 Confocal microscopy of mock infected turkey sinus 3 or 5 days p.i.  Sinus 
tissues were removed from turkeys 3 days (top) or 5 days (bottom) following mock 
infection.  Confocal microscopy was used to separate the auto florescence signal, using 
the settings determined from positive samples. None of the samples showed any eGFP 
signal.
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Dr. N. Eterradossi and Dr. D. Toquin also examined each tissue sample for N gene 
mRNA expression using quantitative real-time PCR and tested the blood of the birds 
culled at 21 days p.i. for seroconversion using an ELISA.  Figure 6.15 shows the results 
of the quantitative real-time PCR experiments (Dr. N. Eterradossi and Dr. D. Toquin, 
personal communication).  This was a more sensitive measurement of virus RNA than 
GFP expression in tissue sections, however the general trend was in agreement with the 
GFP found in tissue section.  The highest signals were seen in the sinuses for birds 
infected with virus CF2ESH 11 at both three and five days p.i.  However, detectable 
signal was also seen in all of the respiratory tissues on both days.  RNA was also seen in 
all other tissues studies at 3 days p.i., though at lower levels, and in all tissues except for 
the liver and bursa of fabricius 5 days p.i.  No RNA was detected in any of the mock 
infected controls.  Overall, virus CF2ESH 11 appears to reach all deeper organs and 
muscle tissues (Dr. N. Eterradossi and Dr. D. Toquin, personal communication).   
 
Examination of the blood samples from the birds by Dr. N. Eterradossi and Dr. D. Toquin 
showed positive ratios of sample (S) to reference positive (P) readings in ELISA 
experiments using an APV subgroup A antigen for both viruses (Table 6.1).  Virus 
CF2ESH 11 had an S/P mean ratio of 0.798, whereas virus CF2EdSH(dG) 56 had an S/P 
mean ratio of 0.153.  None of the control bird showed an S/P mean ratio.  This indicated 
that the virus is capable of stimulating immunity in turkeys.   
 
6.3 Production of GFP-expressing APV SH gene deleted viruses  
Mutant genomes CF2EdSH 34 and CF2EdSH(dG) 56 were created during the cloning of 
genome CF2ESH.  These deletion mutants were interesting as whole gene deletion has 
been considered as a method of attenuating APV for vaccine use (Naylor et al., 2007).  
The substitution of the eGFP gene in place of the SH gene preserves the number of genes 
in the genome and allows for visualization of attenuated virus growth.  
 
Virus was produced from genomes CF2EdSH 34 and CF2EdSH(dG) 56 and the viruses 
were used to infect BSC-1 cells after which the cell culture phenotype was determined.   
Figure 6.15 real-time PCR measurements of number of copies of the N gene 
(shown as log 10 copies per 10mg of tissue).  Drs. D. Toquin and N. Eterradossi 
analysed the combined mRNA and vRNA of tissue samples from CF2ESH 11 virus 
infected turkeys (‘ESH,’ green boxes) at 3 d.p.i. (A) and 5 d.p.i (B) for expression 
of copies of the N gene using real-time PCR. Values in parenthesis are outside of 
the linear range of the real-time PCR control and undetectable reactions (Ct>40) 
are marked as ‘0.’ The samples with duplicate positive values in the linear range
of detection are shaded dark gray, those with  only one such value are shaded 
medium gray and those with positive values which were outside of the linear range 
are shaded light gray.  Samples from mock infected SPF (specific-pathogen-free) 
turkeys were also tested for each organ at 3 and 5 d.p.i and all had undetectable 
levels of expression.  The oviduct tissue samples were not examined.  Data 
provided by Dr. N. Eterradossi and Dr. D. Toquin (personal communication).
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The deletion of the SH gene in both these genomes was expected to result in viruses with 
syncytial phenotype in cell culture (Ling et al., 2008).  Confluent monolayers of BSC-1 
cells infected with either virus CF2EdSH 34 or CF2EdSHdG 56 were photographed using 
confocal microscopy under UV light as above (figure 6.16).   
 
6.3.1 Further characterization of virus CF2EdSH(dG) 
The titre for virus CFEdSH 56 was determined to be 1.1x103 CIU/ml.  As before, 1ml of 
virus was used to infect confluent BSC-1 cells in a 6-well single dish, giving an CIU per 
cell of 3.7X10-4.  Timelapse photography of virus infection was also carried out as for 
virus CF2ESH.  The infection was monitored over 800min (13hr 20min), and showed the 
formation of a syncytial plaque.  Images of cells under ultraviolet and transmitted light 
are shown in figure 6.17 parts I-III and appendix C.  EGFP expression is first seen in a 
single cell, which then fuses with neighbouring cells to form a multi-nucleated syncytial 
cell.   
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Table 6.1 S/P ratios of turkeys prior to and three weeks post inoculation with 
mutant virus CF2ESH 11.  Virus immune system stimulation was measured by 
comparing the sample (S) to reference positive (P) ELISA readings using a subgroup 
A ELISA antigen.  Five birds were tested prior to inoculations and 8 birds were tested 
three weeks post inoculation (three control birds which had not been infected, five 
birds infected by the intranasal route with virus CF2ESH 11).  The mean S/P ratio was 
calculated for each group of turkeys and the range of ratios is presented (Data 
provided by Dr. N. Eterradossi and Dr. D. Toquin, personal communication). 
 
Figure 6.16 eGFP expression of viruses CF2EdSH 34 and CF2EdSH(dG) 56 in  BSC-1 
cells.  Recombinant virus was produced as before in BSR-T7 cells and virus was then used 
to infect BSC-1 cells.  The cells infected with virus CF2EdSH 34 were examined by 
microscopy(A).  The cells infected with virus CF2EdSH(dG) 56 were examined by 
confocal microscopy under 489nm laser line (B) and with transmitted light (C). 
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B C
A
165
166
Figure 6.17 part I: Time lapse photography of infection of BSC-1 cells with virus 
CF2EdSH 56, at 0, 100 and 200min. EGFP expression (left) and bright field (right) was 
images were taken using confocal microscopy.
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Figure 6.17 part II: Time lapse photography of infection of BSC-1 cells with virus 
CF2EdSH 56, at 300, 400 and 500min. EGFP expression (left) and bright field (right) 
was images were taken using confocal microscopy.
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Figure 6.17 part III: Time lapse photography of infection of BSC-1 cells with virus 
CF2EdSH 56, at 600, 700 and 800min. EGFP expression (left) and bright field (right) 
was images were taken using confocal microscopy.
600min
700min
800min
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In order to determine the levels of SH, G and eGFP RNA being produced from mutant 
genomes CF2EdSH(dG) 56, northern blots were carried out as above using the probes 
and standards as described for virus CF2ESH 11.  As can be seen in figure 6.18 (A), G 
gene RNA was expressed only from non-mutated virus CF2.  A larger (approximately  
2.0kb) mRNA can be seen produced from the mutant virus CF2EdSH(dG) 56.  This may 
be a read through transcript containing the eGFP and G genes resulting from the loss of 
the eGFP GE signal from this genome, as a read through transcript would be 
approximately 2.0kb.  Expression of SH mRNA was examined (figure 6.18, B) and, as 
expected, only virus CF2 showed detectable levels of production.  For eGFP expression 
(figure 6.18, C), it was expected that for all eGFP gene mutant viruses an eGFP specific 
mRNA would be detected, however no eGFP expression was observed for virus 
CF2EdSH(dG) 56.   
 
Mutant virus CF2EdSH(dG) 56, having been shown to express eGFP in cell culture, was 
examined in turkeys.  The design of the experiment was as described above.  The 
experimental group was infected by intra nasal inoculation with 0.5ml of CF2EdSH(dG) 
56 virus per bird.  Organs were taken for histology and quantitative real-time PCR 
experiments at days three and five post inoculation.  The respiratory tissue samples 
(sinuses, lung, upper trachea, and lower trachea) were examined for eGFP fluorescence 
as above, however none showed eGFP expression. 
 
Dr. N. Eterradossi and Dr. D. Toquin examined the tissue samples for N RNA expression 
using quantitative real-time PCR (real time RT PCR) and tested the blood of the 21 days 
p.i. birds for sero-conversion using ELISA as for virus CF2ESH 11.  RNA was detected 
for virus CF2EdSH(dG) 56, mainly in the sinuses, but also at low levels in the bursa of 
fabricius and pectoralis muscle 3 days p.i. and in the thymus and bursa of fabricius at 5 
days p.i. (figure 6.19).  Virus CF2EdSH(dG) 56 replicated less well and in fewer organs 
than virus CF2ESH 11 (Dr. N. Eterradossi and Dr. D. Toquin, personal communication).  
Examination of the blood samples from the birds by Dr. N. Eterradossi and Dr. D. Toquin 
showed positive ratios of sample (S) to reference positive (P) readings in ELISA 
experiments using an APV subgroup A antigen for virus CF2EdSH(dG) (table 6.2), with.   
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6.18 Northern blot of virus RNA with G, SH or eGFP specific probes. Total RNA 
was extracted from BSC-1 cells infected with virus CF2EdSH 56 (lane labelled 56), virus
CF2 (lane labelled C), and mock infected cells (lane labelled (-)). A) The membrane was 
probed with G gene specific RNA. Lanes labelled 109.5 to 1077.5 are standards in 
molecules of gene RNA.  The mRNA transcript of the G gene is predicted to be 1.2kb.  
The blot was exposed to UV for 1hr and 12min before photographing. B) The membrane 
was probed with SH gene specific RNA. Lanes labelled 109.5 to 1077.5 are standards in 
molecules of SH gene RNA (right). The mRNA transcript of the SH gene is predicted to 
be 0.5kb. The blot was exposed to UV for 20min before photographing. C) The 
membrane was probed with eGFP gene specific RNA. The mRNA transcript of the eGFP 
gene is predicted to be 0.7kb.  The blot was exposed to UV for 1hr and 53min before 
photographing. 
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Figure 6.19 real-time PCR measurements of number of copies of the N gene (shown 
as log 10 copies per 10mg of tissue).  Drs. D. Toquin and N. Eterradossi analysed the 
combined mRNA and vRNA of tissue samples from CF2EdSH 56 virus infected turkeys 
(‘EdSH,’ pink boxes) at 3 d.p.i. (A) and 5 d.p.i (B) for expression of copies of the N gene 
using real-time PCR. Values in parenthesis are outside of the linear range of the real-time 
PCR control and undetectable reactions (Ct>40) are marked as ‘0.’ The samples with 
duplicate positive values in the linear range of detection are shaded dark gray, those with  
only one such value are shaded medium gray and those with positive values which were 
outside of the linear range are shaded light gray.  The oviduct tissues were not examined.  
Samples from mock infected SPF (specific-pathogen-free) turkeys were also tested for 
each organ at 3 and 5 d.p.i and all had undetectable levels of expression (Dr. N. 
Eterradossi and Dr. D. Toquin, personal communication). 
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Table 6.2 S/P ratios of turkeys prior to and three weeks post inoculation with mutant 
virus CF2EdSH 56.  Virus immune system stimulation was measured by comparing the 
sample (S) to reference positive (P) ELISA readings using a subgroup A ELISA antigen.  
Five birds were tested prior to inoculations and 8 birds were tested three weeks post 
inoculation (three control birds which had not been infected, five birds infected by the 
intranasal route with virus CF2EdSH 56).  The mean S/P ratio was calculated for each 
group of turkeys and the range of ratios is presented (Dr. N. Eterradossi and Dr. D. Toquin, 
personal communication).
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an S/P mean ratio of 0.153.  This S/P mean ratio indicates that the virus is capable of 
stimulating immunity in turkeys  
 
6.4 Discussion    
6.4.1. Detection of eGFP in vitro 
The introduction of eGFP into the APV viral genome allowed visualization of living 
virus-infected cells.  The time-lapse experiments showed the spread of virus in cell 
culture and the development of syncytia formation.  Interestingly, there was some 
suggestion of the possible production of structures reminiscent of  ‘membrane nano 
tubes’ as have been described for HIV-infected T cells (Sowinski et al., 2008).  Higher 
resolution time-lapse microscopy would be necessary to discern such structures, but these 
nano tubes may represent an alternative means by which the virus infects nearby cells.     
 
Introduction of the eGFP gene into the APV genome also showed that the genome is 
capable of accepting large foreign gene insertions, suggesting that recombinant APV 
genomes may be used in the creation of multivalent vaccine.  Since inserting a gene could 
potentially alter expression levels of the downstream genes, the pathogenesis of the virus 
may be affected (Krempl et al., 2007; Naylor et al., 2007) . It could be important to move 
the eGFP tag to the end of the genome to prevent the insertion of an extra gene affecting 
mRNA production.  As seen with the RSV vaccine strain candidate cpts248/404, the 
down regulation of the M2 gene due to a mutation in its GS sequence resulted in virus 
that was attenuation in mice (Whitehead et al., 1998).   However, the addition of eGFP as 
an extra gene in genome CF2ESH 11 did not decrease the production of the downstream 
gene (the G gene) RNA (figure 6.19) compared to the CF2 genome.  Further experiments 
with multiple deliberate gene deletions could use other reporter genes as placeholders, 
allowing for redundancy in virus tracking proteins. 
 
6.4.2. Detection of eGFP in vivo 
The eGFP expression of the CF2ESH 11 virus also allowed visual identification of virus-
infected cells within turkey tissue samples.  Visible levels of eGFP were found in the 
sinus tissues of the CF2ESH 11 virus in both infected birds at 3 days p.i. and one bird at 5 
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days p.i., demonstrating virus replication in the respiratory tract.  Quantitative real-time 
PCR confirmed the presence of the virus at the highest levels in the respiratory tract, but 
also showed low levels of virus in all tissues sampled in at least one bird on day 3 or day 
5 p.i.  In contrast, quantitative real-time PCR on the CF2EdSH(dG) virus infected bird 
organs showed a trend for the virus to be restricted to the upper respiratory tract.  eGFP 
expression was not detected in these tissues by confocal microscopy, suggesting very low 
levels of virus replication.  However, as it was not possible to grow the CF2EdSH(dG) 
virus to the same titre as the CF2ESH virus, it may be that the differences in ability to 
infect tissues was due to the difference in titre of virus used to inoculate the turkeys. 
 
Previously (section 1.2) APV was described as being found primarily in the upper 
respiratory track of birds, with regular reports of virus being isolated from the 
reproductive tract (Cook et al., 1991; Cook et al., 2000; Jones et al., 1988).  The effect of 
APV infection on egg production would suggest some virus infection beyond the 
respiratory tract tissues.  Additionally, for the virus to spread as rapidly (section 1.2) as is 
seen, would suggest that virus may be being shed by non-oral routes.  The spread of APV 
is an area of concern and APV tissue tropism in domestic fowl and sentinel birds requires 
further investigation.    
  
6.4.3. Viruses with SH deleted genomes 
With the creation of mutant viruses lacking the SH and G genes, both of these genes have 
been shown to be unnecessary for APV viral replication in vitro and in vivo.  
Recombinant virus could grow with either the SH or both the SH and G genes deleted 
and showed a syncytial phenotype subsequently demonstrated to be due to the deletion of 
the SH gene (Ling et al., 2008).   
 
The cloning and resulting sequence of the mutant APV genomes CF2ESH 11, CF2EdSH 
34, and CF2EdSH(dG) 56 showed the difficulties inherent in manipulating large 
expression plasmids.  Point mutations were seen in both genomes and the deletion of the 
GE signal in CF2EdSH(dG) 56 suggests that the APV genome has regions that are prone 
to mutation (areas with a high number of AT repeats, for example).  However, the ability 
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of these viruses to replicate in turkey tissues suggests that the APV genome is tolerant of 
mutations and these mutations could be used to attenuate the virus in vivo.  Future work 
will include the full in vivo characterization of virus CF2EdSH 34.  
 
The use of the SH gene-deleted or SH and G gene-deleted viruses as vaccine candidates 
will be an avenue of future work.  Both of these viruses are attenuated in vitro and the 
virus lacking both the SH and G genes is also attenuated and more limited in its tropism 
in vivo.  The fine-tuning of the tropism of any future vaccine strains will be important, 
especially as farms seek to use herd protection to vaccinate flocks more quickly.  A virus 
with increased tropism without increased disease would give a better chance of full 
protection of the flock.    
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Chapter 7: 
Conclusions 
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7.1 Conclusions 
Establishment of the APV plasmid rescue system 
The aims of this thesis revolved around creating and using reverse genetics tools to 
expand our understanding of the molecular biology of avian pneumovirus (APV).  The 
development of a plasmid based rescue system for APV as a RNA virus has allowed 
targeted manipulation of the virus.  With this robust system established and producing 
levels of reporter protein equivalent to that seen for the RSV plasmid rescue system 
(Marriott et al., 1999)(Dr. A. Marriott, personal communication), further characterization 
of the limits of the system was possible.  Analysis of mRNA and protein levels produced 
from the GS sequence mutants demonstrated that they were equivalent, confirming that 
the GS sequences affect only mRNA production and do not result the production of 
aberrant mRNA transcripts.  These experiments also showed that protein quantification 
from the plasmid rescue system was a reliable method of assessing the effects of mutation 
of the cis-acting transcription signals. 
 
Role of N, P, L, M2, SH and G proteins 
Using the plasmid rescue system, the APV M2-1 protein was shown to be a 
transcriptional regulator, although to a lesser extent than the M2-1 proteins of RSV and 
PVM.  The maximum enhancement in the presence of the APV M2-1 protein was only 
three-fold, unlike the ten-fold enhancement seen for RSV and PVM (Collins et al., 
1999a; Dibben and Easton, 2007; Fearns and Collins, 1999).  It was also found that the 
APV M2-2 protein does have an effect on gene expression from the minigenome plasmid, 
suggesting that it may be a factor in the fine-tuning transcription for the pneumoviruses. 
 
The optimal levels of the N, P and L helper proteins for efficient rescue were determined 
and it was shown that the amount of N plasmid was critical, with the addition of too 
much plasmid being as detrimental as too little plasmid.  The P plasmid similarly proved 
have an optimal amount, after which reporter protein expression from the minigenome 
was inhibited.   However, the L plasmid proved to have a minimal required amount, after 
which addition of more plasmid failed to enhance or inhibit reporter gene expression  
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Using the system for the generation of infectious recombinant viruses, the roles of the G 
and SH glycoproteins were also investigated.  The SH and G genes were shown to be 
non-essential but enhancing for APV grown in vitro or in vivo, as has been seen for RSV 
(Bukreyev et al., 1997; Karron et al., 1997; Techaarpornkul et al., 2001).  However, 
deletion of the SH gene from APV resulted in a syncytial virus phenotype in cell culture 
and the deletion of both the G and SH genes attenuated the virus in cell culture compared 
to the eGFP insertion virus.  Hence, the APV SH protein appears to have a role in 
regulation of host cell fusion, although this may be via interaction with other APV 
proteins.  This contrasts significantly with observations of the equivalent SH gene-deleted 
RSV where no change in cytopathic effect was observed.  The APV G and SH genes are 
also required for efficient virus growth.    
 
Transcriptional regulation in vaccine design 
APV vaccines have been difficult to produce, as an attenuated live vaccine must not 
revert to virulence and a killed vaccine must be immunogenic enough to protect the birds.  
It was shown that single point mutations can be responsible for vaccine candidate virus 
phenotypes, here protective and non-protective strains.  Indeed, the only differences 
found between two of the strains were point mutations to the GE sequence of the SH 
gene.  The roles of these gene end sequence mutations in the vaccine strain pathogenicity 
and ability to induce protection from challenge were determined.  Mutations to the GE 
sequence were found to affect production of the downstream gene, as predicted from the 
stop-start model of paramyxovirus transcription.  This was confirmed by carrying out 
northern blots of the RNA from these vaccine candidate viruses where it was found that 
the levels of read-through transcripts were increased and the levels of monocistronic 
mRNA decreased (Naylor et al., 2007).  The G gene, as a surface glycoprotein, would be 
expected to be one of the major antigens for APV antibody production.  Since antibody 
production is not the sole indicator of protection (section 1.2), the G gene may also have 
an interaction with the innate immune system.  For future APV vaccines, it will be 
important to have an SH/G balance that both produces protectivity and is non-pathogenic 
in birds (Naylor et al., 2007).    
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For Paramyxoviruses, general factors in determining the levels of gene expression are the 
position in the genome of the gene and the sequence of gene junctions.  The APV L gene 
was shown to have both positional and GS sequence regulation, as its GS sequence is less 
active than the consensus GS sequence.  This down regulation appears to be important, as 
even with only one or two of the three mutations of the L GS, sequence transcription 
levels are decreased to approximately 50% of genes with the consensus sequence.  
 
APV tissue tropism 
The APV full-length rescue system (Naylor et al., 2004) was used to create an eGFP-
expressing cloned avian pneumovirus.  Three genomes were cloned in which the eGFP 
gene was introduced in addition to the SH gene alone or in place of both the SH and G 
genes and finally where the eGFP gene was introduced as an additional transcription unit.  
These eGFP expressing viruses showed that the APV genome tolerates deletion of the SH 
and G genes and replacement with a heterologous gene.  These deletions affected the 
phenotype of viral infection in vitro, confirming that the deletion of the SH gene from the 
APV genome results in a syncytial phenotype (Ling et al., 2008).  The deletion of the SH 
and G genes affected the tropism of the virus in vivo, which may be due to either virus 
attenuation, to a change in the surface glycoproteins of the virus, or to the lower dose of 
virus administered.  Analysis of mRNA levels by real-time PCR is a more sensitive 
method of detection of virus compared to tissue examination as determined by detection 
of virus RNA in tissues that were negative for eGFP expression.  However, real-time 
PCR cannot show the area (the epithelial cells, for example) of the tissue that is infected.  
Both methods found the highest levels of virus were seen in the sinuses.  The finding that 
the virus (either with or without SH and G genes) can spread to the liver and spleen 
suggests that a low level of viraemia is occurring during infection.  This has not been the 
case with other pneumoviruses (Dr. A. Easton, personal communication).   
 
7.2 Future work 
The tools and preliminary research are now complete to create a panel of mutations with 
known effects on virus pathogenicity and protectivity.  A set of mutations that should be 
tried is the deletion of entire non-essential genes in turn and the introduction of mutated 
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genes in their place.  The determinants of APV tropism are likely to be the surface 
glycoproteins so the effect of SH, F and/or G deletions should be determined.  The APV 
eGFP SH delete virus that has been produced should be put into turkeys to be compared 
to the non-SH delete and SH/G delete viruses.   
 
 The failure of any of the N, P, L or M2-1 proteins from RSV, PVM or hMPV to 
functionally replace the equivalent protein in the APV plasmid based rescue system 
suggests that it should be possible to create chimeras with these viruses.  Chimeric 
proteins can be used to broadly define the functional regions of the proteins.  Once the 
active regions of the protein are defined, point mutations can be introduced to pin point 
key residues.     
 
The question of how the virus switches from transcription to replication is still unsolved.  
Further investigation of the effect of M2-1 and M2-2 proteins on replication might 
provide new avenues of research.  The RNA levels for the genome in the presence of M2-
1 and M2-2 proteins should be measured to distinguish between effects on replication and 
on transcription.   
 
The non-transcribed regions of the APV genome also remain to be fully investigated.  
The dicistronic minigenome could be used to investigate the efficacy of the different GE 
sequences and saturation mutagenesis carried out.  This would provide additional means 
of down regulating key genes and changing the virus’s tropism.   
   
The results of the vaccine candidate gene end mutation studies show that PRS can be 
used as a model for transcription that is comparable to whole virus infection.  This is in 
contrast to Marriott et al., (2001) who found that the PRS differed from helper virus 
rescue in its ability to recognize and replicate the genome or minigenome of related 
viruses.  One interesting aspect of having three possible reverse genetics systems are the 
experiments which show correlation between systems, highlighting regions that function 
consistently when manipulated in the presence or absence of whole virus.  Here, 
comparison of mutation in the IR investigated in both systems shows that similar values 
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can be obtained across systems.  However this may not be true for the leader and trailer 
replication signals (Fearns et al., 2000; Smith, 2001) and needs to be further defined. 
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Appendix A: Primers Sequences 
All sequences are listed 5’ to 3’ 
 
APVNTOPOF 
CGGAACAAGGGATGTCTCTTGAAAGTATTAGACT 
 
APVNTOPOR 
TGAGTCAAGGGTTACTCAAATTTGGATCATCTCT 
 
TRTP4 
CTTTCCCTGAAGGC 
 
TRTP2 
ATAACTACAGATCAAGATTG 
 
APVAM2-2FOR 
GAGAGTGACATGGCAATGGT 
 
APVAM2-2REV 
GGGATCCCTAATTATATGAGG 
 
IntMut/DSMGR   
GTCCCGACCTTTCTTTTTAATTAAATAATACTGTTGCCTATTATTTGGCACTAG
TGTTGTCAAAATTCATTACGCCCCGCCCTG 
 
IntMut/DSMGF  
ATTAAAAAGAAAGGTCGGGACAAGTATCTCTATGGAAGAC 
 
DSMGIR R   
GACATTTCGAAGTACTCAG 
 
DSMG check 1  
ATGAGTGGCAGGGCGGGGCG 
 
DSMG check 2   
GCTGGCGATTCAGGTTCATC 
 
DSMG check 3   
TTATTTATCGGAGTTGCAGT 
  
DSMG check 4   
TACTTCGAAATGTCCGTTCG 
 
DSMG check 5  
GGCCTATTTCCCTAAAGG 
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All sequences are listed 5’ to 3’ 
 
DSMG check 6 
CCGGCATAAAGAATTGAAG 
 
DSMG check 7  
CCTGCGTTATCCCCTGATTC 
 
DSMG check 8   
CCTTTAGGGAAATAG 
 
DSMG check 9  
GAGCAGACAAGCCCGTCA 
 
DSMG check 10   
CATTCATTTAAGGTCAGTTG 
 
IRmut2 FOR long  
GGGCGGGGCGTAATGAATTTTGACAACACTAGTGCCAAATGATAGGCAACAG
TATTATTTAATTAAAAAGAAAGGTCGG 
 
IRmut2 REV long   
CCCGACCTTTCTTTTTAATTAAATAATACTGTTGCCTATCATTTGGCACTAGTG
TTGTCAAAATTCATTACGCCCCGCCC 
 
DSMGIR F   
CCAGTTTTGATTTAAACGTG 
 
IR3 REV LONG   
CCCGACCTTTCTTTTTAATAAAATAATACTGTTGCCTATCATTTGGCACTAGTG
TTGTCAAAATTCATTACGCCCCGCCC 
 
T7prom primer   
TAATACGACTCACTATAGG 
 
FPSHP   
GGGCCACCGGTTAAGCTATAAGTCCAAAAAAGGGTGGGACAAGTCATAATG
GTGAGCAAGGGCGA 
 
FPSHMES 
CGCCGGCCGACCCGGGTTCTTTTTAATTAAATAATCTGTTGCCTATTATTTGG
CACTAGTGTTGTCAAAATTCATTAATTACTTGTACAGCTCGTCCA 
 
TRT22K2     
AAAGATTTTGAGTTTATAGCTAT 
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Molecule:       2G2term-2,  5336 bps DNA Circular
File Name:      2G2term-2.cm5,  dated 10 Apr 2008
Description:    Ligation of inverted term into 2G2sst
Printed:        1 to 5336 bps (Full)
1 ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc
61 gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct
121 cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg
181 tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc
241 cataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga
301 aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct
361 cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg
421 gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag
481 ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat
541 cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac
601 aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac
661 tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc agttaccttc
721 ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt
781 tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc
841 ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg
901 agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca
961 atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca
1021 cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag
1081 ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac
1141 ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc
1201 agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct
1261 agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc
1321 gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg
1381 cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc
1441 gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat
1501 tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag
1561 tcattctgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat
1621 aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg
1681 cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca
1741 cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga
1801 aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc
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1861 ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata
1921 tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg
1981 ccacctgacg tctaagaaac cattattatc atgacattaa cctataaaaa taggcgtatc
2041 acgaggccct ttcgtctcgc gcgtttcggt gatgacggtg aaaacctctg acacatgcag
2101 ctcccggaga cggtcacagc ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag
2161 ggcgcgtcag cgggtgttgg cgggtgtcgg ggctggctta actatgcggc atcagagcag
2221 attgtactga gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa
2281 taccgcatca ggcgccattc gccattcagg ctgcgcaact gttgggaagg gcgatcggtg
2341 cgggcctctt cgctattacg ccagaacttg tttattgcag cttataatgg ttacaaataa
                                 <<..............polyA'................<
2401 agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc tagttgtggt
       <............................polyA'.............................<
2461 ttgtccaaac tcatcaatgt atcttatcat gtctgctcga agcggccggc cgccccgact
       <...............polyA'..............<<
2521 ctagagctta atacgactca ctataggacg agaaaaaaac cgtattcatc aaatttttag
               >>.................>> T7 Universal primer
               <<...T7 promoter...<<
                                    <<............trailer..............<
2581 cttttagttt ttattaacta acattcattt aaggtcagtt gtgtttcagg tgataattat
       <....<< trailer
  Gene end- L <<..........<<
2641 gtgttgagtt gatattgctt tattacctag aattacacgg cgatctttcc gcccttcttg
                                             <<.........Luc'...........<
2701 gcctttatga ggatctctct gatttttctt gcgtcgagtt ttccggtaag acctttcggt
       <.............................Luc'..............................<
2761 acttcgtcca caaacacaac tcctccgcgc aactttttcg cggttgttac ttgactggcg
       <.............................Luc'..............................<
2821 acgtaatcca cgatctcttt ttccgtcatc gtctttccgt gctccaaaac aacaacggcg
       <.............................Luc'..............................<
2881 gcgggaagtt caccggcgtc atcgtcggga agacctgcga cacctgcgtc gaagatgttg
       <.............................Luc'..............................<
2941 gggtgttgga gcaagatgga ttccaattca gcgggagcca cctgatagcc tttgtactta
       <.............................Luc'..............................<
3001 atcagagact tcaggcggtc aacgatgaag aagtgttcgt cttcgtccca gtaagctatg
       <.............................Luc'..............................<
3061 tctccagaat gtagccatcc atccttgtca atcaaggcgt tggtcgcttc cggattgttt
       <.............................Luc'..............................<
3121 acataaccgg acataatcat aggacctctc acacacagtt cgcctctttg attaacgccc
       <.............................Luc'..............................<
3181 agcgttttcc cggtatccag atccacaacc ttcgcttcaa aaaatggaac aactttaccg
       <.............................Luc'..............................<
3241 accgcgcccg gtttatcatc cccctcgggt gtaatcagaa tagctgatgt agtctcagtg
       <.............................Luc'..............................<
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3301 agcccatatc cttgcctgat acctggcaga tggaacctct tggcaaccgc ttccccgact
       <.............................Luc'..............................<
3361 tccttagaga ggggagcgcc accagaagca atttcgtgta aattagataa atcgtatttg
       <.............................Luc'..............................<
3421 tcaatcagag tgcttttggc gaagaaggag aatagggttg gcaccagcag cgcactttga
       <.............................Luc'..............................<
3481 atcttgtaat cctgaaggct cctcagaaac agctcttctt caaatctata cattaagacg
       <.............................Luc'..............................<
3541 actcgaaatc cacatatcaa atatccgagt gtagtaaaca ttccaaaacc gtgatggaat
       <.............................Luc'..............................<
3601 ggaacaacac ttaaaatcgc agtatccgga atgatttgat tgccaaaaat aggatctctg
       <.............................Luc'..............................<
3661 gcatgcgaga atctcacgca ggcagttcta tgaggcagag cgacaccttt aggcagacca
       <.............................Luc'..............................<
3721 gtagatccag aggagttcat gatcagtgca attgtcttgt ccctatcgaa ggactctggc
       <.............................Luc'..............................<
3781 acaaaatcgt attcattaaa accgggaggt agatgagatg tgacgaacgt gtacatcgac
       <.............................Luc'..............................<
3841 tgaaatccct ggtaatccgt tttagaatcc atgataataa ttttttggat gattgggagc
       <.............................Luc'..............................<
3901 tttttttgca cgttcaaaat tttttgcaac ccctttttgg aaacgaacac cacggtaggc
       <.............................Luc'..............................<
3961 tgcgaaatgc ccatactgtt gagcaattca cgttcattat aaatgtcgtt cgcgggcgca
       <.............................Luc'..............................<
4021 actgcaactc cgataaataa cgcgcccaac accggcataa agaattgaag agagttttca
       <<...DSGSCHECK3....<<
                                         >>..DSMG Check 6..>>
       <.............................Luc'..............................<
4081 ctgcatacga cgattctgtg atttgtattc agcccatatc gtttcatagc ttctgccaac
       <.............................Luc'..............................<
4141 cgaacggaca tttcgaagta ctcagcgtaa gtgatgtcca cctcgatatg tgcatctgta
       <.............................Luc'..............................<
4201 aaagcaattg ttccaggaac cagggcgtat ctcttcatag ccttatgcag ttgctctcca
       <.............................Luc'..............................<
4261 gcggttccat cttccagcgg atagaatggc gccgggcctt tctttatgtt tttggcgtct
       <.............................Luc'..............................<
4321 tccatggtta cttgtcccat cgattttttc ataactatta cgccccgccc tgccactcat
       <..<< Luc'
     gene start <<......<<
                ClaI site >>...>>
                    gene end- P <<..........<<
                                                   <<....OMCHECKGS....<<
                                               <<........CAT'..........<
4381 cgcagtactg ttgtaattca ttaagcattc tgccgacatg gaagccatca cagacggcat
       <.............................CAT'..............................<
4441 gatgaacctg aatcgccagc ggcatcagca ccttgtcgcc ttgcgtataa tatttgccca
       <<...DSGSCHECK2 ...<<
       <.............................CAT'..............................<
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4501 tggtgaaaac gggggcgaag aagttgtcca tattggccac gtttaaatca aaactggtga
                                                    DSGSCHECK 4 <<.....<
       <.............................CAT'..............................<
4561 aactcaccca gggattggct gagacgaaaa acatattctc aataaaccct ttagggaaat
       <.DSGSCHECK 4.<<
                                                          <<..DSMG 5...<
       <.............................CAT'..............................<
4621 aggccaggtt ttcaccgtaa cacgccacat cttgcgaata tatgtgtaga aactgccgga
       <..<< DSMG 5
       <.............................CAT'..............................<
4681 aatcgtcgtg gtattcactc cagagcgatg aaaacgtttc agtttgctca tggaaaacgg
       <.............................CAT'..............................<
4741 tgtaacaagg gtgaacacta tcccatatca ccagctcacc gtctttcatt gccatacgga
       <.............................CAT'..............................<
4801 attccggatg agcattcatc aggcgggcaa gaatgtgaat aaaggccgga taaaacttgt
       <.............................CAT'..............................<
4861 gcttattttt ctttacggtc tttaaaaagg ccgtaatatc cagctgaacg gtctggttat
       <.............................CAT'..............................<
4921 aggtacattg agcaactgac tgaaatgcct caaaatgttc tttacgatgc cattgggata
       <.............................CAT'..............................<
4981 tatcaacggt ggtatatcca gtgatttttt tctccatggt gacttgtccc attatttttc
       <.................CAT'................<<
                                                        leader <<......<
5041 tagaacctgc ttgaatgcgt ttttttctcg tgggtcggca tggcatctcc acctcctcgc
       <.............leader............<<
                                         >>.........'ribozyme..........>
5101 ggtccgacct gggcatccga aggaggacgt cgtccactcg gatggctaag ggagagctcg
       >.........................'ribozyme.........................>>
5161 gatccggctg ctaacaaagc ccgaaaggaa gctgagttgg ctgctgccac cgctgagcaa
                                                         >>...Tphi.....>
5221 taactagcat aaccccttgg ggcctctaaa cgggtcttga ggggtttttt gctgaaagga
       >.........................Tphi........................>>
5281 ggaactatat ccggatcgag atcctctaga gtcgggcgag ctcggatctc gagccc
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Molecule: F2_pUCRL4, 16309 bps DNA Circular
File Name: F2_pUCRL4 annotated.cm5, dated 31 Mar 2009
Description: CASAF2
Printed: 1 to 16309 bps (Full)
1 tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca
61 cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg
121 ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc
181 accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgcc
241 attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat
301 tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt
361 tttcccagtc acgacgttgt aaaacgacgg ccagtgaatt cggatccgga cgtcgactct
421 agaggatctc gatccggata tagttcctcc tttcagcaaa aaacccctca agacccgttt
481 agaggcccca aggggttatg ctagttattg ctcagcggtg gcagcagcca actcagcttc
541 ctttcgggct ttgttagcag ccggatccga gctctccctt agccatccga gtggacgacg
601 tcctccttcg gatgcccagg tcggaccgcg aggaggtgga gatgccatgc cgacccacga
661 gaaaaaaacc gtattcatca aatttttagc ttttagtttt tattaactaa cattcattta
721 aggtcagttg tgtttcaggt gataattatg tctcgagttg atattgcttt attactttgt
TTG to CTC mutation >>>
<<L ORF.<
781 gcccaggatg tacccggtga ctttgacgag ctttttcaac tccgacgggt ttaagttgtc
<.............................L ORF.............................<
841 caatagcttc accatgtctg ggtatgtgtt ttctatcacc tcgaaaaaat cgtaatttaa
<.............................L ORF.............................<
901 atcacctttg ggcattttca gaacgtgatt taaccacttc actatatttg acactttgca
<.............................L ORF.............................<
961 caaagcccac ttcttctcta ccactttgct tcccccaatg gttgcccccg tgttcttaat
<.............................L ORF.............................<
1021 tccacttaag cttgaaagat ccaacaagta cttttgcata gcaggctcac taagtggcag
<.............................L ORF.............................<
1081 tgtcaaccca ggtgctagtg atttcaggtt ggcctcgatg gcagatttgt ctagtctaca
<.............................L ORF.............................<
1141 ggggtgttta aaagtacttg tcaaagccat gattgatttc gcagacctaa cctctccgta
<.............................L ORF.............................<
1201 gcaaggtgcc atgttctggt gacctaatgt taacaacata taacattccg atcctgatag
<.............................L ORF.............................<
1261 tttactccct tgcatgatat atattgaaac tactcggaca aaatgtggta gcttctttgc
<.............................L ORF.............................<
1321 ttcagattgt gcatgatact taacaaacat gtacacatta gtcccatatg atgtgcatat
<.............................L ORF.............................<
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1381 gttacaagat agtacatgtt tcctccactg tatcactaaa tgcaggacgt cctccatgtt
<.............................L ORF.............................<
1441 ttttagttca gcatcacaga tggttagcag aagaggatct ttgcacactc tgtggataaa
<.............................L ORF.............................<
1501 atcccaatgt tctctcttag ttgcatcagt tgcttccatt gccaaccctt caccaaggtc
<.............................L ORF.............................<
1561 gattattctg ctgatactcc ccattacacg cacatactct gtgggatgat gatgatcatt
<.............................L ORF.............................<
1621 ggcatctttc agactcctgt atacaaactt tagattaggg tattcacatg cagttctgga
<.............................L ORF.............................<
1681 cataagattc ccagctccct caccgatgaa gtagataatt cttagttcaa gttttgttat
<.............................L ORF.............................<
1741 caacttgcct atacatccct ttacacttac cttacaccct gtggagctat ggacaaagtt
<.............................L ORF.............................<
1801 ataacggttg atgtggtgcc aaggcattaa agtcatgtag ttttttgtca aattgctgcc
<.............................L ORF.............................<
1861 agactgctta gctgtactgc atgttgcatt gaaagtggtc aacttactaa agatgacttt
<.............................L ORF.............................<
1921 cgggaacagc agtagggccc gagtggggtc tacagagggt gtgacatcag ttggagatac
<.............................L ORF.............................<
1981 tgttttcttt atggtgggca cattgtcttg catgttcttg caccttagca agcgtgtcat
<.............................L ORF.............................<
2041 agcatgtgcc atatcggagt aactaagcat tatgactttt acatggacac ctgcagccat
<.............................L ORF.............................<
2101 tattttcaaa tattcagtga caggtttttg ctcgactatg tcaccctcag cattgacaat
<.............................L ORF.............................<
2161 ccatgggatc tccatgtagt ctactgttct taaccggcta acaaaccagt ttttgaaact
<.............................L ORF.............................<
2221 gatactaccc agaacattca atacagatgt atcgtaaagc ataagtcttc tttttacttt
<.............................L ORF.............................<
2281 gggttccagg aacaccttgc tcatcatccg ccaaaagcta ttgtctactc tgataagcct
<.............................L ORF.............................<
2341 gtctatggga tcctctacta tccccaatgt cttgttcttt tcagtttgcc aatggcatag
<.............................L ORF.............................<
2401 gagataagtt ttgaagctca taaggaacca tgtgaagttt atgaaggcat ggtctgttat
<.............................L ORF.............................<
2461 gaatccatct ccccactctt tctggaaaat actattctca gtagtgagta gaatcaaaac
<.............................L ORF.............................<
2521 agtgcaccag tggcaagcaa gacagcttgt tagtgcctct actatgttgt taccattaaa
<.............................L ORF.............................<
2581 gaagttttcg gttgctggtt tgttgttatt tatattgcta cggacagttg gtaataacaa
<.............................L ORF.............................<
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2641 cttcccaagc ataaccaagt cgatgtggtc cggattaaag atatgttgat cagtcacaat
<.............................L ORF.............................<
2701 ctttcttaca ctcttgaaat tcaggtggcc ctggaaatta ggggcggaca ttatgtcaat
<.............................L ORF.............................<
2761 atcttctacg ataggttcta gtatcacttg tttagggcta cgcccagtca attgttcaac
<.............................L ORF.............................<
2821 cacacacatg acactaattc cacaacttat agcattttgg aacacaaggt taatgtcctc
<.............................L ORF.............................<
2881 attgccaaat ctctcactca accgcttgtt tataggacta gtgtcaaaat gaaagtttgt
<.............................L ORF.............................<
2941 agttctatac gccggtactg atgatgggaa ctccataggc ctgctgctca ctgcaagcct
<.............................L ORF.............................<
3001 gtgtaggaaa ttgacgctca taaaccgagg tagaagtggt tttaacagct tatatggaag
<.............................L ORF.............................<
3061 acccagtgtt cctaagcata ttaagtttag aagacgtcgg aggccagtaa cgcctttgta
<.............................L ORF.............................<
3121 gacccacctg attttgccta tggtttctaa ttggtctttt tgttctttcg ataaggcctg
<.............................L ORF.............................<
3181 tctgttgtaa acagctacca attttttctc ttgtgtgctt gaacctaccc atggtgcttt
<.............................L ORF.............................<
3241 cggacctctt ttccctcttg ttgttttttc agctgagaat ttttctacaa tgatacctgg
<.............................L ORF.............................<
3301 cttctgtgct attgtaacat aattaatatc taagctagac aacatgcttg gagatgatac
<.............................L ORF.............................<
3361 accgacaatc tccaacccat cccatgacat ttctcttatt cttttggaaa gctgacaaca
<.............................L ORF.............................<
3421 aagaatccga ttgttgctcc tcagatctat tgtgtcagtg ataggtccag actcaagtat
<.............................L ORF.............................<
3481 tctacccaac aggcccaagt tgagcaacat catgtggact gctctgtcaa tatctacacc
<.............................L ORF.............................<
3541 acttatagca gaagttcttt ggaggatatt tgttatggat ttggttccgg caatcatgtt
<.............................L ORF.............................<
3601 tacaactttt tcagctttgt ggaatgggaa tgcttcatac accactctca gtccatgtgg
<.............................L ORF.............................<
3661 gtagacaggt gatatatcct ccataactgt gcctatttct tcctcattct gactgaaatg
<.............................L ORF.............................<
3721 cacagcacta tcactgaaca aggggtttgg tgcaaggctg agcacactag ttactgctgt
<.............................L ORF.............................<
3781 tctattaatt tcgcttgtta ccttagcctg cctttctgac ccaatagctt gagggtctct
<.............................L ORF.............................<
3841 catcagtgtg gtaagagtgg ctctatcatt tttgcatgtg ttcaacagtg ttaagaagaa
<.............................L ORF.............................<
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3901 gttcatataa actcctctat ccatctctat tgctgttagt agtaactcca tgtgtgttaa
<.............................L ORF.............................<
3961 cacctctgtc aaaaaatctg gtgtccgtct ataaaaactc ctataaacaa caacagggtc
<.............................L ORF.............................<
4021 ccctcccccc aactgcattg gtatgttcat gaacaagtta acagtgctgc tctcatctgc
<.............................L ORF.............................<
4081 taacctgaag aatctcttaa ctttggttaa agttctatta agctcattgg atatttgtgc
<.............................L ORF.............................<
4141 acctgctaag ctatgatctt ttgcctcgac aaagcactgg atgtacaacc agaaattccg
<.............................L ORF.............................<
4201 aactataaga ctagtcacaa atgactcccc tcgaaattct aactcttgac agagacttcc
<.............................L ORF.............................<
4261 aatagcttcc atactagtct tgatgtcatc cagtattgtg tttatccagg gacccactcg
<.............................L ORF.............................<
4321 cagaaccttc ttaattgcag caggatacat tacgccttct gattggatgg tcttgctcat
<.............................L ORF.............................<
4381 aaactggagg tctcttgaaa cataagtctc cccttccttc aacttgtgtc ctatgttata
<.............................L ORF.............................<
4441 gtaggcatcc cttacagcag ttaacatctt gatggcgaga ctataatcag cctgtatttc
<.............................L ORF.............................<
4501 agtttgagca cctgtgagtc gcacaggttt actcacatct atagactggt tgtccccatt
<.............................L ORF.............................<
4561 cagcagtgat gtgagctgca cccgattcct cacagacacc acatcaagga gtgatattgc
<.............................L ORF.............................<
4621 ttccatggtc cacatctttt ggcaccagcc ttctatgcca cccatgtgga acctatacag
<.............................L ORF.............................<
4681 tccactttgc tccggtatct ggtctatgtc gtagattcca cctgtgtcag ggggagcatg
<.............................L ORF.............................<
4741 tctataagtg cagatcatgg ttgtggagga tacagtcaga tgtaaccagc agaaaaggct
<.............................L ORF.............................<
4801 ttgagtccca tgcagttcgt ctgcaacatc agcacacact gaagtagtct cgtatctaaa
<.............................L ORF.............................<
4861 ggcttggtta aacttgctca aatcagtcac tattgaagct cttgctatat aattattgta
<.............................L ORF.............................<
4921 gctatcactt ttccgttttt ttgtagacga tagttcggac ttgagttcca tgattctttg
<.............................L ORF.............................<
4981 taattctaga tctccatacc tagtcaatgt ctctgggaaa aatggcacta tgttatctga
<.............................L ORF.............................<
5041 taacaatttc tcagcaagga tctgcacctg tctttgcttt ccaggttgca ttgcaaacat
<.............................L ORF.............................<
5101 acgacctaca cttagctccc tttcttttcc tgttaaggag accacgtgct ctttgtcatt
T to C mutation >
<.............................L ORF.............................<
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5161 caagtactct tgacctacaa catatttttt gagatcactt tgcttaaaat tagcatcttt
<.............................L ORF.............................<
5221 taagtagaac tctagcaccc tcctggtgcg ctcatgctct agtctgtcaa gagactccaa
<.............................L ORF.............................<
5281 cctgaatctg tcttgtatgt tttgcggaag gtagttacgt ggatacacgg accatatgag
<.............................L ORF.............................<
5341 agatttggga ggagatattg ctttatcatt cagtaccatc tccaaactgg tctggctagg
<.............................L ORF.............................<
5401 tacatagaat tcttggcaaa aactgatccc agcgagctcc aagaagtctt ccacacacaa
<.............................L ORF.............................<
5461 ttcaagattg cttgggtatg tttttgcatt catgtacatc ttccaccttc gactcaatgt
<.............................L ORF.............................<
5521 tgatggattc tttatctttg gccatctttt gtagttccct acgaaacctt tgatcactct
<.............................L ORF.............................<
5581 cagaatgaag gcccccctca tctccgtaag ggccaccaga cttaagattt ttgcagtttc
<.............................L ORF.............................<
5641 actgttatcc ctcactgcat ccatagcctc cctttcttct accataggat gtccgaatat
<.............................L ORF.............................<
5701 gcggaatata aaatacatct ctgcagcatt agcaatctca ttattcacca gaagcttaat
<.............................L ORF.............................<
5761 tattctcagc actctccctg ttgcttccag catttcatgc tcgcctgggt atctatgatg
<.............................L ORF.............................<
5821 ctcaacagat gtgttctgtg tccgccttcg gtatgcagct ctcatcttcc ctattttatc
<.............................L ORF.............................<
5881 agctatgcca ttcaatagcg tattccggaa ccttacactg aattgtgcat gttcagtcat
<.............................L ORF.............................<
5941 ccgcaatatt tcgctcataa tgaatccttc aaattccttt acaatcccat acccctcatt
<.............................L ORF.............................<
6001 gccagtgatg ctcaataact catcagtctc acagtacaat cggttgagta actcaccaac
<.............................L ORF.............................<
6061 taatttgctc cttaatccaa ggccgtcttg ggcactattt aagcaattgc tcacccacac
<.............................L ORF.............................<
6121 acacaagttt gcattaaatc tgctcaaggc aaggtccttc caagtcagga gttgattgta
<.............................L ORF.............................<
6181 ggtacaaaaa catattcttc tactcttgcg acttatgatt atacacccga aagaagaaac
<.............................L ORF.............................<
6241 agcaaaaaag aagttcaggc tacttttccg taatatagca ctggtttggg atacttccaa
<.............................L ORF.............................<
6301 acacctataa gactggatga cgtcattcaa tatcaaccaa gaatcaaacc agtgctccag
<.............................L ORF.............................<
6361 ccagtcaggt aagttctcca cttgaatacg atctattatt tttccccttc ctggtgtctg
<.............................L ORF.............................<
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6421 tgacagttta agccaatcag tcaccatttt caatttgact tcacttatat ccttgcttct
<.............................L ORF.............................<
6481 acccaaccat ttcttgagtt tctttagtct tgcacctgct gcaactttta gcagctcctt
<.............................L ORF.............................<
6541 ctggatcata agaggttcga ccactcgata ttctctgcta atggtaagac tcttgaagag
<.............................L ORF.............................<
6601 ggccctcaac ctctggtgtt caatcactgg attggtcatt gcaacatgtg ctgtatagtc
<.............................L ORF.............................<
6661 atccttaatg tatggccggt tgagtacaca tgatccaatt gcattggtct cactgaatga
<.............................L ORF.............................<
6721 aatgaccccc tttaagtaag agtcaggcag atagacattt acgacagact cattggatat
C to T >
<.............................L ORF.............................<
6781 ttccatattg gtccttgttt ttattgacgt gattgtttta gactatctga tgtgtttttt
<...<< L ORF
CTTTTA to GACGTG >>...>>
6841 tattatcaga tatatatgtg ttcattttta gttaactagt gcaacaccac tcaaccagac
<<.............G..............<
6901 caactccgtc atcacacaag caacgccaga tacgcctcca acagttgaat ggttcggtat
<...............................G...............................<
6961 agtatgtttt catgcacact gtgctataag tggaacacaa aggcacatca attctgcatt
<...............................G...............................<
7021 gctttgtaat attggagttg taagaaccta ctctgtagca gattttttcc ttgccttggg
<...............................G...............................<
7081 ggtcaaaatg ttcacagttg atgctgtttt gagttgtggg gagggattga tctgattcgt
<...............................G...............................<
7141 tggtcggaga gtgtgtgggc ttgtatgtac tgaatgtctt ttcccagggt gttgtgtgct
<...............................G...............................<
7201 ggaggatggt tcttgtgttg tcgtgacttg gcgggggtgt cattcgttgg gtgtgtttat
<...............................G...............................<
7261 tgtgttgccc attggtggtt gaatttggtt ggtttgtggg ccctggttct cggtctgtgg
<...............................G...............................<
7321 ttgtttttcc gttggtgttg ctccccggca aggcttgggg gggccctgat ttgtgtgtcc
<...............................G...............................<
7381 cagtcttcga tgtgagcatg aggcccagac ttgttgagag cagagtggct gtgctggtgg
<...............................G...............................<
7441 ttatgccttg gggatttgga tcggagtctg tgttgtcttg gctaggccat gccgggttgg
<...............................G...............................<
7501 tcttctgggg ctcagaggtg gtgctgctgt tagtgctaat cttgttcacc ttgcagcagt
<...............................G...............................<
7561 ccacacttga aagatctacc ctgcaatggc agagggctgt tgggtcaact tgattatctc
<...............................G...............................<
7621 gctgacaaat tggtcctgat ttgcaaagaa ccaataagcc catacaatca aaaccaccca
<...............................G...............................<
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7681 gtacagtatc actgcggcta tacatatcac cataagaaat ttgcacatgc aaacagcttt
<...............................G...............................<
7741 cagactttct tgttcgagcc gtttgtaatc ctccataatt tcctgctgga gtcgcacttg
<...............................G...............................<
7801 gtgcagtagt tggctgctcc tgggtggttg accaccaatc tctatctcct ccattgtagt
<...............................G...............................<
7861 ttctgcactc ctctaacact gactgttcaa ctatgacgct aacagtgagt gcaatagtga
<...............................G...............................<
7921 ctgtgcaggt cagcccgaaa gctgatagga ctatagccaa tatgtacctc ctcccgatgt
<...............................G...............................<
7981 ccagccagaa ccccactgca gtttgatatg cactggtgcc ctgaaccata tatagtttgg
<...............................G...............................<
8041 accccataga gatacttgtc ccggccgttc tttttaatta aataatactg ttgcctatta
<..G.<<
A to G mutation >
T to G mutation >
8101 tttggcacta gtgttgtcaa aattcattag ttgtagcagc acttagttgc tgtcccattg
<<...............SH.................<
8161 ttggtgcaga tgcattcctt gtaatcctcg ttgtgaccac agggtttccc aacacactcc
<..............................SH...............................<
8221 accactaaat ctatacaatt caaatcttca ccctcccgtg ctcccaagca gcctttagtt
T to C mutation >
<..............................SH...............................<
8281 ttgagatacc tgacctcacc ttcgcacaat tttttctcta ccaggcagtc agggggagta
<..............................SH...............................<
8341 ctacgtcttt cattggttgt cagtttaagt tgatttgtct gtagtgcctc tatcattgta
<..............................SH...............................<
8401 cttggggtag tatagattgc agctgtagtt gtgctcgctc ctgataactt ctgcttgcag
<..............................SH...............................<
8461 ttgtggacct cctgcactgt gaatgccagt ttcacagaca atccgatcgt agcaacaagg
<..............................SH...............................<
8521 aagatcaaag ctaagattgc acaaatcaca gcaacacaac tcactaagat cctgcagcaa
<..............................SH...............................<
8581 gaattgcacc ttgacttgat cactgtccgt tttgaagcag tgtctgaccc aaggttgacg
<..............................SH...............................<
8641 gtagaagtca ttatgacttg tcccaccctt ttttggactt atagcttaac cggttttaat
<....SH...<<
TT to CC mutation >>>
8701 taactaatta tatgaggtat atatagctat aaactcaaaa tcttttcgac actccacaca
<<...........................M2-2............................<
8761 ttgtttccta ttgatgtgat ctattaggac catattggct acttcctcta ttaaatcact
<.............................M2-2..............................<
8821 ccagctcgca atactataat catatatcct acgaaccata cacaatccaa gtgcattgca
<.............................M2-2..............................<
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8881 cttaattatt gctgtcaccc ttctgcaggg tattaccatt ggcattgtca ctctctggcc
<.....................M2-2.....................<<
<<............................M2-1.............................<
8941 ctgcagatag ctgtagtatg atcttggcaa gctttttgag tttttctctg ggaagccgct
<.............................M2-1..............................<
9001 tgaggctgtt gatcaaactt gccggatttt tactcatatc aacataagat agtatcagat
<.............................M2-1..............................<
9061 tgtgtagcgc cacatgttta gggtcttcaa gcattgaatc tctggatgtt ttcacatcat
<.............................M2-1..............................<
9121 tttcctggag ctgttttata atgttgtaca ggctgtagca ggctgctgat ttggtgattg
<.............................M2-1..............................<
9181 ttgtgttccc ttctatataa ttctgtacaa cattggcaga tcctagaaca aaatcctggg
<.............................M2-1..............................<
9241 ttctatcttc tcgtcctgcc cctgatatca aggataggcc atctgtcctg tctgtgtttc
<.............................M2-1..............................<
9301 tcaataattg gttaagcatg tagtttgctc tgactaagag cacatgatca ggccaggacc
<.............................M2-1..............................<
9361 aataattatg gttaaatgta caggatgatc ccctgttgca tttgccccgt atttcatatc
<.............................M2-1..............................<
9421 tgcagggatt tcgcctagac atcttcactt gtcccaattt taaataactt aactgacata
<.........M2-1........<<
<<..F ORF...<
9481 agccatgctg ctatgacctg tcgtggccgg gtaatcatgc tttggtttgg tcttccggac
<.............................F ORF.............................<
9541 tctggaacag taatatatca ctgcaagtaa aaagaagatt cctagaatga ctagcactac
<.............................F ORF.............................<
9601 tattgctata gcaattccag ccttgctctt ggcatctgca cctagcaagt cgttagactt
<.............................F ORF.............................<
9661 atctattaag tcctgagatc tatctatact ctcaaatact tggtcaagtg caacattgaa
<.............................F ORF.............................<
9721 ctgatcctca gggaataata ttgggttaaa attgttcaca actggagctc cttttatggt
<.............................F ORF.............................<
9781 cctctgttcg cctacaacct tgctcaattg gtacacagtg ttatcaatgg ttatcgtgtc
<.............................F ORF.............................<
9841 agcttcgttg ttgggaatgt gggtgcaccc tttgcctagc tgttttatta tccctacttt
<.............................F ORF.............................<
9901 attgctacct atggagcaac ttacactctc ataacaagac actagacccc ctaggggggt
<.............................F ORF.............................<
9961 taaggctacc atactgacag ggtgtctacc tgtgctgact ttgcatgggt atttagaagt
<.............................F ORF.............................<
10021 cgatatgtta tagttgcact gttcaacttc tagggccaca ttaatgccag ctgctgtgtc
<.............................F ORF.............................<
10081 acaaaataca taatcatccc ttacctcaca atcatcttca ttaggataat aagctgtaga
<.............................F ORF.............................<
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10141 gccagcattt gtacagtacc acccttgatc ttctctcagt atacaagcat aattgccttt
<.............................F ORF.............................<
10201 ctctttccta cagagtggtg ctgccaccac cctccaacaa ggtgtctcaa tcacgccgaa
<.............................F ORF.............................<
10261 tatgggcagt tgtaccatat aaacgaccgt tccatcataa acaccaatca atataccaaa
<.............................F ORF.............................<
10321 ccccttcctt ctaaccatgg cacgattgtt caacatcaaa ctaatctgtc ctgatgaagt
<.............................F ORF.............................<
10381 tggcattctg ttaattgctc taacaagttc atcatctgtc attaaatcaa gagacacagc
<.............................F ORF.............................<
10441 tgatgtgata cctgcactat cagagaattg cctcaccaca ttcaggaacc ttctgttatt
<.............................F ORF.............................<
10501 ttggccaaaa ctaattgcca tctttatatc tgctatattg catttgttct ggttaatagc
<.............................F ORF.............................<
10561 aggagtcaat tttttactta taaattcttt gaggtcattg actgcagttg ctagtaccct
T to C mutation >
<.............................F ORF.............................<
10621 cacaccattc cctaatgtgg atactgcctc atttgtgttc cggagggcat tcttaattgc
<.............................F ORF.............................<
10681 cttcacctct ccctctaatc taattgtctt tgcaagtgct acaccagctg ttacggcagc
T to C mutation >
<.............................F ORF.............................<
10741 agcagtcgca acaccaagtg caattgcacc cagcacaaat ctacgtctcc tgggtgagga
> T to A mutation
> T to C mutation
<.............................F ORF.............................<
10801 tagtctgctt tccttagcca cttgatcagc tgacactgtt ttgagctccc tcaaagcatt
<.............................F ORF.............................<
10861 ctttgtgagt actaactcag tgtcaattag gctgggtcca tcattgcaag tgatgttctc
C to T mutation >
<.............................F ORF.............................<
10921 aacattccct atttcgaggt taaatacatt cgtataccac cctgtcctta acacactctt
<.............................F ORF.............................<
10981 ataacctcta gttacagtac tgcaggattc ttcattgtat gtttcttgta tgcagctact
<.............................F ORF.............................<
11041 aggattagat ataaggaaca ataggagaca gattcttaca tccatcctac ttgtcccaat
C to T mutation >
<.....................F ORF....................<<
11101 tttttattga ctataacatt aacagattta tgctttaggg taccctcaac gtgacctcag
<<.....M.......<
11161 tacatacctg gttcgttgat gattccatgt cttgcagatt tttcccagac tctctgcttg
<...............................M...............................<
11221 tacatacggc cccagttcta ctataacttg catacctgca cccaatttct taaagatccc
<...............................M...............................<
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11281 tttagggttg ttcatggtca taatcaagat cagccctgca tatggagcta tccttgcttg
<...............................M...............................<
11341 agttatagcc tggtctgctt ccccacttat tgcagcttcc acagtggctg attctgagtc
<...............................M...............................<
11401 cttgatagag acagctttaa tatatgcagg tatggttatg ggcacccctt tctctatgtc
<...............................M...............................<
11461 tataaaatca cacaatgcga tcaagtcatg agtcttcctc ccaacagacc tcacatctgt
<...............................M...............................<
11521 cattattttg gagaccatgc catatggctt caaggtagtc agataaatgg acctcacatc
<...............................M...............................<
11581 acacacagtc aatgtcccga attccagcct actgtactca tcaagtgcta ctgcagcact
<...............................M...............................<
11641 gacggcaaat ttcttaggta gtgcagacat ggcagcacct tgggctgctg cattgacttg
<...............................M...............................<
11701 gagcacaggg ccttccgggg atgctgtgta ctgggtggtg attgataaag ttttcagttg
<...............................M...............................<
11761 atctaataac actggggcag gcgtacttga ctggaatagg ggaaaccata cagtcagtgt
<...............................M...............................<
11821 tgcagggtta gagtcttttt caatgaggtc aacctgaacg gctgcagtgt agggaacccc
<...............................M...............................<
11881 ctgataagtg tcaattatat aggactccat tttgacttgt cccgctagca ttttttcata
<..............M..............<<
addition >>..>>
11941 actacagatc aagattgtat atgtcgctct cttcctcatc agattcagac tctccactct
<<.............................P...............................<
12001 cttcttcact ctctgactct ccacttgagc tctggtcttc taggactttg ttcaactctt
<...............................P...............................<
12061 tggctttttc ggtaagcttc acgctaccat ctcctatttt tgccctctgg gtgtcctctt
<...............................P...............................<
12121 ctttcatcat ttctgcaatt ttgtctttag cctctgtcat gatgctgttg atcagctctt
<...............................P...............................<
12181 ctctcatccc tatcattgca tcacgtatcc catctctggc ggcggttggg ccagcagttg
<...............................P...............................<
12241 caatattcaa tgttttgagc atgcccaata tcatgctcaa cttttcttct attgcttcta
<...............................P...............................<
12301 atcttgcttc aatagaggta gatgctgtat ctttttcttc aaatgtcaat attgatgact
<...............................P...............................<
12361 tttcatcatt atcctcttca ggatctgaca acagctctag cgcctcttct tccagtttag
<...............................P...............................<
12421 tatattttcc tactttgggg ttgtcaaact tgaccttttt agactttttt gcagactcag
<...............................P...............................<
12481 tactggtaga agtctcagtg tcagtggcaa ctggagcagt cgggagtttt ggatatatag
<...............................P...............................<
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12541 attctatttc tttgaccttg gggacaggag ctttgttagg ttttatacat gatccctttg
<...............................P...............................<
12601 gtgtggtggg gttgcacaaa gggggtaatg gcaccttttc agcaattgtg ttaataggct
<...............................P...............................<
12661 ccccactaat agaacgacct ccagcagagg tgttccttag tgatctttga taggcatcgg
<...............................P...............................<
12721 ccatttttgc agcctcgctg cccatcatta gaatatcctt gccttcaggg aaagacattg
<..............................P.............................<<
12781 ttacttgtcc cggcgcgcca tattttttaa ttactcaaat ttggatgatc tctcatcatc
addition >>.....>>
<<.............N...............<
12841 tccccctagg taggatgttg ctgcttccct ctcatcatca gtgagcccta aggccgctag
<...............................N...............................<
12901 gttgatcttg ttgttctctc tcaatgtccg tgcataactt tcagcagcag caaacagctc
<...............................N...............................<
12961 aaggttgggg gctcgacctt tgtacatgcc tataatacca agcccggcgg cgttcccgag
<...............................N...............................<
13021 gacaacactg gcaaaattgg gacagttggt caatgataaa agacccgctt tgggactctg
<...............................N...............................<
13081 gcgtaagtgt agtaaccctg actcaggtcc cattttcctc actaggtcat agacctcaga
<...............................N...............................<
13141 tacttgcctc aactcagctt ggacagatac atggcccaac attatattgt tggaggatcg
<...............................N...............................<
13201 tgcaatgaca ccccagcgca gcattgtttg ccctgcccca taagcttgca taaaaatatt
<...............................N...............................<
13261 cacaaacagg ctctccatcc tgcttccggt ggatgtactt ccgagtgcct taccgtattc
<...............................N...............................<
13321 aataaataga tttctgtaat acaccttctt ctcaaacaat tcaaagaatg atttggcaat
<...............................N...............................<
13381 ccttggtatg tccatcctgg ggtaccgtga tatggcatcg cttaataccc ttgaggcacg
<...............................N...............................<
13441 ccggatagca gtttcaaggc ctacttcaac agttgaggcc aacttggtga aaatgagggc
<...............................N...............................<
13501 accaatgcat aatagaataa cgggagcatc caaggcagac ggcttttgat tctttgtgag
<...............................N...............................<
13561 ttgcactttt tccctaacca ttgctcccat tgcttctctt gtagtccttt cgacatcatc
<...............................N...............................<
13621 agcccaccca acacctacat cgtgaatgtt tagcacctct cgctttctga cagaaccctc
<...............................N...............................<
13681 tgccgaaagt gttacaatct tggtcataac accctgtact tcactaccgg aatttttcag
A to T mutation >
<...............................N...............................<
13741 tatttgttga gttctatcag ctcctagagc agtactaatg tactgcatgc ctacctctgc
<...............................N...............................<
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13801 tgcaggctca tagtcggtgt gttttgcaaa caacaccata ccgcataatg tggatacttg
<...............................N...............................<
13861 cggctgcagt tcggaaggtg tgatcgcagt ggtagcacca acatcccttc taattgtata
<...............................N...............................<
13921 ctgagagtct tcaagaattg catgtttgta ctccaagtca ctgagtctaa tactttcaag
<...............................N...............................<
13981 agacatatcg atttgacttg tcccattatt tttctagaac ctgcttgaat gcgttttttt
<.N.<<
addition >>..>>
14041 ctcgtcctat agtgagtcgt attacgcgta agcttggcgt aatcatggtc atagctgttt
14101 cctgtgtgaa attgttatcc gctcacaatt ccacacaaca tacgagccgg aagcataaag
14161 tgtaaagcct ggggtgccta atgagtgagc taactcacat taattgcgtt gcgctcactg
14221 cccgctttcc agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg
14281 gggagaggcg gtttgcgtat tgggcgctct tccgcttcct cgctcactga ctcgctgcgc
14341 tcggtcgttc ggctgcggcg agcggtatca gctcactcaa aggcggtaat acggttatcc
14401 acagaatcag gggataacgc aggaaagaac atgtgagcaa aaggccagca aaaggccagg
14461 aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc tccgcccccc tgacgagcat
14521 cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag
14581 gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga
14641 tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg
14701 tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga accccccgtt
14761 cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc ggtaagacac
14821 gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc
14881 ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag aacagtattt
14941 ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag ctcttgatcc
15001 ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt gcaagcagca gattacgcgc
15061 agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga cgctcagtgg
15121 aacgaaaact cacgttaagg gattttggtc atgagattat caaaaaggat cttcacctag
15181 atccttttaa attaaaaatg aagttttaaa tcaatctaaa gtatatatga gtaaacttgg
15241 tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg tctatttcgt
15301 tcatccatag ttgcctgact ccccgtcgtg tagataacta cgatacggga gggcttacca
15361 tctggcccca gtgctgcaat gataccgcga gacccacgct caccggctcc agatttatca
15421 gcaataaacc agccagccgg aagggccgag cgcagaagtg gtcctgcaac tttatccgcc
15481 tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc agttaatagt
15541 ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc gtttggtatg
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15601 gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc catgttgtgc
15661 aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg
15721 ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc atccgtaaga
15781 tgcttttctg tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga
15841 ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag cagaacttta
15901 aaagtgctca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat cttaccgctg
15961 ttgagatcca gttcgatgta acccactcgt gcacccaact gatcttcagc atcttttact
16021 ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata
16081 agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt
16141 tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacaa
16201 ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtctaaga aaccattatt
16261 atcatgacat taacctataa aaataggcgt atcacgaggc cctttcgtc
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Avian pneumovirus (APV) is a member of the genus Metapneumovirus of the subfamily
Pneumovirinae. This study describes the development of a reverse-genetics system for APV.
A minigenome system was used to optimize the expression of the nucleoprotein, phosphoprotein,
M2 and large polymerase proteins when transfected into Vero cells under the control of the
bacteriophage T7 promoter. Subsequently, cDNA was transcribed from the virion RNA to
make a full-length antigenome, which was also cloned under the control of the T7 promoter.
Transfection of the full-length genome plasmid, together with the plasmids expressing the
functional proteins in the transcription and replication complex, generated APV in the
transfected cells. The recombinant virus was passaged and was identified by cytopathic
effect (CPE) that was typical of APV, the presence of a unique restriction-endonuclease site in
the cDNA copy of the genome and immunofluorescence staining with anti-APV antibodies.
Replacement of the full-length wild-type antigenome with one lacking the small hydrophobic (SH)
protein and the attachment (G) genes generated a virus that grew more slowly and produced
atypical CPE with syncytia much larger than those seen with wild-type virus.
INTRODUCTION
Avian rhinotracheitis is an important disease that is res-
ponsible for major economic losses in domestic poultry
throughout most of the world (Jones, 1996). The most
severe clinical effects are seen in turkeys, but there are
significant economic losses in commercial chickens and
it has been implicated in swollen head syndrome. In the
1980s, the combined efforts of several groups showed the
cause to be a pneumovirus, named Avian pneumovirus
(APV) (Jones et al., 1986; Wilding et al., 1986; Cavanagh
& Barrett, 1988; Collins & Gough, 1988; Ling & Pringle,
1988), which is now classified as a member of the family
Paramyxoviridae, subfamiliy Pneumovirinae, genus Meta-
pneumovirus. It is distinguished from members of the
genus Pneumovirus by its different gene order (Ling et al.,
1992; Yu et al., 1992) and the absence of non-structural
protein genes NS1 and NS2 (Randhawa et al., 1997).
Recently, human metapneumovirus, a second member of
the metapneumoviruses, was described, which is responsible
for serious respiratory disease in children (van den Hoogen
et al., 2001, 2002, 2003).
Manipulation of the genome and study of genome func-
tion in APV have been limited, due to the absence of a
methodology whereby precise changes can be made.
Reverse-genetics systems have been developed for other
viruses of the family Paramyxoviridae, which have enabled
specific mutations to be introduced into the virus genome
and the subsequent phenotypic consequences determined.
These have included Human parainfluenza virus 3, Human
respiratory syncytial virus (HRSV), Bovine respiratory
syncytial virus, Newcastle disease virus, Sendai virus,
Rinderpest virus and Simian virus 5 (Marriott & Easton,
1999). These analyses have identified many important
common features of the molecular biology of these viruses.
However, analysis of HRSV by using reverse genetics has
identified several aspects that differentiate it from other
paramyxoviruses. Rescue studies with HRSV have shown
that the minimal replicative unit is comprised of the
nucleocapsid protein (N), phosphoprotein (P), M2 pro-
tein, RNA polymerase (L) and full-length viral genome
in the antigenome sense (Collins et al., 1995). This paper
describes the development of a reverse-genetics system for
The GenBank/EMBL/DDBJ accession number for the APV genome
sequence described in this study is AY640317.
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APV. The system was used to produce APV that entirely
lacked the SH and G genes, indicating that these genes are
not essential for viability in tissue culture.
METHODS
Preparation of a full-length DNA copy of the APV genome.
A full-length DNA copy of the APV genome was constructed in a
series of PCR and ligation steps. The sequence of the APV genome
is available from GenBank under accession no. AY640317. The
cloning strategy is illustrated in Fig. 1 and all oligonucleotide pri-
mers used are shown in Table 1. RNA was extracted from Vero cells
infected with APV (strain LAH A; Lohmann) by using an RNeasy
kit (Qiagen). Two overlapping cDNAs were generated by reverse
transcription (RT) for 1?5 h at 42 uC by using Superscript II
(Invitrogen) (Fig. 1a). These RT reactions used the antigenomic
sense primers APVLead and M2 start, corresponding to the leader
and a sequence in the M2 gene. cDNA corresponding to the 39 end
of the genome was amplified by using primers APVLead ext and
APV 8.2 Sal2 (Fig. 1b). The cDNA corresponding to the 59 end of
the genome was amplified with T7L and APV Trail ext (Fig. 1b).
These reactions were used as templates for eight further PCRs using
Pfu polymerase (Stratagene) (Fig. 1c). These products, APV1, APV2,
APV3, APV4+5, APV6, APV7, APV8 and APV9+10, were gener-
ated with primers listed in Table 1 that created SalI or XhoI sites at
each end of the products. Digestion and ligation of these sites
regenerated the viral sequence whilst eliminating the cloning sites,
enabling insertion of the next fragment by using the same method.
A T7 promoter sequence was added to the leader end to generate
APV1T7 and a Hepatitis delta virus ribozyme (HDVR) sequence was
added to the trailer end to generate APV9+10HDVR. The HDVR was
amplified from pOLTV5 (Peeters et al., 1999) by using the HDVR start
and HDVR back primers (Table 1). This product was ligated onto
APV9+10 and the correct construct was amplified with APV11.9
Xho+ and HDVR back.
APV1T7 and APV9+10HDVR were cloned into the low-copy
plasmid pCTPE (a modified version of pOLTV5 with the HDVR,
T7 terminator and lacZ sequences removed to improve cloning
efficiency; Fig. 1d). The remaining PCR products were cloned into a
modified form of pUC18 with the SalI site changed to an EcoRI site
by site-directed mutagenesis (Quikchange; Stratagene) (Fig. 1d). Site-
directed mutagenesis was also used to correct coding changes that
were identified by sequencing (Imperial College London Medical
School service, London, UK) and to introduce an SstII restriction site
into APV3. The latter introduced conservative (lysine to arginine)
changes at aa 299 and 300 of the predicted F protein.
Sequential ligation of SalI/XhoI-cut fragments generated clones
containing APV1T72+3 or APV6–10HDVR (Fig. 1e). Attempts to
clone APV4+5 into these constructs were not successful. PCRs on
APV1T72+3/APV4+5 and APV4+5/APV6–10 ligations carried out
in the presence of SalI and XhoI were performed by using primers
CTPE 2402 and G112 or M2 mid and CTPE 1902, respectively
(Fig. 1f). Exonuclease I (USB) was used to remove remaining
oligonucleotides and an overlap PCR was used to join the two
products, with T7 APVLead2 and CTPE 1102 being added after two
cycles (Fig. 1g). No primers were present in the first two cycles, in
order to allow the fragments to anneal and copy each other from the
overlap prior to the addition of the PCR primers. A 15?5 kb product
was obtained, which was circularized by ligation and transformed
into Escherichia coli (Fig. 1h). DNA from the resulting colonies was
screened by multiplex PCR and restriction-enzyme digestion. One of
two sequences of midiprep-purified DNA (Qiagen) lacked mutations
in intergenic regions or coding changes.
After cloning, the full-length cDNA copy of the genome was modified
between positions 3828 and 3831 (antigenome sense) by site-directed
mutagenesis (QuikChange; Stratagene) to introduce a convenient
SstII restriction site. This also resulted in a conservative substitution
at aa 299 and 300 of the F gene, with lysines being converted to arginine
residues. Confirmation of the presence of the mutation after passage
of the recombinant virus was obtained by RT-PCR amplification of
the region of the genome between nt 3625 and 4063 using primers
F6+ and F7-B (Table 1).
A defined deletion mutant of APV was generated by high-fidelity
PCR (10 cycles) amplification of the full-length clone to introduce a
deletion in the region of the SH gene. The amplicon was intended to
terminate at genome position 5363, 1 nt prior to the SH gene
transcription start signal, and to restart at position 5965, 2 nt prior to
the G gene transcription start signal. Long-distance PCR (Thiel et al.,
2003) was employed to amplify the full-length genome clone so as
to remove the entire SH gene by using primers SH omit+ and SH
omit2. The PCR mixture was run on an agarose gel to reveal solely
the expected band (approx. 15?0 kb). This was self-ligated and used
to transform competent cells. Resulting colonies were screened by
multiplex PCR and restriction-enzyme analysis and a single clone
from almost 1000 was identified as intact. This was sequenced
across the M2–G gene junction region and it was found that several
bases had been lost from the start of the G gene. The amplicon
terminated at position 5363, as expected. However, the sequence
unexpectedly continued from a point 12 nt into the ORF and hence
the G gene lacked its transcription start, translation start and a small
section of coding region. The entire sequence of the mutant genome
was sequenced to confirm that this deletion was the only mutation
present.
Preparation of plasmids expressing the virus replication
proteins. N, P and M2 gene sequences from strain APV-A were
amplified by PCR and cloned. RNA was extracted (RNeasy; Qiagen)
from infected cells, reverse-transcribed (Superscript II; Invitrogen)
and amplified by PCR (Pfu polymerase; Stratagene) using primers
that amplified the gene to include the start codon (N and P) or
introduced the T7 promoter sequence (M2 and L) immediately
prior to the start codon of each gene, as shown in Table 1. The
downstream primer in all cases terminated beyond the gene’s stop
codon. N and P genes were cloned into the SmaI site of pCI
(Promega) downstream of a bacteriophage T7 promoter, allowing
gene expression under the control of the cytomegalovirus pro-
moter. T7M2 was cloned into the SmaI site of the modified pUC18
mentioned above.
The L gene was cloned in sections into the EcoRV site of pCTPE
by using the sequential approach used for the complete viral genome.
In order, APV9+10, APV8, APV7 and APV6 were ligated into
pCTPE. It proved impossible to add the final section of the gene
(APVT7Lstart), representing approximately the first 400 bp of the
gene, in a similar manner. However, the full L gene, together with
the pCTPE plasmid, was prepared as a single PCR product (Pfu
polymerase; Stratagene) following their ligation. The blunt-ended
product was circularized by ligation and the mixture was treated with
the restriction endonuclease DpnI to remove the original methylated
plasmid and leave only the desired product for transformation into
E. coli. Three resultant clones were sequenced fully and were found to
be free of coding errors.
Testing of support proteins in a minigenome. The four
support genes were tested functionally by using a cloned APV
minigenome in which the virus genome had been modified so that
all genes were replaced by a single copy of the chloramphenicol
acetyltransferase (CAT) reporter gene, flanked by the virus leader
and trailer regions. This adopted the method of Randhawa et al.
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(1997) except that, in this instance, bacteriophage T7 polymerase
was generated by a Fowlpox virus recombinant (FPT7; Britton et al.,
1996) at an m.o.i. of 1 p.f.u. per cell and lipofectamine 2000
(Invitrogen) was used to transfect DNA into Vero cells. CAT reporter-
gene expression was measured 48 h after transfection by ELISA, as
described previously (Ahmadian et al., 2000).
Fig. 1. Schematic representation of cloning strategy for generation of a cDNA clone representing the APV genome. The
primers used in specific steps are given in parentheses. The position of SalI (s) and XhoI sites (x) at the termini of fragments
are shown. Details of the procedures are given in the text.
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Virus rescue. The method adopted followed that used for the
minigenome, except that full-length antigenome (wild-type or dele-
tion) replaced the minigenome and incubation times were increased
to allow time for any virus to produce detectable cytopathic effect
(CPE). Fowlpox virus will destroy most avian cells before this time,
but it is unable to package in mammalian Vero cells; hence, additional
Table 1. Sequence of primers used in the generation of PCR fragments
Fragment generated/primer Sequence
APVT71
APVLead CGAGAAAAAAACGCATTCAAGCAGG
APVLead ext ACGAGAAAAAAACGCATTCAAGCAGGTTCT
T7 APVLead1 TAATACGACTCACTATAGGACGAGAAAAAAACGCATTCAAGCAGG
T7 APVLead2 TAATACGACTCACTATAGGACGAGAAAAAAACGC
APV 1.1 Sal2 CTCAAGGTTGGGGGGTCGACC
APV2
APV 1.1 Xho+ GGCATGTACAAAGCTCGAGCCC
APV 3.1 Sal2 CATTGCAAGTGATGTTGTCGACATTCCC
APV3
APV 3.1 Xho+ CCTCGAAATAGGGAATCTCGAGAACATCAC
APV 4.6 Sal2 GCAGGGATTTCGCGTGGACATCTTC
APV4+5
APV 4.6 Xho+ CAAGTGAAGATCTCGAGGCGAAATCCC
APV 7.6 Sal2 GATCGTATTCAACTCGAGAACTTACCTGAC
APV6
APV 7.6 Xho+ GATCGTATTCAACTCGAGAACTTACCTGAC
APV 8.2 Sal2 GGGTATCTATGATGGTCGACAGATGTG
APV7
APV 8.2 Xho+ GGCGGACACAGAACACATCTCTCGAGCATC
APV 9.9 Sal2 GCTATGATCTTTTGCGTCGACAAAGCAC
APV8
APV 9.9 Xho+ GTACATCCAGTGCTTTCTCGAGGC
APV11.9 Sal2 CAGTGACAGGTTTTTGGTCGACTATG
APV9+10
APV11.9 Xho+ GCTGAGGGTGACATACTCGAGC
APV Trail ext ACGAGAAAAAAACCGTATTCATCAAATTTTTAGC
HDVR start GGGTCGGCATGGCATCTC
HDVR back CTCTCCCTTAGCCATCCGAG
N gene
N start+ GTCAAAATGTCTCTTGAAAG
P start2 CAGGGAAAGACATTGTTAC
P gene
P start+ GTAACAATGTCTTTCCCTG
P stop2ext GACTTGTCCCATTTTTTCATAACTACAGATCAAG
M2 gene
T7-M2 TTAATACGACTCACTATAGGGACAAGTGAAGATGTCTAG
M2-1st2 GCATTGCACTTAATTATTGCTGTCACCC
M2 start GATGTCTAGGCGAAATCC
M2 mid CCAGAGATTCAATGCTTGAAGACCC
Additional primers
T7L TTAATACGACTCACTATAGGACCAATATGGAAATATCCGATGAG
CTPE 2402 CGCCAGCATGTTCTTTCCTGCG
CTPE 1902 CGAGATCCTCTAGCCGGATCCTC
CTPE 1102 CGCCGACATCACCGATGGGGAAG
G112 CCAGATACGCCTCCAACAGTAGAATGG
SH omit+ TCGGGACAAGTATCTCAATGGGG
SH omit2 CCCTTTTTTGGACTTATAGCTTAATTGGTTTT
F6+ GTTAGAGCAATTAACAGAATGCC
F7-B CTACCATACTGACAGGGTGTC
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means of limiting Fowlpox virus replication were unnecessary (Britton
et al., 1996).
Control transfections of two types were also prepared whereby some
cell sheets, containing 106 cells, were inoculated with Fowlpox virus
(at an m.o.i. of 1 p.f.u. per cell) and transfection reagent, whereas
others received solely the latter. The transfected cell sheet was viewed,
freeze–thawed and filtered (0?2 mm) to remove cellular debris and to
eliminate any possibility of effect from residual Fowlpox virus. The
clarified material was used to infect new cells. Resultant cell sheets
were examined daily for signs of CPE typical of APV.
If CPE was not evident, material was passaged further. When CPE was
detected, RNA was extracted for RT-PCR by using an RNeasy kit
(Qiagen) with the optional DNase digestion step. RNA was isolated
4 days post-infection. The region of the genome encoding the F gene
containing the novel SstII mutation was amplified in the case of both
full-length and deleted recombinant genome-derived material and a
further PCR was used to amplify between the M2 and G genes in the
case of the latter. All RT-PCR products were generated by using
primers that were designed to anneal initially to genome RNA and
were sequenced. Standard PCR conditions used were 10 s at 94 uC, 20 s
at 50 uC and 60 s at 72 uC for 30 cycles using Taq DNA polymerase
(Promega). The F gene-derived products were incubated with the
restriction endonuclease SstII to assess their cleavability.
Confluent Vero cells were inoculated with the passaged material.
After 4 days, these were incubated with APV-specific polyclonal
antiserum that was raised in turkeys. After washing, this was further
incubated with fluorescein isothiocyanate (FITC)-linked anti-turkey
conjugate to detect infected cells (Baxter-Jones et al., 1986) and then
viewed by using fluorescence microscopy and photographed.
RESULTS AND DISCUSSION
The minigenome construct was used to identify functional
copies of the genes encoding components of the virus
ribonucleoprotein complex that are responsible for RNA
synthesis. Plasmids expressing the APV N, P, M2-1 and L
genes and the minigenome plasmid were transfected into
cells that had previously been infected with FPT7. After
48 h, expression of the CAT reporter gene in the mini-
genome was assessed by ELISA. Fig. 2 shows that co-
transfection of all four support-gene plasmids directed the
synthesis of CAT protein. In the absence of the L gene
plasmid, no reporter-gene expression was detected, as
shown in Fig. 2. Optimum levels of the various plasmids
to achieve maximal expression of the CAT gene were
established by using this system and were determined to be
400 ng plasmid encoding the N protein, 100 ng plasmid
encoding the P protein, 200 ng plasmid encoding the L
protein and 10 ng plasmid encoding the M2-1 protein
per well of a 12-well plate. Whilst expression of the CAT
reporter gene was observed in the absence of the M2-1
protein, levels were low and expression was enhanced at
least 100-fold in its presence. This is similar to the situation
seen with HRSV (Collins et al., 1995).
A full-length copy of the APV genome was constructed in
such a way that a unique restriction-enzyme site, not pre-
sent in the sequence of the wild-type APV, was inserted
into the genome. This generated an SstII site within the
F gene coding region and altered the lysines at aa 299 and
300 to arginines. The plasmid carrying the modified full-
length genome was under the control of the T7 promoter
in such a way as to generate a positive-sense antigenome
RNA. The plasmid was transfected into FPT7-infected cells
together with plasmids expressing the APV N, P, M2-1 and
L genes, as before. After the initial transfection, it was not
possible to clearly identify areas of CPE, so at 6 days, cells
were harvested and freeze–thawed and clarified supernatant
was used to infect a fresh cell monolayer. Cellular changes
typical of APV infection of Vero cells became apparent
after 3 days, with patches of syncytial CPE visible across
the entire cell sheet. After a further 2 days, this had led to
generalized CPE that, 1 day later, led to multifocal destruc-
tion and detachment of the cell sheet. After harvesting this
second passage in Vero cells, the titre was approximately 106
TCID50 ml
21, which is typical of the yield obtained with
Vero cell-adapted APV field isolates (Naylor & Jones, 1994).
RNA was extracted from the passaged virus in the presence
of DNase I and a 438 bp region of the F gene containing the
altered sequence was amplified by RT-PCR and sequenced
to confirm the presence of the altered bases between
positions 3828 and 3831. In addition, the product was
digested with SstII and the two expected cleavage products
were clear on an agarose gel, as shown in Fig. 3. A control
PCR in which the reverse transcriptase was not included
did not produce any DNA fragments (data not shown).
These data indicate clearly that the passaged virus was
derived from the cloned cDNA and that the amplified
Fig. 2. CAT reporter-gene expression from an APV mini-
genome. A plasmid carrying a minigenome of APV containing
the CAT reporter gene was transfected into 106 cells that had
previously been infected with FPT7 at an m.o.i. of 1 p.f.u. per
cell, expressing the bacteriophage T7 RNA polymerase.
Plasmids carrying the N, P, L and M2 genes of APV under the
control of the T7 promoter were also transfected into the cells
by using the optimized conditions described in the text. CAT
reporter-gene expression was measured by ELISA 48 h after
transfection. 1, Cells infected with FPT7 alone; 2, cells trans-
fected with plasmids encoding the N, P and M2 genes; 3, cells
transfected with plasmids encoding the N, P, M2 and L genes;
4, cells transfected with plasmids encoding the N, P and L
genes alone.
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fragment was not generated from contaminating plasmid
DNA. This represents the first description of rescue of a
metapneumovirus genome from cDNA.
When unfixed cell monolayers that had been infected
3 days previously with the fully competent recombinant
virus were incubated with APV hyperimmune serum and
stained with anti-turkey–FITC conjugate, intense fluores-
cence that was absent from the uninfected controls was
observed (Fig. 4).
In order to extend these observations and to investigate
the requirement of specific genes for growth in vitro, a
second APV genome construct was generated in which
the entire transcribed region encoding the SH gene was
deleted. The sequence of the entire insert in the plasmid
bearing the recombinant virus genome was determined and
showed that the cloning procedure had also generated an
extension of the deletion to include the conserved G gene
start, together with the first 11 nt of the G gene coding
region. The deletion in the G gene included the trans-
lation initiation codon. No other unexpected sequence
alterations were present. The plasmid was transfected into
cells together with the support plasmids, as before. Obvious
CPE was not detectable initially in the transfected cells
but, following passage of clarified cell extracts, very small
syncytial areas were seen after 6 days. When this was
passaged again, the number of syncytial patches increased,
but still required 6 days to be readily visible. In contrast to
the wild-type rescue, neither generalized CPE nor mono-
layer detachment was observed and this was considered to
be a clear indication of altered behaviour in cell culture.
When passaged a third time, giant syncytia could be seen
(Fig. 5). This CPE is strikingly different from that seen
with conventional strains of APV. In addition, the deletion
mutant was found consistently to generate yields of 105?3
TCID50 per standard well of cells. This contrasts with the
value of 106?8 TCID50 per well that was seen with the
1 2 3 4 5
232
211
443
Fig. 3. RT-PCR amplification of cDNA from APV. A region of
the F gene of APV was amplified between nt 3620 and 4063
of the APV genome RNA for both a wild-type non-recombinant
and the recombinant virus derived from a full-length cDNA
clone. Virus had been passaged twice in tissue culture follow-
ing the original transfection and RNA was prepared 4 days
after infection. Lane 1, 443 bp fragment amplified from non-
recombinant wild-type virus; lane 2, DNA fragment from lane 1
digested with SstII; lane 3, size markers; lane 4, 443 bp frag-
ment amplified from the recombinant virus recovered from a full-
length cDNA clone; lane 5, DNA fragment from lane 4 digested
with SstII, showing the generation of two novel fragments.
(a) (b)
Fig. 4. Immunofluorescence staining of cells infected with rescued wild-type virus. Cells were stained 3 days post-infection.
(a) Cells were infected with virus recovered from transfections with a full-length genome and virus antigen was detected by
immunofluorescence. (b) Cells were infected with FPT7 alone and anti-APV antibodies were used to show lack of cross-
reactivity with the control cells.
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wild-type virus and suggests that the deletion mutant may
be impaired slightly in its growth in vitro.
To confirm the presence of the deletion in the recombinant
DSH/G-APV by RT-PCR, genomic RNA of the virus, iso-
lated after three passages in tissue culture, was amplified
between the M2 gene (antigenome position 5273) and the
G gene (antigenome position 6605). Genomic RNA was
prepared and treated with DNase I before amplification to
ensure that no DNA from the original transfection had
been carried forward during virus passage. This produced
a product of 690 bp in size, in contrast to the 1330 bp
product that would be expected from a virus with a full
complement of genes (Fig. 6). The sequence of the short-
ened fragment was identical to that of the original plasmid
in the junction region. No fragment was obtained in the
absence of reverse transcriptase. This confirmed that the
recombinant virus lacked the regions of the SH and G genes
that had been deleted in the cDNA.
The function of the SH protein in APV and HRSV is
unknown at present. Its removal without apparent loss
of viability is a finding similar to that of Bukreyev et al.
(1997) for HRSV and shows that functional similarity
extends across the subfamily Pneumovirinae. The timing
and character of the CPE produced by this virus was
indistinguishable from that seen with the rescued wild-type
virus. The DSH-RSV recombinant was also attenuated when
administered to chimpanzees (Whitehead et al., 1999) and
it be will be interesting to explore whether DSH/G-APV is
also attenuated. The similarity between the members of the
genera Pneumovirus and Metapneumovirus may extend to
being able to remove other genes that have been shown to
be non-essential in HRSV, such as the second ORF of the
M2 gene (Schmidt et al., 2002; Jin et al., 2003). Similarly,
additional genes may be inserted into the APV genome.
By analogy with HRSV, the G gene of APV is anticipated to
encode the attachment protein that mediates the initial
interaction between the virus and host cell (Levine et al.,
1987). Despite its central role in the virus life cycle, the
HRSV G protein has been shown to be dispensable for
virus growth in cell culture. Karron et al. (1997) reported the
characterization of an HRSV vaccine candidate that was
shown to contain a deletion that removed both the SH and
G genes. Reverse-genetics approaches subsequently con-
firmed that loss of the G gene in HRSV, either singly or
together with removal of the SH gene, did not result in loss
of infectivity in vitro (Techaarpornkul et al., 2001; Teng
et al., 2001). This is consistent with the observations
(a) (b) (c)
Fig. 5. CPE of recombinant APV in Vero cells. Images of cells showing: (a) uninfected control cells; (b) cells 5 days post-
infection with recombinant APV derived from a full-genome cDNA, showing standard CPE; (c) cells 5 days post-infection with
the DSH/G-APV recombinant virus, showing abnormal syncytium formation.
1 2 3 4 5
1330
690
Fig. 6. RT-PCR between the M2 and G genes of APV. The
region between nt 5273 and 6605 in the APV genome was
amplified by using standard conditions described in the text.
Lane 1, non-recombinant wild-type APV; lane 2, recombinant
APV derived from a full-genome cDNA; lane 3, DSH/G-APV
recombinant virus; lane 4, RT-PCR using RNA from Vero cells
infected with FPT7 alone; lane 5, size marker.
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reported here for DSH/G-APV and further strengthens the
similarity of the two systems. However, deletion of the
HRSV G gene was shown to affect the efficiency of repli-
cation in certain cell types (Teng et al., 2001). It was
suggested that this effect was primarily at the level of
attachment and entry, although the precise reasons for the
host cell-dependent differences are not yet clear. As with
the SH- and G-deleted vaccine candidate, recombinant
virus analysis showed that the G protein is important
for infection in vivo. It will be of interest to study the
replication characteristics of DSH/G-APV in various cell
types and in vivo.
The new ability to manipulate the APV genome will lead
to fundamental questions being addressed concerning gene
function. Several recombinant HRSV viruses have been
shown to be attenuated (Marriott & Easton, 1999). Com-
mercially derived, live APV vaccines for administration
to poultry have been available for over 10 years in Europe
and these have led to major improvements in disease
control (Cook, 2000). However, doubts remain about their
performance under certain conditions, especially where
vaccine administration may not be optimal and significant
numbers remain unvaccinated (Jones, 1996; Cook, 2000).
APV vaccines are known to revert to a virulent state under
experimental conditions (Naylor & Jones, 1994) and there
is evidence to suggest that this also occurs in the field,
especially where vaccine administration is poor (Naylor
et al., 2003). It is widely believed that the current vaccines
may represent the maximum stability that is achievable
by empirical cell passage (Naylor et al., 2003) and attempts
to protect by using recombinant and DNA vaccines have
to date conferred protection markedly inferior to that
conferred by the current products (Yu et al., 1994;
Kapczynski & Sellers, 2003). Killed vaccines have been
shown to be poorly effective unless preceded by an initial
live vaccination (Cook, 2000). Current work in our
laboratory, involving the study of previously derived
empirical vaccines, together with associated progenitor
strains and virulent revertants (Naylor & Jones, 1994), is
starting to identify genome regions where specific muta-
tions may significantly alter pathogenesis. It is anticipated
that the reverse-genetics system described here will open
new avenues for the development of live vaccines to improve
on the empirical types that are currently in use. It is also
probable that such developments may have directly useful
applications in studies of the recently discovered human
metapneumovirus (van den Hoogen et al., 2001).
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Seven of the eight genes in the avian pneumovirus (APV) genome contain a conserved 9 nt
transcriptional start sequence with the virus large (L) polymerase gene differing from the consensus
at three positions. The sequence requirements of the APV transcriptional gene start sequence
were investigated by generating a series of mutations in which each of the nine conserved bases
was mutated to each of the other three possible nucleotides in a minigenome containing
two reporter genes. The effect of each mutation was assessed by measuring the relative levels of
expression from the altered and unaltered gene start sequences. Mutations at positions
2, 7 and 9 significantly reduced transcription levels while alterations to position 5 had little effect.
The L gene start sequence directed transcription at levels approximately 50% below that of the
consensus gene start sequence. These data suggest that there are common features in
pneumovirus transcriptional control sequences.
Avian pneumovirus (APV) causes acute respiratory infec-
tion in domestic poultry throughout most of the world
(Jones, 1996) and it has been detected in several wild bird
species, although the disease impact in these species is not
yet clear (Bennett et al., 2002, 2004; Lwamba et al., 2002;
Shin et al., 2000, 2002). APV is classified as a member of the
family Paramyxoviridae, the subfamily Pneumovirinae and
the genus Metapneumovirus (Cavanagh & Barrett, 1988;
Collins & Gough, 1988; Ling & Pringle, 1988). It is dis-
tinguished from members of the genus Pneumovirus by the
order of its genes – 39-N-P-M-F-M2-SH-G-L-59 (Ling et al.,
1992; Randhawa et al., 1996, 1997; Yu et al., 1992a, b) and
the absence of non-structural protein genes (Randhawa
et al., 1997).
RNA synthesis in pneumoviruses requires a ribonucleopro-
tein complex comprising the nucleocapsid (N) protein
bound to the genomic RNA together with the phospho-
protein (P) and large (L) polymerase protein. Efficient,
progressive, transcription is enhanced by the M2-1 protein,
a feature that is unique to the members of the subfamily
Pneumovirinae (Collins et al., 1995; Naylor et al., 2004).
Transcription of virus mRNA is carried out by the virion-
associated polymerase complex in a progressive stop–start
manner from the 39 to the 59 end of the genome (Dickens
et al., 1984; Pringle & Easton, 1997), and is directed by
gene start and gene end sequences that flank the transcrip-
tion units. The gene order in non-segmented negative-
strand RNA viruses is significant, as their transcription
strategy results in more mRNA transcripts from genes at the
39 end of the genome, with levels of mRNA progressively
decreasing in a step-wise manner to the 59 end. In Human
respiratory syncytial virus (HRSV) and APV, the gene start
sequence is conserved in all of the genes except for the L gene
(Li et al., 1996; Ling et al., 1992, 1995; Randhawa et al., 1996;
Yu et al., 1991, 1992a), although the HRSV gene start
sequence is 10 nt in length (Collins et al., 1986; Kuo et al.,
1996). The APV consensus is GGGACAAGU in mRNA
sense (Li et al., 1996; Ling et al., 1992, 1995; Randhawa et al.,
1996; Yu et al., 1991, 1992a) and the L gene start sequence
has three differences (underlined), giving a sequence of
AGGACCAAU (Randhawa et al., 1996). A consensus gene
end sequence at the 39 end of the transcription unit is
thought to be involved in termination and polyadenylation
(Bukreyev et al., 1996; Jacobs et al., 2003; Ling et al., 1992;
Randhawa et al., 1996). Termination and polyadenylation of
the mRNA occur at the gene junction, followed either by
progression of the polymerase across the non-transcribed
intergenic region to the next gene or relocation of the
polymerase complex to the genome 39 terminus to begin the
process again. The reinitation of transcription of the next
gene then occurs (Collins et al., 1986).
Here, we report the effect of mutation of the APV gene start
sequence on gene expression, and identify the key residues in
the gene start sequence that control transcription. Each of
the nine bases of the conserved APV gene start sequence
was mutated to the three other possible nucleotides. A
dicistronic minigenome for APV, similar to the dicistro-
nic HRSV minigenome (Kuo et al., 1996), was kindly
provided by Dr J. Smith, University of Warwick, UK. The
minigenome was constructed using the APV leader and
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trailer sequence flanking genes for chloramphenicol acetyl-
transferase (CAT) and firefly luciferase (Luc). The conserved
gene start sequence was located at the beginning of both
reporter genes. The CAT gene end transcription termination
sequence was taken from the APV P gene and the Luc gene
was terminated with the L gene end sequence. The intergenic
region between the two reporter genes was UCGAU. Placing
this next to the last A residue of the polyadenylation site of
the P gene end sequence generated a ClaI site that was used
for cloning. The newly created intergenic region contains a
pyrimidine as the first base, which is common with APV
intergenic regions, but does not otherwise resemble any of
the wild-type regions. The consensus gene start sequence at
the beginning of the Luc gene was followed with a 4 nt
AACC sequence (in mRNA sense) to preserve the Kozak
sequence (Kozak, 1986) around the Luc AUG start codon.
Mutagenic primers of 22–29 nt in length were designed to
create each of the 27 desired mutants of the Luc gene start
sequence in the APV dicistronic minigenome. PCRs were
carried out using a mutagenic primer and a standard T7
promoter primer that annealed with the T7 promoter
sequence in the vector. In addition, a non-consensus APV L
gene start sequence and an ‘intermediate’ mutant with two
of the three bases unique to the non-consensus L gene start
sequence were also created using mutagenic primers. All
mutations were confirmed by sequencing. Details of the
primer sequences are available upon request from the
authors.
The dicistronic minigenome, shown diagrammatically in
Fig. 1, was transfected into BSR-T7 cells (Buchholz et al.,
1999) that had previously been infected with APV, as
described by Marriott et al. (2001). To quantify the effect of
the gene start mutations on gene expression, the levels of
protein production from the reporter genes were deter-
mined as described previously (Marriott et al., 2001) and the
level of Luc gene expression was normalized to the CAT
reporter gene expression. The values for the two reporter
genes expressed from the dicistronic minigenome with an
unaltered consensus gene start sequence for the CAT gene
were determined. For each mutant, three to eight individual
transfection experiments were averaged and a standard
deviation determined.
The levels of expression of the Luc protein, relative to the
level of the CAT protein, compared with the wild type for
each of the mutations were calculated and are presented in
Fig. 2. Although the levels of reporter gene expression from
the mutants covered a wide range, all but one mutation
(C5U) decreased activity to below 60% of the control.
Consideration of all of the mutations showed that changes
from a G to an A, in which the purine nature of the base
is conserved, were better tolerated than alteration of a G
residue to either a U or C. Mutations were more detrimental
(any change resulting in a value below 25%of control) when
present at positions 2, 7 and 9. At position 1 the change from
a G to an A was the best tolerated mutant with the other
alternatives giving very low (G to U) or no (G to C) gene
expression. At positions 2 and 3, the change of the conserved
G residue to any other nucleotide reduced expression
significantly, with little difference between the three mutants
at each position, although the introduction of a U residue at
position 2 reduced expression more than the A or C
substitutions. The nucleotide that tolerated mutation with
the least effect on transcription was at position 5, where the
introduction of a U residue gave little reduction in reporter
gene expression. Overall, levels of gene expression of the
mutants ranged from 0% for G1C to almost wild-type levels
for C5U.
Of particular interest for APV was the set of mutations that,
individually and collectively, form the L gene start sequence.
It was found that these three mutations caused a similarly
decreased level of expression (40–50%) when present
individually or when combined in the L gene start sequence,
and also that a change of two of the three bases (G1A/G8A)
that make up the L gene start sequence similarly reduced
gene expression (Fig. 2). It is interesting to note that there
was no additive effect of the multiple mutations. The
conserved APV gene start sequence appears to be very
important for efficient transcription and the differences in
the L gene start sequence from the consensus maintained in
the other genes may, coupled with the effect of the position
of the L gene in the APV genome, be an important factor in
transcriptional regulation of the L gene.
It should be noted that the A7U mutant introduces a
translational start codon, AUG, which may alter the protein
reading frame from the naturally occurring one. This will
affect the observed activity of the Luc enzyme produced
from these transcripts, and hence the level of expression for
this mutant cannot be considered to be truly representative
of transcriptional capacity. Results of CAT ELISA and Luc
enzyme assays have previously been shown to closely match
levels of mRNA transcription from minigenomes measured
by Northern blot analysis (Marriott et al., 1999). To clarify
the effect of the introduction of this start codon, and to
confirm that the mutations were affecting mRNA transcrip-
tion rather than having an indirect effect on another aspect
of gene expression, Northern blot analysis was carried out
Fig. 1. Diagram of negative-strand RNA dicistronic minige-
nome. The virus genome sense RNA transcribed from the dicis-
tronic minigenome plasmid used in the study contained CAT
and Luc genes each flanked by conserved APV gene start and
gene end transcriptional regulation sequences. The construct
contained the APV leader and trailer terminal sequences, as
indicated.
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using mRNA isolated from HEp2 cells previously infected
with recombinant vaccinia virus expressing T7 RNA poly-
merase in a plasmid-based rescue system as described by
Marriott et al. (1999), with plasmid amounts optimized for
APV (0?4 mg of the N plasmid and dicistronic minigenome,
0?2 mg of the P and L plasmids and 0?02 mg of the M2-1
plasmid) transfected into approximately 26106 cells using
Lipofectin (Invitrogen). A range of mutants were chosen to
represent the different levels of Luc activity seen in Fig. 2
and this included the A7U mutant (Fig. 3). A riboprobe
containing sequences from both CAT and Luc genes was
generated by transcription from an APV dicistronic
minigenome and the blots were processed as described by
Marriott et al. (1999). It can be seen that the levels of Luc
mRNA relative to those of CAT mRNA are consistent with
the protein levels determined for the mutants. ThemRNA of
the mutant found to have the least effect, C5U, had both the
CAT and Luc band at a similar relative intensity to that of
the wild-type minigenome. The mutations with the most
detrimental effect in the protein assay were G1C where no
Luc protein was detected and mutant G1U which expressed
Luc protein at levels of approximately 5% of the wild-type
control. From Fig. 3 it can be seen that no LucmRNA can be
detected for either of these mutants. In contrast, mutant
G1A had an intermediate effect on Luc protein production
and it can be seen that the Luc mRNA band is of moderate
intensity compared with the wild-type Luc mRNA and their
CAT mRNA levels are of similar intensity. It can be seen
that mutant A7U did not direct the synthesis of detectable
levels of Luc mRNA, indicating that this mutation had a
significant effect on transcription.
The APV gene start sequence is similar to that of HRSV,
the representative virus for the subfamily Pneumovirinae.
Mutational analysis of the gene start sequence has been done
for HRSV (Kuo et al., 1997) and features similar to the data
obtained here were found. At position 1, the APV and the
HRSV sequences were intolerant of change, with no
mutation achieving above 40% of wild-type sequence
activity and a change from a G to an A was the best tole-
rated mutation. The favouring of the A at position 1 was
unexpected because this nucleotide is not found naturally in
anyHRSV gene start sequence, though it is seen in the APV L
gene start sequence. At positions 2 and 3 of the HRSV
consensus sequence, any change significantly reduced gene
expression, but a change from a G to an A had the least effect
Fig. 2. Effect of mutations of the APV gene start sequence on the relative levels of reporter gene activity. The effect of
mutational analysis of each of the conserved gene start sequence nucleotides of APV was assessed by measuring the relative
levels of reporter gene activity in a synthetic dicistronic minigenome expressed as a percentage of the relevant control, wild-
type minigenome. Mutants are labelled with the nucleotide to be changed, the position of the change and the nucleotide of the
mutation expressed in the positive sense. LGS is the L gene start sequence (AGGACCAAU). The mutant A7U is indicated (*).
This mutant generated a translational start codon as discussed in the text.
Wild type G1A G1C G1U C5U A7U
Luc
CAT
Fig. 3. Effect of selected mutations of the APV gene start
sequence on mRNA expression. The effect of mutation of the
APV gene start sequence at positions 1, 5 and 7 on the pro-
duction of CAT and Luc mRNA was determined by using
Northern blot analysis.
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on gene expression. Position 5 for both HRSV and APV was
more tolerant of mutation and mutation to a U gave almost
100% activity in both systems. A change at position 6 for
HRSV significantly reduced gene expression, but the effect
of mutation at this position was less dramatic for APV.
For both APV and HRSV a mutation at position 5 to a C
residue gave the highest level of expression. At position 7,
for both viruses, any change decreased the expression levels
to below 20% of controls. Position 9, for both viruses, was
least tolerant of mutation of any kind, with any change
decreasing expression levels to below 10% of the wild-
type level. Overall, both viruses were relatively sensitive to
change at positions 7 and 9, and position 5 was relatively
insensitive to change.
The APV gene start sequence mutation data presented here
differ from those of HRSV in that the APV gene start
sequence showed a trend to more readily accept changes
from a G to an A. However, the APV gene start sequence was
also more sensitive to mutation overall than that of HRSV
and none of the mutations resulted in enhanced activity of
the gene start sequence. The APV gene start sequence also
tolerated best the changes at the positions found to differ
from the consensus in the L gene start sequence over any
other possible nucleotide. This trend was also found at
positions 4 and 10 of the HRSV gene start sequence (mRNA
sense) in the gene start sequence for the L gene if the A at
position 9 of the HRSV gene start sequence is considered to
be an insertion rather than a substitution (Kuo et al., 1997).
The data presented here, together with those of Kuo et al.
(1997) for HRSV, indicate that there is a consistent pattern
for the nucleotides important for initiating efficient
transcription by pneumoviruses. In addition, the expression
of the L gene is regulated not only by genome location but
also by its unique gene start sequence, which is less efficient
than the consensus present in the other genes.
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A prototype avian metapneumovirus (AMPV) vaccine (P20) was previously shown to give variable
outcomes in experimental trials. Following plaque purification, three of 12 viruses obtained from
P20 failed to induce protection against virulent challenge, whilst the remainder retained their
protective capacity. The genome sequences of two protective viruses were identical to the P20
consensus, whereas two non-protective viruses differed only in the SH gene transcription
termination signal. Northern blotting showed that the alterations in the SH gene-end region of the
non-protective viruses led to enhanced levels of dicistronic mRNA produced by transcriptional
readthrough. A synthetic minigenome was used to demonstrate that the altered SH gene-end
region reduced the level of protein expression from a downstream gene. The genomes of the
remaining eight plaque-purified viruses were sequenced in the region where the P20 consensus
sequence differed from the virulent progenitor. The seven protective clones were identical,
whereas the non-protective virus retained the virulent progenitor sequence at two positions
and contained extensive alterations in its attachment (G) protein sequence associated with a
reduced or altered expression pattern of G protein on Western blots. The data indicate that
the efficacy of a putative protective vaccine strain is affected by mutations altering the balance
of G protein expression.
INTRODUCTION
Vaccines must demonstrate two key characteristics to be
successful: they must be attenuated for disease and their
administration must be able to induce an appropriate level
of protection in the vaccinee. Protection from infection
generally involves the induction of a suitable immune
response from both the humoral and cellular arms. Much
attention has focused on the molecular basis of attenuation
in vaccine candidates, but there is little understanding of
the factors that relate to the establishment of protective
immunity other than the inclusion of appropriate epitopes
in antigenic proteins. Avian metapneumovirus (AMPV) is
responsible for major economic losses in domestic poultry
throughout most of the world (Jones, 1996). The most
severe clinical effects of infection are seen in turkeys, but
there are significant economic losses in commercial
chickens where it has also been implicated in swollen head
syndrome. AMPV is a member of the family Paramyxo-
viridae, subfamily Pneumovirinae and genus Metapneumo-
virus (Cavanagh & Barrett, 1988; Collins & Gough, 1988;
Ling & Pringle, 1988), and is distinguished from members
of the genus Pneumovirus by the order of its genes (39-N-P-
M-F-M2-SH-G-L-59) (Ling et al., 1992; Randhawa et al.,
1996, 1997; Yu et al., 1992a, b) and the absence of non-
structural protein genes (Randhawa et al., 1997). The only
other member of the genus Metapneumovirus is the species
Human metapneumovirus (van den Hoogen et al., 2002).
Several AMPV vaccine candidates have been described, but
most suffer from problems of either incomplete protection
and/or reversion to pathogenicity (Catelli et al., 2006). The
genetic basis for field strain attenuation and vaccine
instability is not clear and an understanding of this is
important for the rational design of vaccine candidates.
AMPV type A field strain #8544 was isolated in northern
England in 1985 during a severe outbreak of turkey rhino-
tracheitis that rapidly spread across the whole country.
When tested as a candidate vaccine, it proved to be highly
protective against virulent challenge, but also caused severe
post-vaccine disease in a number of cases (Williams et al.,
1991a). Subsequently, strain #8544 was passaged exten-
sively in Vero cells in our laboratory to yield an uncloned
virus (named P20) that protected turkeys against virulent
AMPV challenge (Williams et al., 1991b). However, on
occasions, the putative P20 vaccine produced respiratory
disease, typical of AMPV infection, during serial passage
in turkeys. This was ascribed to a small subpopulation
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of virulent virus in less than 1 in 105 infectious doses
(Naylor & Jones, 1994). To remove the virulent sub-
population, stock P20 was plaque purified and 12
derivative viruses were prepared as candidate vaccines
and, as anticipated, all were shown to be free of the virulent
subpopulation.
Here, we describe the protection conferred by these 12
plaque-purified viruses and demonstrate that the loss of
ability to confer protection from virulent challenge is
associated with an alteration in the balance of protein
expression, particularly the attachment (G) glycoprotein.
METHODS
Viruses. The vaccine candidate P20 was used to infect monolayers of
Vero cells, and 12 individual plaques were picked and purified. These
purified viruses, designated A–H and J–M, were grown in Vero cells
and used to inoculate 1-day-old turkey poults.
Clinical assessment of plaque-purified viruses. An established
challenge model was used to assess the ability of the plaque-purified
viruses to confer protection from pathogenic virus challenge (Naylor
et al., 1997a; Williams et al., 1991a). One-day-old turkey poults were
divided into 13 groups, each comprising ten birds. Twelve groups
received intraocular inoculations, each with a different virus (A–M),
at a dose of 103.0 TCID50 per poult. The final group was not inocul-
ated. Clinical disease was assessed on a daily basis. At 3 weeks of age,
half of the uninoculated control group was combined in one room,
together with all of the birds from the inoculated groups and all were
challenged by intraocular inoculation with virulent field virus strain
#8544 at a dose of 103.0 ID50. This ensured that all birds receiving a
virulent challenge were in identical conditions and received the same
challenge. For each bird, the clinical signs were assessed prior to its
identification by wing band number and then scored on a daily basis
until signs ceased, using a four-point scoring system, with a score of
0 representing no signs, 1 representing clear nasal exudates, 2 repre-
senting turbid nasal exudates and 3 representing swollen infraorbital
sinus and/or frothy eye (Catelli et al., 2006). The disease severity for
each group was expressed by summing the daily mean scores for the
entire period of clinical disease to give a single cumulative score for
each. It has been shown previously that turkeys with no protection
typically achieve a score of between 8 and 10 on this scale, whereas
fully protected birds score between 0 and 1. These scores have been
shown to correlate closely with the level of virus replication in the
trachea, which, together with the nasal turbinates, constitute the key
tissues for replication of the virus (Naylor et al., 1997a; Williams et al.,
1991b). At 3 weeks of age, prior to combining the groups, serum was
collected from all birds prior to challenge to provide a baseline for
AMPV serology by ELISA to confirm that virus had replicated and
induced an antibody response.
Sequencing of viruses. The complete genomic sequences of field
virus strain #8544, vaccine P20, and two protective (C and K) and
two non-protective (F and H) plaque-purified viruses were deter-
mined. RNA was extracted using an RNeasy kit (Qiagen) and cDNA
was prepared as overlapping leader, central and trailer regions, using
Superscript II reverse transcriptase (Invitrogen). The cDNAs were
amplified with PfuTurbo (Stratagene) for 12 cycles and then
amplified further to provide three overlapping PCR products for
sequencing. The PCR products were treated with exonuclease I and
shrimp alkaline phosphatase (GE Healthcare) to remove primers and
dNTPs, respectively, and sequenced. If any region of sequence showed
a difference to the other viruses, the process was repeated and the
sequence difference confirmed using a new RNA extraction from the
relevant virus followed by RT-PCR spanning the base(s) in question.
The remaining eight cloned vaccine viruses were sequenced in all
regions where any differences were found between strain #8544,
vaccine P20 and purified viruses C, F, H and K. This included the
putative mutation together with a flanking sequence of about 250
bases in both directions. Subsequently, the G gene of purified virus L
was fully sequenced after detection of additional mutations at the
start of the G gene.
Western blotting of cloned viruses. Protein expression of selected
viruses was studied by Western blotting. Viruses F, K, G and L were
grown in Vero cells and 107.5 TCID50 of each was purified by ultra-
centrifugation through a 25% sucrose cushion followed by protein
separation on 10% SDS-PAGE gels. The proteins were electroblotted
onto nitrocellulose and incubated with serum raised during natural
infection of turkeys with strain #8544. As a control, a separate gel was
silver stained to confirm that similar amounts of material were
present in each sample (not shown). The bound antibodies were
detected using horseradish peroxidase-conjugated secondary anti-
bodies and diaminobenzidine as the substrate.
Generation of recombinant viruses. Recombinant viruses, based
on the subgroup A AMPV strain CVL-14/1, were created by reverse
genetics. Full-length cDNA copies of the virus genome were prepared
with modifications to the sequence to insert restriction enzyme
recognition sites before the N gene initiation codon, in the L gene
untranslated region and before the gene-start signals of the P, M, SH,
G and L genes. The parental clone, designated F2, was modified by
introducing the sequence of the SH gene-end and SH–G intergenic
region from protective C and unprotective F and H viruses. This was
achieved by PCR amplification of the region from the intergenic M2–
SH to the intergenic region of the SH–G genes including restriction
sites enabling it to be inserted into F2 digested with the same
enzymes. Virus was rescued from these plasmids in the T7 RNA
polymerase-expressing cell line BSR-T7 (Buchholz et al., 1999)
following transfection with plasmids containing the full-length anti-
genome and the N, P, M2-1 and L genes in pCITE4 (Novagen). Virus
was propagated in BS-C-1 cells and cells infected at the third passage
were used for RNA extraction.
Measurement of SH, G and SH–G readthrough mRNA levels.
RNA was extracted from BS-C-1 cells infected with viruses C and F or
recombinant viruses using an RNeasy MIDI kit (Qiagen). RNA (1 mg
per lane) was analysed by Northern blotting using glyoxal gels along
with serial dilutions of in vitro transcripts [generated using Megascript
T7 or T3 kits (Ambion) and purified on 5% acrylamide/urea gels] corre-
sponding to the SH or G genes to allow quantification of RNA levels.
Blots were probed with antisense RNA probes generated with a Maxi-
script kit (Ambion) directed against the SH or G genes and containing
5% of a probe generated against the Millenium markers (Ambion),
which were included on each gel. Hybridized and washed blots were
wrapped in cling film and exposed to an imaging plate for reading in an
FLA5000 imager (Fuji). Analysis of 16-bit TIFF files was carried out with
TOTALLAB 2003 (nonlinear dynamics) and Microsoft EXCEL to give the
number of copies of each specific RNA (mg total RNA)21.
Use of a dicistronic minigenome to measure the effects of
different SH gene-end regions on a downstream reporter.
Overlap-extension PCR was used to alter the gene-end region of the
first gene in a dicistronic minigenome, as described previously
(Edworthy & Easton, 2005), to that of strain #8544 or of virus C, F or
H sequence. The sequences in the minigenome constructs contained
the desired SH gene end and the subsequent intergenic region
sequence of the appropriate virus (Fig. 1). The minigenomes were
rescued in a recombinant vaccinia T7 virus-based transfection system,
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and chloramphenicol acetyl transferase (CAT) and luciferase (Luc)
reporter expression were measured as described previously (Edworthy
& Easton, 2005).
RESULTS
Clinical assessment of plaque-purified virus from
P20 vaccine stock
All of the viruses were attenuated for disease and no clinical
signs were seen after inoculation with any of the purified
viruses. After challenge with virulent virus, the progression
of clinical signs was followed and details are given in
Table 1. Only seven of the purified viruses generated high
levels of protection, two were partially protective and three
(viruses F, H and L) had similar levels of disease to the
unvaccinated and challenged control group. Sera from all
vaccinated groups were weakly positive prior to challenge,
showing that the viruses had replicated to levels sufficient
to induce an immune response (Table 1). There was no
significant difference in antibody titres among groups
receiving different viruses.
Fig. 1. Genome-sense RNA sequences (39A59) of the SH gene-end, intergenic and G gene-start sequences of the parental
viruses (#8544 and P20), non-protective viruses (F, H and L) and protective viruses (A, B, C, D, E, G, J, K and M). Differences
are shown in white. The position of the SH gene, the SH gene transcription termination sequence (boxed) and the SH–G gene
intergenic region are shown. Numbers indicate the nucleotide positions of the mutations in the AMPV genomic sequence.
Table 1. Cumulative clinical scores of poults inoculated at 1 day of age with plaque-purified viruses
and challenged at 3 weeks of age
Animals were bled to prepare sera for ELISA 1 day before challenge.
Plaque-purified
virus
Disease post-challenge
Description of clinical signs Cumulative clinical score Mean ELISA titre*
A None 0.0 6.9
B Mainly clear nasal exudate 2.5 7.1
C None 0.0 6.5
D Mainly clear nasal exudate 2.4 6.6
E None 0.0 6.7
F Severe signs 7.2 6.2
G None 0.0 6.8
H Severe signs 8.2 7.0
J None 0.0 6.4
K None 0.0 6.3
L Severe signs 8.3 6.7
M None 0.0 6.5
None Severe signs 10.8 5.4
*Log2 ELISA titres pre-challenge. Titres .6.0 indicate significant APMV antibody titres. All groups showed
low but significant antibody titres. Differences between protected and unprotected groups were not significant.
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Nucleotide sequences of protective and non-
protective viruses
The complete sequences of the genomes of the pathogenic
field strain #8544 and the protective virus P20 derived from
it were determined. As shown in Table 2, comparison of the
consensus sequences of the #8544 and P20 genomes
identified a total of nine base substitutions that had occurred
during the attenuation process. Only three of these differ-
ences resulted in changes in amino acid sequence: two in the
F protein and one in the M2-1 protein. When the two
complete genomic sequences of the fully protective viruses C
and K were determined, they were found to be identical to
the P20 consensus sequence, indicating this to be the
dominant sequence found in the population of viruses in
the P20 stock. In contrast, the genomes of two (F and H) of
the three viruses conferring negligible protection differed
from those of the protective viruses only in the SH intergenic
region where there were single point substitutions in the SH
transcription termination (gene-end) sequence. A summary
of the sequences in the SH gene-end, SH–G intergenic and G
gene-start sequences is shown in Fig. 1.
Sequencing of the remaining eight plaque-purified viruses
in regions spanning the 11 mutations that arose during the
conversion of strain #8544 to P20 found them all to be
identical to the P20 consensus sequence with the exception
of virus L. This virus genome retained the original strain
#8544 sequence at nt 2941 and 11624, suggesting that it
represented an intermediate between the progenitor and
the dominant protective clones. Mutations were also found
in the G gene of virus L, so the remainder of this virus
genome was sequenced. The G gene of virus L contained
extensive mutations between nt 132 and 697 of the open
reading frame. In total, 55 AAG (genomic sense)
substitutions were found, which altered 29 amino acid
residues of the protein. For some codons, more than one
nucleotide was altered. The details and distribution of
nucleotide sequences and altered amino acids is shown in
Fig. 2. Except for changes in the differences at positions
2941 and 11624 and in the G gene, no other genetic
differences were detected in purified virus L.
Western blots of protective and non-protective
viruses
Proteins prepared from Vero cells infected with selected
representative plaque-purified viruses (protective G and K;
non-protective F and L) were analysed by Western blotting
using anti-AMPV serum prepared in birds infected twice
by the respiratory route (Fig. 3). For all viruses, a strong
band was seen at 55 kDa, which has been identified pre-
viously as the F protein (Cavanagh & Barrett, 1988; Collins
& Gough, 1988; Ling & Pringle, 1988). Protective viruses K
and G both produced a band of approximately 85 kDa
corresponding to the G protein (Cavanagh & Barrett, 1988;
Collins & Gough, 1988; Ling & Pringle, 1988). As shown
previously, the heavily glycosylated protein was seen as a
faint, diffuse band. Larger bands were also seen, which have
been described as G protein multimers (Cavanagh &
Barrett, 1988; Collins & Gough, 1988; Ling & Pringle,
1988). For non-protective viruses, the intensity of the G
protein bands was much lower relative to the G protein
bands of protective viruses. This suggested that expression
of the G protein was reduced in the viruses that did not
confer protection from infection compared with those that
protected against challenge.
Table 2. Sequence differences among strain #8544, P20 vaccine and plaque-purified viruses A–M
The nature, location and resulting amino acid alteration, if any, of each of the differences are shown. The amino acid alteration is given as that
occurring between the pathogenic progenitor strain #8544 and the P20 vaccine derived from it.
Nucleotide
position*
Genome location Strain
#8544
Vaccine
P20
Amino acid alteration
on attenuation
All protective
clones
Virus
F
Virus
H
Virus
LD
2941 F gene start C U None U U U C
3553 F A G VAA G G G G
3825 F C U EAK U U U U
5055 M2-1 U C KAR C C C C
5140 M2-1 A G None G G G G
M2-2 None
5929 SH untranslated U C None C C C C
5946 SH gene end A A None A U A A
5949 SH gene end U U None U U A U
6358 G A G None G G G G
10022 L A C None C C C C
11624 L A G None G G G A
*Sequences are shown in the 39A59 genomic sense.
DSequence changes in the G gene are not shown.
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Effect of SH gene-end mutations on levels of
SH–G dicistronic RNAs and G gene expression
The effects of the SH gene-end mutations on transcription
of the downstream G gene were determined using RNA
extracted from cells infected with the plaque-purified
viruses. This was studied further using recombinant viruses
containing the same mutations in the SH–G intergenic
region.
Total cellular RNA was prepared from virus-infected cells,
separated by electrophoresis, blotted and probed. The
results of samples probed with plus-strand-specific SH and
G gene probes are shown in Fig. 4(a, b). The SH gene probe
showed that the wild-type (F2, equivalent to #8544) and
protective virus SH gene ends (Fig. 4b, tracks C and rC)
allowed only negligible readthrough into the G gene, as
shown in Table 3. In contrast, a significant level of SH–G
gene readthrough mRNA was seen for all non-protective
vaccine SH gene ends (Fig. 4a, b, tracks F, rF and rH).
The ratios of G gene transcripts to SH gene transcripts
(SH+dicistronic SH–G), as calculated from G- and SH-
probed blots, are shown in Table 3. In general, the relative
amount of G gene transcribed was lower in the non-
protective viruses, but only to a marked degree for rF.
To determine the effect of the SH gene-end mutations
directly on the level of downstream gene protein expres-
sion, a reverse-genetics approach involving a dicistronic
synthetic minigenome was used. A similar approach has
been used previously to determine the effect of mutations
in AMPV gene-start sequences (Edworthy & Easton, 2005).
A minigenome was constructed containing two reporter
genes, CAT and luc, with the CAT gene positioned to be
transcribed first from the synthetic genome. The wild-type
gene-end, intergenic and second gene-start sequences were
those found in strain #8544, and constructs containing the
SH gene-end sequences from plaque-purified viruses C, F
and H were also generated. The plasmids containing the
Fig. 2. Comparison of the sequences of the G genes of the P20 and plaque-purified L viruses. The nucleotide sequence of the
G gene of P20 virus is shown with the amino acid sequence of the predicted G protein below. The nucleotide sequence of the
G gene of virus L is shown above the P20 virus sequence and differences in its G protein sequence are shown above.
Fig. 3. Western blot analysis of AMPV proteins. Proteins from
Vero cells infected with vaccine stock P20 and plaque-purified
viruses F, G, K and L were purified by ultracentrifugation and
separated by SDS-PAGE, blotted and probed with polyclonal
antisera collected from turkeys infected with APV under experi-
mental conditions. A similarly purified but uninfected cell prepara-
tion was also used. Molecular masses are indicated.
AMPV vaccine strains
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minigenomes under the control of the bacteriophage T7
promoter, together with plasmids expressing the AMPV N,
P, L and M2-1 genes, also under the control of a T7
promoter (Naylor et al., 2004), were transfected into cells
infected with a recombinant vaccinia virus expressing the
T7 RNA polymerase.
The levels of expression of CAT protein (measured by
ELISA) and Luc (in arbitrary units) were expressed as a
ratio (Luc/CAT) for each minigenome. In Table 3 and
Fig. 4(c), each ratio is given as a percentage of the ratio of the
wild-type #8544 virus (which gave the highest ratio). This
approach provided a relative measure of expression of the
second gene compared with the first gene for the various
sequences. The level of expression of the luc gene in pro-
tective virus C was almost identical to that of the parental
virus. However, for the sequences from the two non-
protective viruses, the level of expression of the luc gene was
significantly reduced compared with the protective viruses,
with the sequence from virus F causing the most reduction
(43% of the control). This demonstrated that the alteration
in the SH gene-end sequence that altered the level of
readthrough mRNA at the SH–G gene junction also reduced
the level of expression of the downstream gene. This was in
agreement with the reduction in the level of G protein seen in
the Western blots of the virus proteins (Fig. 3).
Fig. 4. Analysis of the effect on transcription and gene
expression of alterations in the SH gene-end sequence.
(a) Northern blot of mRNA extracted from cells infected
with the plaque-purified viruses C and F, or recombinant
viruses with the SH gene end corresponding to #8544
(F2) or to clones C, F or H (rC, rF or rH, respectively).
The blot was probed with a G gene-specific probe. The
positions of molecular size markers are indicated on the
right. For quantification purposes, various amounts of
AMPV-specific RNA synthesized in vitro were included
on the gel and are indicated as the log10 of the number of
molecules. The positions of the SH, G and readthrough
mRNAs are indicated. Also indicated is the position of
the antigenome RNA, which was also detected by the
negative-sense probe. (b) Northern blot similar to that
described in (a) but probed with an SH gene-specific
probe. (c) Graph showing the relative levels of expression
of the luc gene compared with the CAT gene in a
dicistronic AMPV minigenome assay. The minigenomes
contained the SH gene-end and SH–G gene intergenic
regions from the viruses indicated (see also Fig. 2). The
levels of expression were determined as described
previously (Edworthy & Easton, 2005).
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DISCUSSION
It is generally accepted that a small number of alterations in
genome sequence can lead to dramatic differences in
pathogenicity. This has led to the proposal that it will be
possible to develop rationally designed vaccine candidates
lacking pathogenicity determinants. However, another
important aspect of a vaccine is its ability to establish
protection from challenge. The parameters that affect the
ability to confer protection have been little studied, but it
will be necessary to clarify what they are for successful
vaccine design. In our current study, analysis of 12 plaque-
purified viruses derived from the original attenuated and
protective P20 stock showed that all were still attenuated,
but three failed to confer significant protection when tested
as candidate vaccines (Table 1). The remaining plaque-
purified viruses gave either complete or near-complete
protection from challenge and presumably represented the
majority of the protective virus in the original vaccine
stock.
The complete genomic sequences of the parental patho-
genic strain #8544 and the P20 vaccine derived from it
were determined to locate the mutations associated with
the loss of pathogenicity and the inability to protect from
infection. This indicated that there were only nine
nucleotide changes between the two viruses, only three of
which resulted in amino acid changes, two in the F protein
and one in the M2-1 protein, whilst of the remainder, four
were silent mutations and two occurred in a non-coding
region.
The complete genome sequences of two protective viruses,
C and K, and two non-protective viruses, F and H, were
determined. The protective viruses were identical in
sequence to the P20 consensus sequence. In contrast, the
non-protective viruses, F and H, both contained a single
mutation, not present in the protective viruses, in the
transcription termination signal of the SH gene (Fig. 1).
The mRNA profile of the parental and selected plaque-
purified viruses showed that the level of transcriptional
readthrough at the SH–G gene junction in the non-
protective viruses was considerably greater than that seen
for protective viruses. In addition, a similar alteration in
the frequency of SH–G readthrough was seen in recombi-
nant viruses engineered to contain the altered SH gene-end
sequence (Fig. 4a; Table 3). When the levels of gene expres-
sion for a series of dicistronic minigenomes containing SH
gene-end sequences from either the protective or non-
protective viruses was assessed, the level of protein expres-
sion from the downstream gene was significantly reduced
compared with the control (Fig. 4c), indicating that the
alteration in transcriptional readthrough led to a reduction
in gene expression of the downstream gene, which was that
for the G protein in the virus genome (Fig. 4b; Table 3).
A Western blot of the P20 vaccine and the four plaque-
purified viruses using polyclonal antiserum raised during
infection of turkeys by a natural route under experimental
conditions showed antibody responses primarily to the F
protein, irrespective of whether the viruses were protective
or not (Fig. 3). Assuming that there were similar responses
in the inoculated birds, this indicates that, for AMPV, an
antibody response to the F protein alone is not sufficient to
protect birds from challenge. The detection of high levels of
antibodies directed against the F protein after infection by
a natural route is in contrast to the antibody profile seen for
other similar viruses in mammals. However, the immune
systems of mammals and birds are significantly different. It
should be borne in mind that a previous study showed that
virus stock P20 fully protected bursectomized turkeys
where antibody was undetectable (Jones et al., 1992).
Equally, turkeys with high levels of circulatory antibody
can be unprotected (Naylor et al., 1997b). This implies that
viruses that do not protect are likely to have lost T-cell
rather than B-cell epitopes. It is possible that the non-
protective viruses may not be expressing sufficient levels of
key T-cell epitopes on the G protein gene.
Whilst Western blotting of the proteins from selected
protective and non-protective viruses only showed a weak
diffuse band in the region corresponding to the reported
size for the G protein, this was noticeably reduced in blots
of non-protective viruses (Fig. 3). Taken together, these
Table 3. Effect of different SH gene-end sequences on
readthrough and downstream gene expression
The quantification of mRNA was derived from Northern blots of
RNA from virus-infected cells Fig. 4(a, b). The relative levels of expres-
sion of the luc gene compared with the CAT gene in a dicistronic
minigenome construct are presented as the mean of data derived from
Luc and CAT assays on plasmid rescue of dicistronic minigenomes, as
shown in Fig. 4(c). Ratios are expressed as a percentage of that
obtained with the wild-type strain #8544 SH gene-end sequence.
Virus/SH–G
sequence in
minigenome
Fractional
readthrough at
SH gene end*
Ratio of
G RNA to
SH+SH–G
RNAD
Luc/CAT
ratio as a
percentage
of #8544d
#8544 0.009 0.423 100
Virus C 0.012 0.347 99
rC§ 0.007 0.466
Virus F 0.314 0.294 43
rF§ 0.683 0.173
rH§ 0.231 0.380 79
*Fraction of dicistronic RNA [SH–G dicistronic RNA/(SH mono-
cistronic RNA+SH–G dicistronic RNA)], calculated from an SH-
probed Northern blot.
DComparison of the fraction of G RNA relative to transcripts initiated
at the upstream gene (SH+SH–G dicistronic RNA) determined from
SH- and G-probed Northern blots.
dComparison of Luc (measured as relative light units) to CAT
(measured as pg CAT) ratios, expressed as a percentage of the highest
value.
§Virus on which the recombinant virus was based.
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data strongly suggest that an alteration in the balance of
level of expression of virus proteins, in particular a
reduction in the relative level of the G protein, can
significantly reduce the potential protective efficacy of a
vaccine candidate.
Alterations of transcription termination signals have been
shown to have an effect on transcriptional readthrough,
but did not result in any significant difference in the ability
of the altered viruses to replicate in vitro or in vivo (Tran
et al., 2004). An AAG substitution (genomic sense) at
position 5937 (strain #8544 numbering) in the SH gene
end inadvertently introduced into a recombinant AMPV
has been shown to produce increased readthrough at the
SH–G gene junction and reduced expression of G mRNA
(R. Ling and A. J. Easton, unpublished data).
The conservation of strain #8544 sequences in plaque-
purified virus L at positions 2941 and 11624 might lead to
the expectation that it would be more virulent and more
protective than the other clones. However, the G protein
gene in virus L also contained extensive mutations, which
may have resulted in the reduced level of protection to
challenge as well as the absence of virulence (Fig. 2). The
predicted protein sequence of the G protein of virus L
contained more potential O-linked glycosylation sites than
was the case for the G protein of the other plaque-purified
viruses. The additional potential glycosylation sites were at
positions 109 (IAT), 130 (LAS), 170 (IAT) and 217
(MAT), whilst two were lost at positions 45 (TAI) and
160 (SAP; Fig. 2). The origin of the G gene mutations in
virus L is unclear, but it may have been present as a
subpopulation in the original strain #8544 isolate or have
been generated some time later during passage in tissue
culture. A possible explanation for the AAG transitions in
the genomes of negative-strand RNA viruses involving
cellular adenine deaminase enzymes has been described
(Bass et al., 1989).
Reduction of G gene expression or sequence variations in it
therefore appear to reduce protection afforded by potential
vaccine viruses. The importance of the G protein in genera-
ting a fully protective response has been demonstrated in
respiratory syncytial virus using a recombinant virus in
which the G gene was deleted (Johnson et al., 2004).
However, this contrasts with the data from human meta-
pneumovirus (HMPV) where a virus lacking the G gene
was shown to confer effective protection to African Green
monkeys in challenge trials (Biacchesi et al., 2005). The
reasons for the differences seen with HMPV are not clear,
and it is possible that this reflects differences in the host
species or in the challenge protocols in the different sys-
tems. In the current study, it was possible that the
reduction in protection observed in protective viruses
was due in part to a reduction in replication rates of non-
protective viruses. Serology indicated that replication
occurred, but this may not be a measure of the relative
levels of in vivo replication when comparing protective and
non-protective viruses.
The data presented here clearly show that the features
required in an effective vaccine – the ability to replicate in
the host without causing disease and the ability to confer
protection from subsequent infection – are quite different.
Also, the factors that determine whether a vaccine candi-
date can confer protection from disease can be very subtle
and can be affected by as little as a single point mutation.
The data also show that a critical factor for AMPV in
determining the ability to confer protection is the balance
in levels of G protein expression compared with other virus
proteins, even when the other major antigen, the F protein,
is expressed at effective levels. It will be of interest to
explore further the potential effects of altering the balance
of other virus proteins to determine whether this is a G
protein-specific effect or whether it applies more generally
to the overall balance of virus protein expression.
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